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Abstract 
The GIPIO (Gastrointestinal Peptides in Obesity) collaboration was set up with EU 
(FP7) funding in 2008, with the aim to develop a series of peptide analogues for the 
treatment of obesity. Based on the dual Y2/Y4 agonist, Obinepitide ([Q
34
]hPP), and the 
Y4 agonist, TM30339 (hPP2-36), novel peptides were developed and subsequently 
modified by either PEGylation or lipidation to improve their relatively short half-life 
and pharmacokinetic profile. This thesis presents a detailed study of the in vitro 
pharmacological data performed to aid the progression of the most promising peptide 
candidates. An assessment of Y2Y4 potency and activity was made, using optimised Y4 
(human colonic epithelial monolayers) and Y2Y4 (human colon mucosae) bioassays, 
where preparations were mounted in Ussing chambers and changes in short-circuit 
current (Isc) recorded. In addition, receptor specificity of the most promising agonists 
was dissected using Y1 and Y2 antagonists. Furthermore, an assessment of Y4 receptor 
desensitisation was made by application of a subsequent addition of the native hormone, 
hPP. With a lysine linker at position 30 or 22, chemical modification of Obinepitide 
with either PEGylation or Palmitoylation resulted in prolonged reductions in Isc in both 
preparations compared with the transient response seen with their respective 
predecessors. Increasing the PEG size resulted in greater reductions in Isc, though a 
PEG22 modification resulted in a loss of functional activity. Mid to long chain 
lipidation of TM30339 (lauric acid and palmitic acid) also resulted in sustained 
reductions in Isc. Interestingly, lipidation with a short chain fatty acid (caprylic acid) 
caused a biphasic response, with an initial transient drop in Isc followed by a sustained 
anti-secretory response. Importantly, PEG and lipid side chains had no effect upon Isc. 
Pre-treatment of either human mucosa or epithelial monolayers with PEG2-, or 5-ylated 
Obinepitide did not cause significant subsequent Y4 desensitisation, an effect that was 
greater with the larger PEGylated peptide. Contrary to this, long chain lipidated 
peptides seemed to facilitate rapid and sustained desensitisation, revealed by the loss of 
further Y4 signalling even after nM lipidated agonist. This divergence in receptor 
signalling was also observed in fluorescent imaging studies performed by our 
collaborators. The data presented herein provides the first functional evidence of 
prolonged activity at the Y2 and Y4 receptors and these modified peptides have the 
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1.1 The pancreatic polypeptide family 
1.1.1 Discovery of PP, PYY and NPY 
The circulating hormones pancreatic polypeptide (PP), peptide YY (PYY), the carboxyl 
(C)-terminal fragment PYY(3-36) and the neurotransmitter neuropeptide Y (NPY) all 
belong to the PP family, and in their full length form, consist of 36 amino acids. PP, the 
first of these peptides to be identified, was recognised as a by-product of insulin 
purification in chicken pancreas (Kimmel et al., 1968), followed by successful isolation 
of the peptide by the same group (Kimmel et al., 1975). PP immunoreactivity was 
subsequently measured in human pancreatic cells (Larsson et al., 1975), in addition to 
mouse, rat (Larsson et al., 1976) and a number of other mammalian, avian, reptilian, 
and amphibian species (Lundell et al., 2000). 
 
It was twelve years before a second peptide with sequence homology to that of PP was 
isolated, from the pig intestine (Tatemoto and Mutt, 1980). With the use of an 
innovative isolation technique, Tatemoto and Mutt characterised a 36-amino acid 
polypeptide possessing a tyrosine (Tyr) at both the N- and the C-terminal ends. It was 
these Tyr (Y) amino acids that led to the peptide being named peptide YY, or PYY. 
Using the same technique, subsequent studies in porcine (p) brain extracts led to the 
discovery and isolation of NPY (Tatemoto et al., 1982), which possessed a structure 
similar to that of PP and PYY. Degradation of the PP family members (excluding PYY 
in non-mammals) by the dipeptidyl peptidase IV (DPPIV) enzyme results in the C-
terminal fragments of PYY and NPY (Mentlein et al., 1993); the enzyme cleaves the 
first two N-terminal Tyr and proline (Pro) residues generating the products PYY(3-36) 
and NPY(3-36). Gastrointestinal (GI) DPPIV mRNA expression levels were shown to 
be most abundant in the human distal small intestine, with second highest expression 
levels found in the colon (Darmoul et al., 1994). 
 
1.1.2 Synthesis of PP, PYY and NPY 
Synthesis of PP, PYY and NPY occurs in the endoplasmic reticulum (ER) where these 
peptides are generated as large precursor molecules. These precursor molecules are 
subsequently translocated to the Golgi-apparatus following post-translational 
modification, whereby they undergo sorting in the trans-Golgi network. In the pre-pro-
peptide form, the mature peptides are flanked by a 28-29 amino acid N-terminal signal 
peptide, and a 27-31 amino acid C-terminal peptide sequence, connected to the mature 
peptide sequence by a glycine-lysine-arginine cleavage sequence. The signal peptide is 
  18 
then removed to produce the pro-peptide form (Boel et al., 1984; Leiter et al., 1984; 
Leiter et al., 1987). Following hydrolysis of the pro-peptide form at the cleavage site, 




Figure 1.1 The post-translational modification of PP, PYY and NPY. The peptide is 
generated as a large precursor consisting of the pre-pro-peptide and then flanked by a C-
peptide and a signal peptide. After enzymatic cleavage of the signal peptide, a pro 
peptide is generated (1). Enzymes including carboxypetidase E (CPE) and prohormone 
convertase (PC) cleave the pro-peptide at the dibasic site (2), thereby generating a 
mature peptide (3), which can then be truncated to PYY(3-36) by the DPPIV enzyme. 
 
1.1.3 The PP-fold structure of PP, PYY and NPY 
Each member of the PP family has the key residues required to adopt the PP-fold, which 
comprises a polyproline helix and an interdigitating amphipathic α-helix and a β-turn 
(Figure 1.2). The structure of turkey PP was first elucidated in 1981 with the use of X-
ray crystallography (Blundell et al., 1981), which also highlighted an amidated C-
terminal Tyr residue as part of the structure. Despite being the first peptide to be 
discovered, PP is predicted to be the most recent member of the NPY family in terms of 
evolution and was thought to have arisen by the duplication of the PYY gene in early 
pre- pro-peptide
signal  peptide peptide C-terminal 
peptide sequence
28-29 27-3136





















removed to produce 
pro-peptide
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tetrapods (amphibians, birds, reptiles and mammals; Larhammar et al., 1993). More 
recently, Larhammar and Bergqvist (2013) provided evidence for the occurance of this 
duplication very early in the sarcopterygian lineage, before the origin of tetrapods, by 
demonstrating PYY gene duplication in the West Indian Ocean coelacanth (Latimeria 
chalumnae), thus indicating a much earlier origin of PP.  In comparison, the more 
ancient genes for both NPY and PYY are present in all major vertebrate groups. It is 
hypothesised that the initial replication process which led to the separate genes for NPY 
and PYY took place at the time of the whole genome duplication (in which the multiple 
HOX gene clusters were produced), suggesting a common ancestral origin.  On the 
other hand, the generation of the PP genes arose from a tandem duplication of the PYY 
gene at the time of, or immediately before, the emergence of tetrapods (Conlon, 2002; 
Hort et al., 1995; Larhammar et al., 2004). 
 
 
Figure 1.2 The PP-fold adopted by the NPY family. The PP family is characterised 
by a polyproline helix, a β-turn, and an interdigitating α-helix as determined by X-ray 
crystallography of turkey PP (Blundell et al., 1981). Hydrophobic interactions between 
side chains of the a-helix and the prolines in the N-terminal section ensure that the α-
helix and polyproline helix are secured in a folded configuration. The green and grey 
residues demonstrate alternative hydrophobic polar pairs. 
 
1.1.4 High sequence homology between PP, PYY and NPY 
NPY is the most highly conserved between different species, so much so that 33 of the 
36 amino acids in Torpedo marmorata are identical compared with mammalian NPY. It 
is thought that the evolution of PYY and NPY involved duplication from a common 
ancestral gene; the corresponding genes are now located on different chromosomes. 
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mouse (m) and rat (r) PYY. It is now known that PP arose by duplication of the PYY 
gene, with both genes situated on chromosome 17q21.1 in close proximity (Hort et al., 
1995). In contrast to NPY and PYY, PP exhibits least conservation and thus a high 
degree of species specificity; for example, mPP and rPP share 94% sequence identity, 
whereas mPP and hPP share 83% sequence identity (Figure 1.3). A significant loss in 
sequence identity is observed when comparing mPP to that of chicken (ch), with only 
42 % identity between the two species.  
 
Figure 1.3 A comparison of the human, mouse and rat peptide variants of (A) PP 
and (B) PYY, illustrating sequence homology. Alterations in the amino acids between 
the three species are highlighted in blue. Adapted from Larhammar (1996). 
 
1.1.5 Distribution of PP, PYY and NPY 
Largely, expression of PP is limited to endocrine cells; PYY is expressed in both 
endocrine cells and discrete neurone populations, while NPY has a high prevalence in 
neuronal tissue with some detection additionally in platelets (Ericsson et al., 1987). The 
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considerable structural similarity between each peptide of the PP family has made the 
detection of their distribution patterns complex.  However, in recent years, the 
development of new and selective antibodies, coupled with the use of in situ 
hybridisation has enabled the in depth knowledge about the distribution of each member 
of the NPY family. The major sites of PP, PYY and NPY expression in the periphery, 
particularly in the GI tract, are outlined below. 
 
1.1.5.1 PP 
PP expression is predominately found in the pancreas; in human pancreas, PP is 
contained in two distinguishable cell types; the PP-poor dorsal lobe cells and the PP-
rich ventral lobe cells. The former cells contain small PP positive electron-dense 
granules, comparable to those seen in rodents, whereas the latter cells contain PP 
positive (F-type) cells with much larger and less electron dense granules (Fiocca et al., 
1983). Interestingly, cells have been identified in human foetal pancreas as early as 10 
weeks using immunohistochemistry, a phenomenon which has not been reported in 
rodents (Paulin and Dubois, 1978). 
 
In terms of GI expression, very little PP-immunoreactivity has been detected in 
endocrine cells. In fact, PP immunoreactive cells in the stomach have only been 
described in opossum, cat and dog (Feurle et al., 1985; Larsson et al., 1976; Sundler et 
al., 1984), and only seem to correspond to a subpopulation of the gastrin cells, as 
demonstrated in dog antrum. Only a few PP cells have been detected in the gastric 
mucosa for a short postnatal period in human (Tsutsumi et al., 1984) and rat (Sundler et 
al., 1977). Proof of PP immunoreactivity in the intestine is limited; in dog, PP cells 
seem to be constrained to the duodenum (Sundler et al., 1984; Feurle et al., 1985). 
Shortly after the discovery of PYY, the detection of PP-containing cells in the distal 
human bowel was controversial due to the possibility of antibody cross-reactivity 
(Fiocca et al., 1980; Lehy et al., 1981). Stronger evidence for the presence of PP-
immunoreactive enteroendocrine cells in the human colon and rectum (distinguishable 
from PYY-containing enteroendocrine cells) was subsequently published (el Salhy et 
al., 1983a; el Salhy et al., 1997). More recently, Habib et al. (2012) utilised microarray 
expression profiling and quantitative reverse transcriptase-polymerase chain reaction 
(QRT-PCR) to demonstrate detectable PP expression in colonic L-cells in the mouse. 
Interestingly, PP expression was not observed in upper small intestinal L-cells, which is 
in accordance with the endogenous peptide playing a modulatory peripheral role in 
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distal colonic ion transport and lower gastrointestinal motility (discussed further in 
section in 1.5). 
 
1.1.5.2 PYY 
PYY circulates in two active forms: PYY(1-36) and PYY(3-36) (Grandt et al.,1994). 
The truncated PYY(3-36) results from the cleavage of the tyrosine-proline residues 
from the N-terminal end of the polypeptide via DPPIV (Medeiros and Turner, 1994). 
Grandt and colleagues found that PYY(1-36) accounted for 60% of the PYY 
immunoreactivity in fresh canine colon and the truncated form, PYY(3-36), represented 
the remaining 40% of immunoreactivity (Grandt et al.,1994). 
 
The major source of PYY in the GI tract is the endocrine L-cell (Ekblad and Sundler, 
2002; Ueno et al., 2008), which increase in density along the proximal–distal gut axis; 
hence the largest source of PYY is found in the distal gut. PYY-positive L-cells contain 
the proglucagon-derived peptide, glicentin (Böttcher et al., 1984; Solcia et al., 1985), 
glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) (Ekblad and 
Sundler, 2002). Early studies performed in human tissue by Sjölund et al. revealed ~ 
45% of PYY- immunoreactive cells are found in the rectum, ~27% in the colon and 
~4% in the jejunum. These expression levels were based on the number of glicentin 
immunoreactive cells in the lower gut (Sjölund et al., 1983). More recently, Habib et al. 
reported a high proportion of L-cells in the upper small intestine which expressed 
message for a range of gut hormones, including gastric inhibitory polypeptide (GIP), 
cholecystokinin (CCK), secretin, neurotensin and PYY, with the latter being expressed 
in 20 % of all upper small intestinal L-cells. Furthermore, Habib et al., corroborated 
earlier studies by revealing that a large number of colonic L-cells co-expressed GLP-1 
and PYY, and that the percentage of L-cells containing PYY increased progressively 
towards the colon, demonstrated through immunostaining and fluorescence-activated 
cell sorting analysis (Habib et al., 2012). 
 
Besides its intestinal endocrine cell expression, evidence has been provided for the 
localisation of PYY in specific enteric neurones. Bottcher et al. demonstrated the 
existence of PYY immunoreactivity in the upper GI tract of the rat, cat, ferret and pig by 
immunocytochemistry and radioimmunoassay combined with high performance liquid 
chromatography. In the rat, PYY-immunoreactive nerve fibres were virtually restricted 
to the stomach smooth muscle of the minor curvature where its expression was 
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abundant. In the cat and ferret, PYY-immunoreactive nerve fibres occurred in the 
circular smooth muscle layer of both the minor and major curvatures of the stomach and 
also in the upper small intestine; these fibres were also abundant in myenteric ganglia in 
these regions. In 1983, El Salhy et al. demonstrated that the enteric nerves containing 
PYY were distinct from those containing NPY (El Salhy, 1983), and this evidence was 
further supported by Bottcher et al. who identified PYY in extracts of enteric ganglia 
with a radioimmunoassay not recognising NPY (Bottcher et al., 1984). 
 
1.1.5.3 NPY 
Contrary to the endocrine localisation of the PP and PYY, peripheral NPY is widely 
expressed in the enteric nervous system (ENS), as well as in extrinsic sympathetic and 
parasympathetic neurones (Furness, 2006). Within the gut, the ENS constitutes both 
myenteric and submucosal ganglia which integrate with the muscular and mucosal 
regions (see section 1.5 for details). Studies with the guinea pig small intestine have 
revealed that NPY is localised in three distinct neurone types: myenteric inhibitory 
motor neurones that innervate circular smooth muscle; descending myenteric 
interneurones; and submucosal secretomotor (nonvasodilator) neurones (Sang and 
Young, 1996). Examination of mouse small intestine has also revealed that 26 % of the 
total numbers of neurones of the myenteric plexus express NPY, with expression in cell 
bodies and nerve fibres (Sang and Young, 1996). Interestingly, co-localisation studies in 
the myenteric cell bodies have demonstrated that NPY is co-localised with vasoactive 
intestinal polypeptide (VIP) in 50% of all VIP positive neurones. In addition, co-
localisation of NPY with nitric oxide synthase (NOS) has been demonstrated in 66% of 
all NPY positive myenteric cell bodies. In the human colon, the submucosal plexus 
comprises of three distinguishable layers of ganglia; Henle’s plexus, which is found 
close to the circular muscle, Meissner’s plexus, which is found next to the muscularis 
mucosa; and an intermediate plexus located between Henle’s plexus and Meissner’s 
plexus, and in close proximity to the blood vessels of the submucosa (Hoyle and 
Burnstock, 1989). Evidence from Hoyle and Burnstock did initially contradict another 
early study which demonstrated little NPY immunoreactivity in adult sigmoid colon 
(Crowe et al., 1992); however Nichols et al (1994) demonstrated its presence in 41% of 
neuronal cell bodies identified in all three ganglia of the infant submucosal plexus. As a 
result, this group hypothesised a potential role for NPY in epithelial function due to 
discovery of extensive innervations of varicose fibres to the mucosa. 
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1.2 The Y receptor family 
1.2.1 The categorisation and cloning of different Y receptor types 
Historically, the NPY receptors were categorised into the different types following the 
observation that C-terminal fragments of NPY or PYY, e.g. NPY(13–36) could mimic 
various responses to NPY such as pre-junctional inhibition of twitch responses in the rat 
vas deferens, but were unable to the cause vasoconstriction in guinea pig iliac vein 
(Wahlestedt et al., 1986). From these findings, the Y1 and Y2 receptor types were 
distinguished based on their ability to become activated by either full length peptide 
sequences or the C-terminal fragments, respectively. With the use of PYY and NPY 
analogues with Pro substitutions at residue 34 (as is the case with PP), the categorisation 
of the receptors were further supported, as the two peptides exhibited increased potency 
at the Y1 receptor and reduced efficacy at Y2 receptor following the amino acid 
substitution (Fuhlendorff et al., 1990; Grandt et al., 1994). Subsequently, additional 
receptor types came to light; in 1986, Gilbert et al. injected radiolabelled bovine (b) PP 
into dogs and binding in small intestinal mucosa was analysed (Gilbert et al., 1986). For 
the first time, this group reported receptors to have preference for PP over PYY and 
NPY. Two years later, the same group revealed PP-preferring receptors in displacement 
binding studies using [
125
I] PP in isolated preparations of canine intestinal mucosa 
(Gilbert et al., 1988). In 1991, PP binding to the canine intestinal receptor and receptor 
cross-reactivities to various PPs and bPP fragments led to the discovery that PP required 
an intact N-terminus, since loss of the first two amino acids resulted in the affinity being 
reduced to half  (Gingerich et al., 1991). The same group went on to demonstrate that 
not only were the first 4 amino acids of the PP sequence essential for binding to the 
receptor, but also that intact amidated C-terminal tyrosine was necessary for full 
agonism with the peptide.  
 
With an NPY preferring phenotype, the “Y3” receptor was described in rat colon 
(Dumont et al., 1994), although no receptor has been cloned, and for this reason it is no 
longer thought to exist. Before the existence of selective Y receptor antagonists, a novel 
fourth receptor was hypothesised in rabbit colon, since PP, PYY and NPY were able to 
inhibit anion secretion (Ballantyne et al., 1993); however, using mouse and human 
colon, the reduction in ion secretion was demonstrated to be the result of stimulation of 
multiple receptor types; Y1, Y2 and Y4 receptors (Cox et al., 2001a; Cox and Tough, 
2002). 
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Progress in molecular biology techniques resulted in the identification of five NPY 
receptor types, Y1, Y2, Y4, Y5 and y6. All NPY receptors are seven-transmembrane 
(TM) domain G protein-coupled receptors (GPCRs), which couple preferentially to the 
Gi/Go family, and are thus sensitive to pertussis toxin. The receptor types share only 30-
50% sequence identity and are characterised by distinct tissue localisations and unique 
pharmacological profiles (discussed in more detail below). Based on this, each type is 
placed into one of three groups; the Y1-like receptors, the Y2-like receptors, and the Y5-
like receptors. The Y1-like receptors consist of the Y1, Y4 and y6 receptors, the Y2-like 
receptors include the Y2 receptor and the Y7 receptor which was more recently isolated 
from zebrafish and frog (Fredriksson et al., 2004) and the Y5-like receptors which 
consists of the Y5 receptor only. In 2004, Larhammar et al. demonstrated that Y5 
receptor is more phylogenetically similar to the Y1 subfamily compared to the Y2-like 
receptors. Table 1.1 indicates the agonists and antagonists associated with each 
mammalian Y receptor type and their relative potencies.  
 
 
1.2.1.1 The Y1 receptor  
The Y1 receptor was the first of the NPY receptor family to be identified; cDNA was 
cloned from rat forebrain (Eva et al., 1990) which was subsequently found to encode 
the Y1 receptor (Krause et al., 1992; Petitto et al., 1994; Herzog et al., 1992). 
Thereafter, homologs from various species such as humans (Larhammar et al., 1992), 
mice (Eva et al., 1992) and Xenopus laevis (Blomqvist et al., 1995) were published. 384 
amino acid residues encompass the hY1 receptor and display a 94% sequence homology 
identity with the rY1 and mY1 receptors. Y1 transfection studies have revealed an order 
of potency of full length NPY and PYY ≥ Pro34 analogues >> C-terminal fragments > 
Table 1.1 The pharmacology corresponding to each mammalian Y receptor types. 
 Y1 Y2 Y4 Y5 y6 
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PP (Larhammar et al., 1992; Eva et al., 1992; Krause et al., 1992), as indicated by early 
pharmacological studies. BIBP3226, a non-peptide antagonist developed in 1995, 
exhibits high potency for the Y1 receptor (with Ki or KB values of between 1 to 10 nM) 
and importantly, its affinity at the Y2, Y4 and Y5 receptor exceeds 10 µM (Wieland et 
al., 1995; Gerald et al., 1996). A further selective antagonist at the Y1 receptor, 
BIBO3304, was developed shortly afterwards; this antagonist displayed a 1000-10000-
fold lower affinity for the human and rat Y2, Y4 and Y5 receptor, compared to 
subnanomolar affinity at the Y1 receptor in SK-N-MC cells (Wieland et al., 1998). 
Additional Y1 antagonists have been reported, including SR120819A or GR231118, 
however little data exists regarding their selectivity towards the Y5 and y6 receptors 
(Daniels et al., 1995; Serradeil- Le Gal et al., 1995).  
 
1.2.1.2 The Y2 receptor 
Y2 receptor cDNA was first cloned from human SMS-KAN cells (Rose et al., 1995) and 
thereafter from human brain cDNA libraries (Gehlert et al., 1996; Gerald et al., 1995) 
and the human neuroblastoma cell line KAN-TX (Rimland et al., 1996). In later studies, 
the receptor was cloned from mouse (Nakamura et al., 1996) and rat brain (St Pierre et 
al., 1998). In terms of Y2 receptor pharmacology, the receptor exhibits an order of 
potency of NPY ≈ PYY ≥ C-terminal fragments >> Pro34 analogues > PP. The hY2 
receptor is 381 amino acids long and shares 92% and 94% identity with the rY2 and 
mY2 variants, respectively. Currently, the non-peptide antagonist BIIE0246 exhibits the 
highest potency selective for the Y2 receptor (Doods et al., 1999), and is extensively 
used to study this receptor type. 
 
1.2.1.3 The Y4 receptor 
The Y4 receptor gene was at first cloned from a human genomic library and named 
“PP1” (Lundell et al., 1995). Since then, Y4 receptors from several other species have 
been isolated and characterised including the murine receptors (Gregor et al., 1996a) 
and the rat (Lundell et al., 1996; Yan et al., 1996). The Y4 receptor is comprised of 375 
amino acids, with 75% of the sequence being identical to the rY4 and 76% sequence 
being shared with the mY4. Between the rY4 and mY4, a 94% identity exists between the 
two sequences. Compared with the other members of the NPY family, PP exhibits the 
most preference for the Y4 receptor, followed by Pro
34
PYY > PYY ≥ Pro34NPY > NPY 
> PYY C-terminal fragments > NPY C-terminal fragments > hPP C-terminal fragments 
(Bard et al., 1995), determined by studies on canine intestinal mucosa. The same group 
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also reported a high extent of ligand-receptor specificity between different species since 
a variation in potency for the Y4 receptor was observed; hPP ≈ bPP > rPP > frog PP. 
This species specificity appears to be unique to the Y4 receptor compared with any other 
member of the NPY receptor family. To date, a high affinity Y4 receptor antagonist has 
not yet been developed, however GR231118, a dipeptide founded from the C-terminal 
sequence of NPY (Daniels et al., 1995), has been reported to be a partial agonist at the 
Y4 receptor (Tough et al., 2006), exhibiting picomolar affinity (Gehlert et al., 1996). 
 
1.2.1.4 The Y5 receptor 
In terms of sequence homology, the hY5 and rY5 receptors are 88% identical and are 
both comprised of 445 amino acids. Interestingly, the mY5 receptor consists of 466 
amino acids and has a 97% sequence identity to the rY5 and 89% with its human 
equivalent. The Y5 receptor was first cloned in 1996 from the rat hypothalamus (Gerald 
et al., 1996), followed by cloning from mouse (Weinberg et al., 1996; Nakamura et al., 
1997) and human (Hu et al., 1996) genomic libraries, in addition to a number of other 
species. Initial studies utilising rY5 receptor-transfected LM-TK-cells suggested that 
NPY, PYY, Pro
34
 analogues, small C-terminal fragments and hPP were all capable of 
activating the Y5 receptor with equal potency (Gerald et al., 1996). Subsequent 
displacement studies however, indicated a much lower affinity with rPP compared with 
its human counterpart, when using transfected COS-7 cells and [
125
I]PYY (Borowsky et 
al., 1998). Given its extensive central localisation and principal role in food intake, 
much attention has been paid to the Y5 receptor, and several groups have attempted to 
develop selective agonists and antagonists to further elucidate its significance. Initial 
studies successfully utilised the Y5 agonist, [D-Trp
32
]NPY (Gerald et al., 1996), 




, the recognition 
motif for the Y5 receptor, are more favourable at this receptor type (Cabrele et al., 2000; 
Cabrele et al., 2002; Dumont et al., 2003; Hofliger et al., 2003). In 1998, the first non-
peptidic potent antagonist at the Y5 receptor was reported by Criscione and co-workers 
(Criscione et al., 1998); CGP71683A inhibited the effects of NPY on intracellular Ca
2+
 
levels in a concentration-dependent manner in vitro. The same group also demonstrated 
complete inhibition of the effects of NPY with concentrations of the Y5 antagonists as 
low as 50 nM (Criscione et al., 1998). 
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1.2.1.5 The y6 receptor 
To date, the y6 receptor has been isolated from dogfish (Salaneck et al., 2003) guinea 
pig (Starback et al., 2000), mouse (Gregor, et al. 1996b), pig (Wraith et al., 2000) and 
chicken (Bromée et al., 2006) but interestingly the receptor appears to be completely 
absent from the rat (Burkhoff et al., 1998). In human, guinea pig and pig, the y6 
receptors exist as pseudogenes resulting in non-functional proteins, in contrast to the 
mouse and rabbit, in which the y6 receptor is functional. The existence of the y6 
pseudogenes in humans is thought to occur as a result of a frameshift mutation; a single 
base deletion in the coding sequence of the predicted third intracellular loop results in a 
stop codon in TM6 (Gregor et al., 1996a). Contradictory radioligand binding data exists 
regarding the pharmacological profile of the murine y6 receptor; in 1996, Weinberg et 
al. reported an order of potency of NPY ≈ PYY ≈ [Pro34] substituted analogue > 
NPY(13–36) >> PP (>1000nM) (Weinberg et al., 1996), however in the same year 
Gregor et al reported an order of potency of PP >> [Pro
34
]substituted analogue >> PYY 
≈ NPY > C-terminal fragment (NPY(3–36), NPY(13–36), each > 1000 nM) (Gregor et 
al., 1996b). 
 
1.2.2 Distribution of Y receptors in the GI tract 
The Y1 receptor has an widespread distribution pattern and extensive use of Northern 
analysis, in situ hybridisation and RT-PCR has now confirmed expression in both the 
central nervous system (CNS) and various peripheral organs such as the heart, skeletal 
muscle, lung, adrenal glands and intestinal tract (Wharton et al., 1993; Ball et al., 1995; 
Nakamura et al., 1995; Goumain et al., 1998). Y1 receptor immunoreactivity in the 
intestinal tract has been reported in human (Peaire et al., 1997; Mannon et al., 1999), rat 
colon (Jackerott and Larsson, 1997) and mouse and rat small intestine (Matsuda et al., 
2002). The Y1 receptor has an extensive distribution pattern in both myenteric and 
submucosal neurones in the human colon, detected by positive immunoreactivity 
(Peaire et al., 1997). This group highlighted staining in fibres along the longitudinal and 
circular smooth muscle and the muscularis mucosa (Peaire et al., 1997). Y1 labelling is 
also co-localised with NPY positive cell soma in Henle's plexus of human colon. This 
provides evidence of a pre-synaptic inhibitory role for the Y1 receptor on NPY release. 
This NPY and Y1 co-localisation however is not seen in the myenteric plexus but 
instead, NPY positive nerve fibres are surrounded by Y1 positive cell bodies (Peaire et 
al., 1997). Y1 receptor expression is also present the basolateral domain of epithelial 
cells, in close proximity to PYY positive endocrine L-cells. This indicates that PYY 
  29 
released from L-cells into the lamina propria has the potential to exert significant 
paracrine, epithelial-derived Y1 actions in addition to modulating neuronal mechanisms 
(Mannon et al., 1999). 
 
Similarly to the Y1 receptor, Y2 receptor expression is found in both central and 
peripheral locations. In situ hybridisation and Northern analysis has demonstrated the 
expression of central Y2 gene transcripts in the rat (Zhang et al., 1997; Gustafson et al., 
1997; St Pierre et al., 1998), mouse (Diez et al., 1997; Naveilhan et al., 1998) and man 
(Rose et al., 1995; Gehlert et al., 1996; Caberlotto et al., 2000). Unlike the Y1 receptor, 
the distribution patterns of Y2 receptors in the mammalian ENS are more discrete, and 
are based on information from RT-PCR, autoradiographic and functional studies. The 
limited availability of selective Y2 receptor antibodies has led to only a small number of 
published immunohistochemical studies. Ferrier et al. examined Y2 mRNA levels in 
human intestinal segments and reported high levels in muscle layers of the ileum and 
left colon and in mucosal layers of the ileum and right colon, however the same group 
were unable to detect Y2 receptor mRNA in muscle preparations of rat intestine (Ferrier 
et al., 2002). Despite Y2 receptor-mediated NPY contractions being observed in rat 
proximal colon (Pheng et al., 1999), there was no Y2 receptor mRNA detected in nerve-
muscle preparations of the same species (Ferrier et al., 2000). These studies collectively 
provide evidence that Y2 receptors are predominantly neuronal. Y2 expression on 
submucous and myenteric plexi indicates a neuromodulatory role in the ENS. This idea 
was further supported by Hyland et al. (2003) who demonstrated pre-junctional 
localisation of Y2 receptors in isolated mouse mucosa and showed a reduction in 
epithelial ion transport via PYY(3-36). More recently, Wang et al (2010) detected Y2 
receptor transcripts using RT-PCR, both in the mouse mucosa layer and submucosa plus 
muscle layers. This group detected high levels of receptor expression in the mucosa 
compared to other layers of the proximal and distal colon, and comparison of the two 
colonic preparations revealed a higher signal in the distal than proximal colon. With the 
use of a polyclonal rabbit anti-Y2 serum, immunofluorescent staining revealed Y2 
localisation in the mouse submucosal and myenteric plexi. As with internal controls, 
pre-absorption of the primary antibody with the Y2 immunogenic peptide 
(TDSFSEATN-COOH) was performed to establish antibody specificity. As a result, Y2 
labelling was established mainly in nerve varicosities around neurone cell bodies and 
running between ganglia.  
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In situ hybridisation has allowed the identification of Y4 receptor gene transcripts in rat 
tissue. In human peripheral tissue, Y4 receptor mRNA has been detected in the intestinal 
tract, the heart and reproductive organs, with lower levels being reported in the pancreas 
and kidney (Lundell et al., 1995; Bard et al., 1995; Yan et al., 1996; Gregor et al., 
1996b). Several studies have focused on Y4 receptor expression in the human 
gastrointestinal tract, and it has now been established that Y4 mRNA is present in the 
small and large bowel (Lundell et al., 1995), as determined by northern analyses. 
Constitutive Y4 receptor expression has been detected in three human colonic 
adrenocarcinoma cell lines with the use of RT-PCR (Cox et al., 2001b). When pre-
treated with VIP, these cell lines exhibit consistent inhibitory responses to low nM 
concentrations of hPP (Cox & Tough, 1995; Holliday et al., 1997; Cox et al., 2001b), an 
effect that is also observed in human colon mucosa and mouse descending colon 
mucosa (Tough et al., 2006). One particular study demonstrated Y4 receptor localisation 
on rat goblet cells and on intestinal villi, specifically on the basal lamina (Campbell et 
al., 2003), suggesting a number of potential undefined roles for the Y4 receptor, such as 
mucus secretion in the intestine. 
 
Contrary to the extensive peripheral and central localisation patterns for the Y1, Y2 and 
Y4 receptor, the Y5 receptor has very limited expression in peripheral tissue and is 
largely localised to the CNS. In rat GI tissue, Y5 mRNA was not measured in the 
fundus, antrum, duodenum, jejunum, ileum, caecum or distal colon (Ferrier et al., 
2002). The same group also reported lack of Y5 mRNA human ileum, colon, and rectal 
tissues. Y5 mRNA is however present at low levels, in rat proximal colon (Feletou et 
al., 1998) in colonic muscle layers and possibly in jejunal crypts (Goumain et al., 1998) 
although functional data indicates that this receptor type has no functional role in rodent 










hNPY was only active at micromolar concentrations. This 
suggests that Y5 receptors do not play a significant role in reducing ion secretion.  
 
The y6 receptor is a pseudogene in primates, containing a single base pair deletion in the 
sixth transmembrane domain resulting in a truncated, non-functional receptor 
(Matsumoto et al., 1996). Peripheral expression of the y6 receptor is limited; it is not 
expressed in rat but is expressed in the mouse; y6 mRNA has been detected in the small 
intestine (and at lower levels in embryonic colon, Gregor et al., 1996a, although the 
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detailed distribution patterns have not been described. Messenger RNA for the y6 
receptor has also been identified in human and rabbit small intestine and colon (Gregor 
et al., 1996a; Matsumoto et al., 1996) however, the lack of y6 receptor antibody has 
hindered the detection of protein expression.  
 
Taken together, the patterns of peptide and receptor localisation in the intestine show 
variation along the length of the gut within species, as well as clear differences between 
species. Given their extensive presence within the basolateral aspect of the epithelial 
layer (Y1 and Y4 receptors) or on enteric neurones (Y1 and Y2 receptors) and their 
activation by endogenous NPY, PYY (Y1 and Y2 receptors) or PP (which prefers Y4 
receptors), it is evident that these receptors play a significant functional role in the 
human GI tract, as well as in particular rodent models (e.g. mouse). 
 
1.2.3 Signalling and internalisation of the Y receptors, with a focus on Y1, Y2 and 
Y4 receptors and their desensitisation 
Each Y receptor signals via pertussis toxin-sensitive G proteins, e.g. members of the Gi 
and Go family, which mediate the inhibition of adenylyl cyclases (AC), and consequently, 
the inhibition of cyclic adenosine monophosphate (cAMP) synthesis (Figure 1.4). In their 
inactive form G proteins are found in a heterotrimeric complex with guanosine-5'-
diphosphate (GDP) bound to the  subunit (GDP). Following agonist-mediated 
receptor activation, a conformational change in the Gα subunit promotes exchange of GDP 
for guanosine-5'-triphosphate (GTP). GTP binding results in the complex dissociating into 
a  dimer and the free, active GDP subunit. The Gα subunit contains an integral GTP-
ase and once AC is inhibited, the Gα subunit hydrolyses GTP to GDP and re-associates 
with the βγ subunit. 
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Figure 1.4 Signal transduction following Y receptor activation. Preceding agonist 
binding, Gα and Gβγ subunits exist in a heterotrimeric complex and interact with the Y 
receptor C-terminus. Adenylate cyclase, stimulated by the Gs subunit from another 
receptor, stimulates cAMP production. Following activation, the Gα and Gβγ subunits 
dissociate and the active, unrestrained Gα inhibits cAMP production whereas the Gβγ 
subunit can interact with Gq coupled receptors to stimulate inositol phosphate (IP) 
production, elevate intracellular Ca
2+
 levels, increase arachidonic acid (AA) release and 
activate mitogen activated protein kinases (MAPK). Adapted from Holliday et al. 
(2005) and Tough (2006). 
 
The onset of GPCR desensitisation is a mechanism in which there is a loss in 
intracellular signalling, despite the presence of a ligand (Ferguson, 2001). This process 
is the consequence of a combination of different mechanisms. The cloning of the β2-
adrenergic receptors (β2-AR) in 1986 and its shared homology with the rhodopsin 
receptor (Sibley et al., 1986) led to the understanding of receptor desensitisation. Now, 
GPCRs are traditionally thought to signal via activation of heterotrimeric G proteins and 
then desensitise by G protein-coupled receptor kinases (GRKs) (Ribas et al., 2007), 
which are recruited to and specifically phosphorylate agonist-occupied receptors leading 
to “homologous desensitisation” (Benovic et al., 1986; Hausdorff et al., 1990). GRKs 
phosphorylate GPCRs at both serine and threonine residues localised within the third 
intracellular loop or C-terminal tail domain (Premont et al., 1995). GRK-
phosphorylation of receptors is not sufficient for desensitisation, but instead serves to 
create high affinity sites to promote the recruitment of the cytoplasmic accessory 
proteins, arrestins, and target the receptors for internalisation via clathrin-coated pits. 
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bound to the phosphorylated rhodopsin, thereby interfering with its coupling to 
transducin (Wilden et al., 1986). The protein was later renamed arrestin (Zuckerman 
and Cheasty, 1986). The arrestin recruitment subsequently induces desensitisation by 
preventing further coupling to G proteins (Lohse et al., 1990). 
 
Besides their role in desensitisation, β-arrestins recruit GPCRs such as the Y1 receptor 
to clathrin coated pits and as a consequence, the receptor undergoes rapid internalisation 
(Gicquiaux et al., 2002; Parker et al., 2002; Pheng et al., 2003; Holliday et al., 2005). 
This process is thought to occur through interactions with the endocytotic machinery, 
such as the clathrin heavy chain or the clathrin adaptor protein AP2 (Goodman et al., 
1996; Laporte et al., 1999) (Figure 1.5). Dynamin then facilitates the detachment of 
clathrin-coated pits from the plasma membrane (Doherty & McMahon, 2009).  
Desensitisation is an essential process which is required to prevent over-activation in 
response to persistent ligand stimulation. In the same way, to avoid prolonged 
desensitisation, GPCRs have the capacity to reactivate or resensitise once the ligand has 
been removed. Once internalised, GPCRs are either: rapidly targeted to the lysosome 
for its degradation resulting in complete termination of receptor signal activity, rapidly 
recycled back to the plasma membrane resulting in resensitisation and hormone signal 
recovery, or are retained in endosomes, crossing over to the degradative or recycling 
pathways at a much slower rate (Hanyaloglu and Zastrow, 2008; Marchese et al., 2008). 
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Figure 1.5 Schematic diagram of signal transduction in GPCRs following receptor 
activation. Arrows A and B illustrate ligand-activated receptors which signal to 
downstream effects via α and/or βγ complexes. Subsequent to phosphorylation of the 
receptor, arrestin is recruited from the cytoplasmic domain, promoting receptor 
endocytosis via clathrin-coated pits. Recent published data suggests that a number of 
GPCR-mediated signalling events may possibly occur from an endosomal compartment 
(arrow C). Adapted from Hanyaloglu and Zastrow, 2008. 
 
Rapid Y1 and Y4 receptor desensitisation has been well documented with the use of 
cAMP assays in human embryonic kidney (HEK) 293 cells (Gicquiaux et al., 2002) and 
also in ion transport studies using epithelia (Cox and Tough, 1995; Cox et al., 2001b; 
Holliday and Cox, 2003; Holliday et al., 2005). Early reports by one group suggested 
that hY4 receptor was not susceptible to agonist-induced desensitisation or 
internalisation in Chinese hamster ovary (CHO) cells (Voisin et al., 2000). One 
explanation for this may be the long-term (24 hours) PP pre-treatment used in that study 
resulting in the inability to measure degradation of the agonist. The same group also 
reported the inability of C-terminal tagged hY4 receptors to redistribute from the plasma 
membrane after 24 hour pre-treatment with hPP, however this was contradictory to 
findings reported by Parker et al. (2001 & 2002) whereby it was shown that [
125
I]PP 
was effectively and rapidly sequestered from the plasma membrane following binding 
to rat Y4 receptors in the same cell line. This rapid Y4 desensitisation was later found to 
be highly associated with β-arrestin-3, verified by bioluminescence resonance energy 
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for each Y receptor has shown that the Y4 receptor is much slower than the Y1 receptor 
(Parker et al., 2001), but has faster kinetics compared with the Y5 receptor (Parker et al., 
2003; Bohme et al., 2008). 
 
In contrast to the rapid internalisation seen with the Y1 and Y4 receptors, the Y2 receptor 
interestingly has been reported to internalise slowly (Berglund et al., 2003a; Gicquiaux 
et al., 2002; Ouedraogo et al., 2008). This slow internalisation is thought to be 
attributed to slower interactions with arrestin. Berglund et al. provided further evidence 
to support this hypothesis and showed that the Y1 receptor rapidly recruits the adaptor 
protein whereas Y2 receptor recruitment of β-arrestin is much slower (Berglund et al., 
2003b) or not observed (Ouedraogo et al., 2008). Using BRET techniques, this group 
also demonstrated that differences in radiolabelled agonist internalisation of the other Y 
receptors i.e. Y1, Y4, Y5 > Y2 also broadly corresponds to their affinity for β-arrestin 2 
(i.e. Y1, Y5 >Y4>Y2) (Berglund et al., 2003b).  More recently, NPY was shown to have 
a significantly lower potency at the Y2 receptor in terms of arrestin stimulation 
compared to the Y1 receptor in a bimolecular fluorescence complementation assay 
(Kilpatrick et al., 2010), however this data did not corroborate earlier fluorescence 
microscopy studies, whereby it was shown that the Y2 receptor has a similar rate of 
internalisation to the Y1 receptor (Bohme et al., 2008; Lindner et al., 2009). 
 
A vast amount of published data has suggested a key role for the Y2 and Y4 receptor in 
the anorexigenic response to feeding (see section 1.3 for details). From a clinical 
perspective, the evidence described above for the Y2 receptor suggests that its low 
association with arrestin may potentially reduce the risk of developing tolerance, a 
current problem observed with anti-obesity CCK analogues (Moran and Dailey, 2009). 
The differential endocytic pathways seen with the Y2 and Y4 receptors calls for the need 
to investigate the clinical repercussions if these receptors are to be targeted in treatment 
of obesity and to ascertain whether these processes can be controlled to accomplish 
greater therapeutic potential. 
 
1.3 The role of the PP family in satiety 
The accumulation of body fat to a degree which is disadvantageous to health has 
become a major concern in the western world. Regardless of its pandemic proportions, 
high morbidity and mortality rates and the financial impact on governments, obesity still 
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remains a severe health problem in both children and adults. The onset of obesity not 
only increases the risk of developing serious chronic conditions such as type 2- 
diabetes, hypertension and coronary heart disease, but is also associated with several 
types of cancer (Neary et al., 2003; Meister, 2007). 
 
1.3.1 Current treatments for obesity 
Currently, the only successful treatment for achieving significant weight loss is surgery. 
Despite improving morbidity and mortality rates in obese patients (Sjostrom, 2008), 
these procedures are associated with a peri-operative risk of mortality of 0.5% (Mark et 
al., 2008). Pharmacological treatments including the drugs orlistat, sibutramine and 
rimonabant have not been as successful as initially predicted, due to their limited 
efficacy and unwanted adverse effects; the centrally acting 5-HT/NA (5-
hydroxytryptamine/noradrenaline) reuptake inhibitor, Sibutramine, was recently 
removed from the European market, as evidence suggested an increase in cardiovascular 
events including hypertension, tachycardia, arrhythmias, myocardial infarction (Sharma 
et al., 2009). Likewise, the cannabinoid (CB) receptor antagonist, Rimonabant, was also 
recalled from the market as a result of high incidences in anxiety and depression 
(Christensen et al., 2007). The peripherally acting GI lipase inhibitor, Orlistat is 
currently the only pharmacotherapy on the European market for use in obese patients; 
however, its use is associated with unwanted side effects include intestinal flatulence, 
borborygmi (a rumbling noise made by the movement of fluid and gas in the intestines), 
abdominal cramps and faecal incontinence (Rucker et al., 2007), thus resulting in poor 
tolerability and minimal weight loss. A few currently marketed drugs, approved for 
other indications, can also be useful for the treatment of obesity. Since obesity is 
commonly associated with insulin-resistance and type 2 diabetes, currently available 
drugs are GLP-1 receptor agonists (exenatide and liraglutide) for the treatment of type 2 
diabetic patients. Both exenatide and liraglutide stimulate insulin secretion, inhibit 
glucagon secretion and increase or sustain the level of GLP-1 in circulation via 
increased protection from DPP-IV degradation (the improved pharmacokinetic profile 
of liraglutide is discussed further in Section 1.4.3). Notably, clinical trials have 
demonstrated a suppression in food intake and appetite with exenatide and liraglutide in 
patients with type 2 diabetes (Monami et al., 2009; Norris et al., 2009 and Jendle et al., 
2009; Nauck and Marre, 2009, respectively), when used as monotherapy or as part of 
combination treatment. Regarding additional new pharmacotherapies licensed for 
obesity, the FDA has not approved a new prescription anti-obesity drug since 1999 
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when it opened the US market to orlistat. Now more than ever, the development of new 
pharmacological strategies is crucial to tackle obesity alongside the adoption of a more 
active lifestyle. 
 
1.3.2 Gut-brain axis and the regulation of food intake 
An extensive number of peripheral signals from the GI tract, liver, endocrine pancreas 
and adipocytes have the capacity to modulate energy intake and expenditure controlled 
in the CNS (Morton et al., 2006; Cummings & Overduin, 2007). For these peripheral 
signals to influence central pathways in the regulation of food intake, 2 key 
transmission routes are involved; either they can cross the blood-brain barrier to elicit 
an effect directly on CNS neurones, or they can act upon vagal afferents. The brainstem 
and hypothalamus are the key CNS regions accountable for the regulation of energy 
homeostasis, receiving peripheral neural and hormonal signals regarding nutritional 
state and adiposity (Murphy and Bloom, 2006). It is the arcuate (ARC) nucleus of the 
hypothalamus which plays a central role on food intake and contains two populations of 
neurones with opposing effects (Chaudhri et al., 2008). The medially located orexigenic 
(hunger-stimulating) neurones express NPY and Agouti-related protein (AgRP) 
(Broberger et al., 1998; Bewick et al., 2005). Opposing anorexigenic (satiety-
stimulating) neurones in the lateral ARC express α-melanocyte stimulating hormone (α-
MSH) derived from pro-opiomelanocortin (POMC), and cocaine- and amphetamine-
regulated transcript (CART) (Elias et al., 1998). Since the ARC borders the median 
eminence, a region which has partial blood-brain barrier protection (Peruzzo et al., 
2000), circulating peripheral hormones therefore have access and can manipulate ARC 
neurones directly. Evidence suggests GI hormones in response to food intake convey 
signals to the ARC to indicate short-term nutrient availability. On the contrary, 
peripheral factors such as insulin and leptin originating from the pancreas and adipose 
tissues, respectively, are thought to signal information corresponding to long-term 
energy stores (Porte et al., 2002), both of which act on excitatory receptors on the 
POMC neurones to inhibit food intake and also inhibit the release of orexigenic NPY 
from the NPY/AGRP neurones (Niswender and Schwartz, 2003). The interactions 
between the brain and periphery are summarised in Figure 1.6. The stimulation of food 
intake occurs with an initial release of ghrelin, from endocrine cells of the oxyntic 
mucosa of the stomach (Tschop et al., 2000; Wren et al., 2001). Via activation of 
growth hormone secretagogue (GHS) receptors located on NPY and AgRP-containing 
neurones in the ARC (Nakazato et al., 2001), ghrelin is able to cause release of NPY 
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which subsequently stimulates the orexigenic Y1 receptors in the paraventricular 
nucleus (PVN) (Broberger et al., 1999). There is also some evidence which suggests 
that high levels of NPY may stimulate Y4 receptors located in the PVN (Parker and 
Herzog, 1999). Orexigenic signals are then relayed to the nucleus tractus solitarius 
(NTS) in the medulla, pituitary, limbic system, cortex and adrenal glands, resulting in 




Figure 1.6 The modulation of central pathways via peripheral factors to 
manipulate energy expenditure and food intake. Ghrelin released from the oxyntic 
mucosa of the stomach activates NPY/AGRP neurones via the GHS receptor. NPY 
activates Y1 and possibly Y4 receptors in the PVN resulting in ingestion. Insulin and 
leptin stimulate their receptors on POMC neurones and inhibit NPY/AGRP neurones. In 
the lateral hypothalamic area (LHA), melanin-concentrating hormone (MCH) and 
orexin neurones stimulate the PVN. In addition, inhibitory Y2 receptors on NPY 
neurones of the arcuate nucleus may become activated by PYY released from distal 
colon, signalling satiety. Furthermore, PYY can also activate the ‘ileal brake’, 
contributing to satiety. PP release from the pancreas is also thought to inhibit appetite 
via the Y4 receptor in the ARC, LHA and brainstem. Dotted lines correspond to 
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1.3.2.1 The role of PYY(3-36) in satiety 
In 1985, Adrian et al. first demonstrated that circulating levels of PYY(3-36) rise within 
15 minutes following food consumption, and remain elevated for up to 6 hours (Adrian 
et al., 1985).  The extent at which PYY(3-36) levels rise is proportional to the number 
of calories consumed (Degen et al., 2005). Protein-rich meals in particular have been 
shown to heavily stimulate the release of PYY(3-36), compared to other macronutrients 
(Batterham et al., 2006; Pedersen-Bjergaard et al., 1996). In 1993, the gut hormone was 
first shown to reduce food intake, following peripheral administration of the peptide in 
rodents (Okada et al., 1993). Batterham et al. then went on to successfully support these 
findings by demonstrating decreased appetite for a minimum of 12 hours with PYY(3–
36) injections (Batterham et al. 2002). Although early studies could not replicate the 
acute inhibitory effects of PYY(3–36) on feeding in rodents, several studies have now 
reproduced and confirmed these findings in rodents (Abbott et al. 2005; Koda et al. 
2005; Unniappan et al. 2006; Vrang et al. 2006; Unniappan & Kieffer, 2008), in non-
human primates (Koegler et al. 2005) and also in humans (le Roux et al. 2006; 
Batterham et al. 2007; Sloth et al. 2007a; Sloth et al., 2007b). 
 
Strong evidence indicates that anorectic actions of PYY(3–36) are mediated via 
inhibitory pre-synaptic Y2 receptors in the ARC. The fact that PYY(3–36) reduces NPY 
mRNA levels and release of NPY from ex vivo hypothalamic explants, further supports 
this hypothesis. Furthermore, concentrated patterns of c-fos immunoreactivity are 
highlighted in ARC, a region where Y2 receptors are localised, following peripheral 
administration of PYY(3–36). Further evidence for the role of the Y2 receptor in feeding 
has been provided by Batterham et al. who showed reduced food intake following 
peripheral PYY(3–36) is lost in Y2 receptor knock out (KO) mice (Batterham et al. 
2002). PYY(3-36) is thought to exert its effects through vagal brainstem mediated 
pathway; following bilateral sub-diaphragmatic total truncal vagotomy or transectioning 
of the brain stem hypothalamic pathway in rodents, the effects of PYY(3-36) on feeding  
(Abbott et al., 2005; Koda et al., 2005), and on ARC neuronal activation are lost 
(Abbott et al., 2005), implicating the vagus nerve in the regulation of appetite. 
 
Besides its centrally acting mechanisms, PYY(3–36) is also able to modulate appetite 
via effects on GI motility; PYY is able to exert inhibitory actions on gastric acid 
secretion, gastric emptying, and mouth-to-caecum transit time (Field et al., 2010). With 
respect to upper small intestinal transit, PYY acts as an ‘ileal brake’, slowing intestinal 
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motility and resulting in satiety (Lin et al., 1996; Maljaars et al., 2008). Interestingly, 
obese individuals have lower levels of PYY(3–36) (Le Roux et al., 2006), and its 
anorexigenic effect is preserved, unlike leptin, making the gut hormone a promising 
therapeutic target. 
 
1.3.2.2 The role of PP in satiety 
PP is released from the endocrine pancreas and like PYY, this process occurs in 
response to ingestion of a meal. Several studies have now successfully elucidated a role 
for PP in the anorectic response to feeding. Acute peripheral administration of the gut 
hormone significantly reduced appetite and food intake in both lean human subjects 
(Batterham et al., 2003; Jesudason et al., 2007) and obese patients with Prader Willi 
Syndrome (Berntson et al., 1993; Glaser et al., 1988; Gettys et al., 1991). Using both 
freely fed and fasted mice, Balasubramaniam et al. (2006) also demonstrated a dose-
dependent reduction in food intake following peripheral injection of PP. This reduction 
was Y4 receptor-mediated, since the effect was completely abolished in Y4-/- mice. 
 
The anorectic effects of PP through Y4 agonism are mediated via both central and 
peripheral mechanisms. Central Y4 receptor expression was shown in the hypothalamic 
ARC of mice (Parker and Herzog, 1999; Parker and Herzog, 2000; Figure 1.6) and in 
2003, Asakawa et al. demonstrated reduced mRNA expression of NPY and orexin in 
the hypothalamus of mice following repeated administration of PP over a 24 hour 
period (Asakawa et al., 2003). In 2009, Lin et al. corroborated these findings by 
showing intense c-Fos activation in the ARC in response to i.p. injection of PP in wild 
type (WT) but not in Y4
-/-
 mice, an effect that was particularly strong in neurones co-
expressing α-MSH. This group provided further evidence of central Y4 receptor 
activation via PP, since a number of other hypothalamic areas such as the PVN and 
ventromedial nucleus indicated c-Fos immunoreactivity following PP administration. 
Furthermore, in situ hybridisation experiments demonstrated an upregulation of POMC 
mRNA in the ARC (Lin et al., 2009). To ascertain whether this effect was Y4-specific, 
Lin et al. utilised hypothalamus-specific conditional Y4
-/- 
mice and revealed a loss in 
both PP-induced c-Fos activation in the ARC and increased POMC mRNA expression, 
suggesting a central role for Y4 signalling.   
 
Along with PP’s central actions, the gut hormone has been reported to reduce appetite 
via a reduction in gastric emptying. In addition, PP has an inhibitory action on intestinal 
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and colonic motor activity and peristalsis (Fujimiya and Inui, 2000), an effect that is 
dependent on intact vagal signalling (Murphy and Bloom, 2006; Field et al., 2010).  
 
Encouraging data indicating PP's and PYY’s anorectic actions led to 7TM Pharma 
(Copenhagen) to develop two synthetic analogues for the treatment of obesity: 
TM30339 and TM30338. Peripheral administration of the selective Y4-receptor agonist, 
TM30339, exhibited significant weight loss in diet-induced obese mice. This led to a 28 
day human study in which safety, tolerability and the effective dose to induce weight 
loss were ascertained in healthy obese individuals (7TM Pharma meeting report, 2008). 
The novel Y4 agonist was reported to be well tolerated and exhibited few side effects. 
TM30338, named Obinepitide, binds to both the hY2 and the hY4 receptor. Replacement 
of Pro at position 34 with glutamine (Gln) on the hPP amino acid sequence led to a dual 
agonist with nM potency at both Y receptors (Schwartz, 2006). In Phase I/II clinical 
trials, Obinepitide demonstrated a promising safety profile in patients with a body mass 
index (BMI) averaging 34 and was able to reduce ghrelin levels and inhibit food intake 
by ∼10% when administered as a single daily subcutaneous dose (7TM Pharma meeting 
report, 2008). The most promising aspect of this novel peptide is that it lacks significant 
Y1 receptor affinity, this reducing the possibility of any adverse cardiovascular events 
(Pedrazzini, 2004). Besides the potential synergistic efficacy, the Y2/Y4 dual agonist 
does not induce the emesis previously observed with Y2-selective agonists, as suggested 
by the preclinical monkey studies described by 7TM Pharma (7TM Pharma meeting 
report, 2008). 
 
1.3.3 Y2/Y4 synergy 
Since both the Y2 and Y4 receptors play a key role in regulation of appetite and 
adiposity, it is postulated that the dual peptide, Obinepitide, may evoke a synergistic 
action in terms of its satiety-inducing activity, compared with single Y2 or Y4 agonists. 
With the use of germline knockout mice, several groups have demonstrated marked 
synergy between the two Y receptors in terms of fat mass accumulation (Sainsbury et 





) in mice revealed a greater reduction in fat mass compared to 
mice possessing single Y2 and/or Y4 deletions (Sainsbury et al., 2003). Furthermore, the 
implications of single, double, or triple loss of Y1, Y2, or Y4 receptors were assessed in 
terms of alterations in energy balance. A high-fat diet in wild type mice resulted in the 
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mice displayed a resistance to the effects of obesity, thought to be related to a 
reduction in food intake and increased glucose tolerance. Interestingly, both wild-type 
and Y1
-/-
 mice displaying diet-induced obesity demonstrated decreased hypothalamic 




 mice fed a high-fat diet, who 
appeared to be resistant to the effects of obesity. The authors concluded a synergistic 
action between the Y2 and Y4 receptor, since dual deletion of these receptors results in 
protection against obesity, partly via alterations in feeding and hypothalamic POMC 
expression (Sainsbury et al., 2006). In addition, Y2 receptor knockout mice appear to 
have dismissed symptoms of the massive obesity normally observed in leptin-deficient 
ob/ob mice, although this is not the case with Y4 receptor knockout mice (Sainsbury et 
al., 2002), signifying differential mechanisms of each receptor to modulate adiposity. 
To further support these results in ob/ob mice, Lee et al showed a significantly reduced 
body weight and fat mass in ob/ob mice possessing deletion of Y2 and Y4 receptors, and 
this effect was enhanced compared to ob/ob mice with single Y2 receptor deletion (Lee 
et al., 2008). Since ablation of both Y2 and Y4 receptors synergistically reduces 
adiposity significantly more in obese ob/ob mice compared with their lean counterparts, 
it is predicted a novel dual Y2/Y4 receptor analogue will induce considerably enhanced 
effects on appetite and food intake.  
 
1.4 Use of PEGylation and lipidation to increase therapeutic potential of 
peptides 
1.4.1 The shortcomings of PYY and PP as therapeutics 
The use of peptides and proteins as therapeutic agents has several drawbacks; their 
relatively small size makes delivery difficult and they are often cleared by the kidneys 
or mononuclear phagocyte system within minutes of administration (Pasut and 
Veronese, 2009). In addition, their susceptibility to degradation by proteolytic enzymes 
results in an exceptionally short half life. Adrian et al demonstrated that exogenously 
administered bPP is rapidly cleared from the circulation in humans with a half-life of 
7.0 min, after infusion of 0.98 - 4.58 pmol/kg/min PP (Adrian et al., 1978). Similarly, 
the circulating half life of PYY in plasma is 11 min in dogs (Pappas et al., 1985).  In 
rats, peak plasma levels of PYY(3-36) are reached at 15 min post injection, however in 
this study, the half-life was not reported (Batterham et al., 2002). Despite the fact that 
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PYY(3–36) levels elevate rapidly after a test meal (4,500 kcal) and can remain elevated 
for 6 hours post meal (Adrian et al., 1985), these levels unfortunately fall to baseline 
within 30 min when the peptide is infused (Batterham et al., 2002). A number of 
research groups have attempted to improve the clinical properties of polypeptides via 
amino acid alteration, with the aim to protect against enzymatic degradation. Such 
methods have included polypeptide fusion to albumin, or incorporation of the peptides 
into drug-delivery vehicles such as liposomes (Mateo et al., 2000; Lyczak & Morrison, 
1994; Syed et al., 1997). Although the use of liposomes has, in some cases, been 
successful, limitations such as rapid entry into the liver, spleen, kidneys and 
reticuloendothelial systems, as well as leakage of the drugs while in the circulation 
(Allen, 1997) have led to the need to additional drug delivery systems. PEGylation (the 
attachment of polyethylene glycol (PEG) to a peptide) and lipidation (acylation of a 
peptide with fatty acids) are alternative methods that overcome these deficiencies. In 
fact, liposomes are now PEGylated to improve the delivery of encapsulated drugs, such 
as the anticancer agent doxorubicin (Gabizon & Martin, 1997). 
 
1.4.2 PEGylation of peptides 
The process of PEGylation is based upon the covalent linking of a PEG polymer to 
thecore sequence of a peptide or macromolecule. Most commonly, the PEG exists in a 
linear or branched form with terminal hydroxyl groups, as depicted below in Figure 1.7. 
 
 
Figure 1.7 Structural formula of a PEG entity.  
 
For a stable reaction the PEG entity is frequently linked to a lysine, a known reactive 
group on the peptide. Other reactive linkers utilised in this process include glutamic 
acid, aspartic acid, free cysteine, threonine, the C-terminal carboxylic acid or the N-
terminal amine of the peptide. The attachment of a PEG dramatically increases the 
overall molecular weight of the peptide, through binding to 2–3 water molecules per 
ethylene oxide unit (Figure 1.7). The flexibility of the PEG polymer in conjunction with 
the highly hydrated characteristic of the PEG-bound peptide allows the peptide to 
mimic a soluble protein which has a 5 to 10 times larger molecular weight compared 
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with the parent peptide. These properties of the PEG conjugate thus enable the PEG to 
precipitate proteins (Polson, 1977), reduce immunogenicity and antigenicity 
(Abuchowski et al., 1977) and shield the peptide from proteolytic degradation. In 
addition, given that the renal glomeruli filter molecules based on their size, peptides 
conjugated to a PEG polymer exhibit reduced renal clearance. Thus, PEGylation offers 
a number of advantages which subsequently lead to an increased bioavailability and 
potentially the possibility of lower doses and less frequent administration. Furthermore, 
PEG induces a low risk of immunogenicity, even at high molecular weights (Caliceti 
and Veronese, 2003); to date there have been no reported situations in which the 
administration of a PEGylated molecule has led to the generation of anti-PEG 
antibodies in a clinical setting (Caliceti and Veronese, 2003). 
 
An unintended outcome of PEGylation is a reduction, or sometimes even complete loss, 
in biological activity, thought to be a result of steric hindrance of the target site induced 
by the large PEG polymer. Techniques involving site-specific PEGylation have been 
described (Harris and Chess, 2003; King et al., 1994), in which an unpaired cysteine 
linker is targeted by the PEG polymer and is engineered in such a way that it does not 
interfere with the binding motif. This approach has been successfully applied (Chapman 
et al., 1999; Weir et al., 2002), whereby it has been demonstrated that PEG chains with 
molecular weights of between 2 kDa and 40 kDa can be conjugated to antibody 
fragments without detrimental effect to their affinity. It should be noted however that 
conflicting reports exist with regards to the effects of PEGylation on affinity; in 2005, 
Kubetzko et al. site-specifically coupled a 20 kDa PEG moiety to the C terminus of an 
antibody construct, specifically to a cysteine residue separated by a glycine linker, to 
avoid PEG interference between the antibody and antigen interaction. A reduction in the 
functional affinity was reported when evaluating the binding properties of the 
PEGylated constructs to their unPEGylated equivalent. Examination of the binding 
kinetics revealed that the association rate between the PEGylated construct and the 
antigen were in fact slower, which was attributed to a combination of both intra-
molecular/inter-molecular blocking mechanisms. Using Mass-transport limited BIAcore 
measurements, it was established that from the total number of PEGylated antibodies in 
solution at any given time point, only less than 7% were capable of interacting and 
binding to their target. The remaining PEG-antibodies in solution were considered to be 
intra-molecularly blocked in terms of binding. The authors concluded that although 
PEGylation led to a reduction in the association rate constant, all PEGylated antibody 
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constructs could ultimately successfully bind to their target, albeit with a slower 
equilibrium (Kubetzko et al. 2005). Although a reduction in in vitro binding affinity is 
often observed following PEGylation of a peptide, the marked increase in stability and 
prolonged half-life of the peptide in vivo is considered to more than compensate, since 
extended exposure and receptor occupancy are usually a consequence.  
 
1.4.2.1 PEGylated peptides currently in development  
Adagen, a PEGylated bovine adenosine deaminase, used for the treatment of Severe 
Combined Immunodeficiency Disease (SCID), was the first successful PEGylated 
pharmaceutical to be authorised by the Food and Drug Administration (FDA) in March 
1990 (Chess and Harris, 2003). Subsequently, a number of PEGylated peptides moved 
swiftly into the clinic including Oncaspar, a PEGylated L-asparaginase responsible for 
the degradation of asparagines (Chess and Harris, 2003). In this case, PEGylation 
enhances the enzyme’s circulating half life by 337 hours in addition to reducing the 
possibility of an immunogenic adverse reaction, thus making it an ideal treatment for 
leukaemia. 
 
With obesity and type 2 diabetes becoming increasingly prevalent in the western 
countries, many attempts have been made to develop stable, long acting 
pharmacological drugs with promising selectivity. In 2006, Lee et al. applied the 
PEGylation technique to GLP-1, a therapy for type 2 diabetes, as a method to overcome 
the rapid clearance and inactivation of the peptide via DPP-IV (Kieffer et al., 1995) and 
the neutral endopeptidase (NEP) 24.11 (Plamboeck et al., 2005). Mono-PEGylation of a 
GLP-1 analogue (Lys-PEG/GLP-1) exhibited 40-, 28- and 10- fold enhanced stability in 
plasma, kidney and liver homogenates, respectively, compared with the native hormone. 
Furthermore, Lys-PEG/GLP-1 not only stimulated insulin release from rat pancreatic 
islets in vitro with a comparable potency to that of GLP-1, this also occurred in a 
glucose-dependent and concentration-dependent manner. Responses to glucose also 
appeared to stabilise following i.p. injection of Lys-PEG/GLP-1 (9 nmol/kg) in non-
fasted db/db mice, and the PEGylated analogue displayed improved potency with regard 
to modulating glucose levels, compared with GLP-1 (Lee et al., 2006). Pan et al 
engineered hybrid peptides which displayed both GLP-1 agonism and glucagon 
antagonism, as a result of targeted mutations. Site-specific PEGylation at the C terminus 
with either a 22 kDa or 43 kDa PEG-maleimide resulted in retention of in vitro 
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biological activity and a significantly prolonged mechanism of action in vivo (Pan et al., 
2006). 
 
The success of PEG modified GLP-1 agonists led to the pursuit of long acting 
analogues of PYY and PP for potential treatments of obesity. In 2007, a novel Y2 
agonist was synthesised and conjugated with either a linear PEG (5 or 20 kDa) or 
branched PEG (40 kDa) at the N terminus via a Cys residue (DeCarr et al., 2007). 
Administration of PEG5-modified PYY(24-36)-Leu
31 
(5.6mol/kg) in mice induced a 
reduction in food intake, although this was not greater than that observed with PYY(3-
36). Increasing the PEG size to 40 kDa (PEG40-PYY(24-36)-Leu
31
, 5.6mol/kg) resulted 
in inactivity in vivo within the first four hours of administration, however a small but 
statistically significant reduction in food intake of 12% and 8% was seen at 24 and 48 
hours, respectively. Interestingly, an intermediary PEG size of 20 kDa (PEG20-
PYY(24-36)-Leu
31
, 5.6mol/kg) led to comparable reduction in food intake to PYY(3-
36), however unlike the native hormone, this effect was sustained from 4 to 24 hours 
and remained significant at 48 hours. Thus, this study demonstrated superior in vivo 
efficacy following a 20 kDa PEG modification of PYY(3-36) whilst a minimal effect 
feeding was observed after conjugation with a 40 kDa PEG, highlighting the 
significance of the PEG molecular weight in determining exposure at the drug target 
site. In addition, DeCarr et al. (2007) reported that the N-terminal modification of 
PYY(24- 36)-Leu
31
 was tolerated with a reduced EC50 of approximately 6-fold. On the 
contrary, modification of the C-terminus of PYY(24-36)-Leu
31
 was detrimental to in 
vitro receptor binding.  
 
Consequently, Ortiz et al. (2007) synthesised a novel selective Y2 receptor agonist, 
consisting of a peptide core PYY(13-36) and an N-terminally located non-peptidic 
moiety (2-mercaptonicotinic acid) linked to a 20 kDa PEG polymer. The in vitro 
pharmacological profile was assessed and compared with a previously published 20 kDa 
PEG-PYY analogue with a shorter peptide core (PYY(25-36); Lumb et al., 2007). Use 
of the longer peptide core corresponding to residues 13 to 36 of hPYY increased the in 
vitro Y2 potency 4-fold compared with the original shorter PYY analogue, with Ki and 
EC50 values of 9.1 ± 2.2 and 6.5 ± 1.6 nM, respectively. Importantly, the longer peptide 
core did not exhibit high selectivity for the hY1 and hY5 receptors (Ki = 760 ± 70 and 
630 ± 30 nM, respectively). Additionally the peptide was able to bind rodent Y2 
receptors with similar affinity to the h receptor, with Ki values of 21 ± 2 and 31 ± 6 nM 
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for the mouse (whole brain) and rat (hippocampus) Y2 receptors, respectively. 
Therefore, increasing the length of the peptide core improved in vitro receptor affinity 
while maintaining a high degree of specificity for the Y2 receptor. In lean C57BL/6 
mice and Wistar rats, the PEG-modified PYY(13-36) analogue elicited a dose-
dependent reduction in food intake which continued for 72 and 48 hours, respectively. 
Administration of the Y2 antagonist, BIIE0246, abolished the inhibition of food intake 
in lean C57BL/6 mice, providing evidence of Y2 selectivity with the PEGylated peptide. 
Daily dosing of the PYY analogue for 14 days in diet-induced obese (DIO) mice 
resulted in a dose-dependent reduction in body weight, which also persisted following 
dosing for 40 days (Ortiz et al., 2007).  
The data published by Lumb et al. (2007) and Ortiz et al. (2007) exemplifies a strategy 
to attain a series of selective Y2 receptor peptide agonists which have been modified by 
an N-terminally located non-peptidic moiety and a 20 kDa PEG polymer. The structural 
features of these peptides have included improved in vitro Y2 receptor potency (more so 
with the longer peptide core), enhanced Y2 receptor selectivity over the Y1 and Y5 as 
well as improved in vivo efficacy as a result of the PEG polymer conjugation. These 
groups have thus generated a selective Y2 peptide agonist which outperforms the 
clinical candidate PYY(3-36) in reducing food intake in both lean mice and leans rats 
following a single dose. Furthermore, the results provide preclinical evidence in two 
animal species that this peptide has potential for the management of obesity via 
selective activation of the Y2 receptor. 
 
1.4.3 Lipidation of peptides 
The principle behind lipidation involves the attachment of an acyl group to a peptide 
backbone; this provides it with the ability to non-covalently bind to plasma proteins, 
such as albumin and thus protect the peptide from enzyme degradation. Just as a PEG 
side chain sterically shields the peptide, the lipid moiety is thought to behave in the 
same way. The ability of a lipid moiety to facilitate plasma protein binding has been 
studied extensively by Kurtzhals et al. (1995).  They investigated the binding of 
immobilised human serum albumin to various derivatives of lipidated insulin. It was 







which interestingly was dependent on non-polar and ionic interactions and less so on 
lipid chain length. 
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Inspired by this, Bellman-Sickert et al. (2011) developed the first lipidated (and 
PEGylated) dual Y2/Y4 analogue for the treatment of obesity. A Lys linker at position 
13 was introduced to Obinepitide (TM30338) to enable site-specific modification with a 



















revealed nanomolar affinities for both hY2 and hY4 receptor (IC50 = 1.1 and 2.1 nM, 
respectively). Modification with the palmitoyl moiety was not detrimental to Y2 
receptor binding capacity (IC50 = 0.6 nM) but a modest loss at the Y4 receptor was 
reported (IC50 = 26.0 nM). While modification with PEG2 did reduce the affinity 
marginally compared to the unmodified ligand (IC50 was reported as 2.3 and 4.5 nM for 
Y2 and Y4, respectively), increasing the PEG size (PEG20) dramatically decreased Y2 
and Y4 receptor affinity (IC50 = 34.0 nM and 231.0 nM, respectively). Proteolytic 
stability studies in human blood plasma also revealed increased resistance with the long 









]hPP both demonstrated approximately 10% degradation, compared 




]hPP, both of which rapidly metabolised with a 




]hPP was observed but to a much 





]hPP is unexpected, as several groups have demonstrated a much higher 
stability with PEGylated peptides. For example, Na et al., (2004) revealed no 
degradation of PEGylated salmon calcitonin (sCT) after incubation with nasal mucosa, 
compared with the unmodified sCT, which rapidly degraded by half with the 
observation period of 70 min. The data reported by Bellman-Sickert et al., (2011) 
suggests that increasing the size of the PEG side chain may be detrimental to the 
receptor binding affinity and thus it is essential to determine the PEG size threshold at 
which the binding affinity is retained for the receptor.  
 
Several groups have studied the effect of varying the fatty acid length on peptide 
stability; Yamamoto et al. (2003) observed dramatic stabilisation in skin homogenates 
following tripeptide acylation with increasing fatty acids, butyric, hexanoic, and 
octanoic acid. This data supports that of Bellman-Sickert et al. (2011) where little 
degradation was seen with the lipidated peptide. Importantly, Bellman-Sickert et al. also 
demonstrated prolonged anorexigenic effects with the lipidated hPP analogue. 




]hPP peptide (3 mg/kg) in mice significantly 
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reduced food intake within 0.5 hours compared to vehicle treated mice. Although a 
reduction in food intake was not observed within 4.5 hours of administration of the 
palmitoylated variant, accumulated food intake remained lower compared to control 
mice throughout the total observation period of 12 hours. A further example of an 
improved pharmacokinetic profile obtained by successful fatty acid (C16) acylation is 
the successful GLP-1 derivative, liraglutide. Slow release from the injection site and 
increased protection from DPP-IV degradation are the two key benefits that the GLP-1 
analogue has acquired through lipidation (Knudsen et al., 2000). The increase in plasma 
stability (and thus half life) is substantial; subcutaneous injection of the peptide in pigs 
has shown an increase in plasma half life from 1.2 hours to 14 hours following chemical 
modification (Knudsen et al., 2000). As a result, the peptide can now be used as a once 
daily subcutaneous injection in the treatment of type 2 diabetes (Ribel et al., 2002; 
Arulmozhi and Portha, 2006). 
As described above, significant advances have been achieved by the synthesis of 
peptides with additional chemical modifications to overcome limitations such as 
proteolytic susceptibility and limited bioavailability. PEG/lipid modifications have 
proved useful as tools in increasing the efficacy of novel peptide analogues and 
therefore may have promising therapeutic potential.  
 
1.5 The role of the PP family in gastrointestinal functions 
1.5.1 Intestinal anatomy and coordination of the ENS  
Gastrointestinal function depends on the coordinated activity of enteric neurones within 
the GI tract (Bayliss and Starling, 1899). The ENS is composed of enteric ganglia, the 
neural connections between these ganglia, and nerve fibers that supply effector tissues, 
including the muscle of the gut wall, the epithelial lining, intrinsic blood vessels and 
gastroenteropancreatic endocrine cells (Figure 1.8). Two plexuses comprise the ganglia 
which are involved in the intrinsic innervations of the gut ENS (see section 1.1.5.3); the 
myenteric plexus (or Auerbach’s plexus) and submucosal plexus (or Meissner’s plexus). 
The former is situated between the outer longitudinal and the inner circular muscle 
layers and the latter is found between the muscularis mucosae and the circular muscle 
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Figure 1.8 The organisation of the ENS of mammalian small intestine. The 
ganglionated myenteric and submucosal plexus are situated between the longitudinal 
and circular layers of the external musculature and between the muscularis mucosae and 
the circular muscle, respectively. The two plexuses are interconnected via nerve fibre 
bundles which subsequently innervate the longitudinal and circular muscle layers, as 
well as the muscularis mucosae, intrinsic arteries and the mucosal lining (taken from 
Furness, 2012). 
 
The ENS has multiple roles: determining the patterns of movement of the 
gastrointestinal tract; controlling gastric acid secretion; regulating movement of fluid 
across the lining epithelium; changing local blood flow; modifying nutrient handling; 
and interacting with the immune and endocrine systems of the gut (Furness, 2006). The 
ENS also contributes, along with glial cells, to maintaining the integrity of the epithelial 
barrier between the gut lumen and cells within the gut wall (Toumi et al., 2003; Savidge 
et al., 2007). At least 11 different types of neurones in the myenteric plexus of guinea-
pig ileum have been identified based on their neurochemistries and projections (Costa et 
al., 1996). If results from retrograde tracing of neuronal projections in the submucosal 
plexus are included, then 18 different neuronal subclasses can be identified in the 
guinea-pig ileum (Brookes, 2001). The neurones of the ENS can be split into four main 
categories: motor neurones supplying either the circular or longitudinal muscle layers, 
interneurones, intrinsic primary afferents (IPANs) and secretomotor neurones. 
 
In the guinea-pig small intestine, the enteric inhibitory motor neurones supplying the 
circular muscle represent about 12% and the excitatory motor neurones innervating this 
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muscle layer are about 10% of the total number of myenteric neurones (Costa et al., 
1996; Grider et al., 1998). Identification of transmitters used by enteric motor neurones 
advanced in parallel with the discovery that each class of enteric neurone may utilise 
multiple transmitters. This began with the identification of neurokinins (NK) as co-
transmitters with acetylcholine (ACh) of the excitatory enteric motor neurones (Taylor 
and Bywater, 1983; Holzer et al., 1993). Inhibitory neurones also express multiple 
transmitters with the relative importance of each varying with the region of the digestive 
tract and species; ATP, nitric oxide (NO), VIP, NPY and pituitary adenylyl cyclase 
activating peptide (PACAP) have all been identified as mediators of inhibitory 
neuromuscular transmission (Lecci et al., 2002; Furness, 2006). VIP and PACAP are 
co-localised with NOS within inhibitory motor neurones (Brookes and Costa, 2002). 
This basic pattern holds true for most species including the guinea-pig, mouse, rat and 
human (Porter et al., 1997; Sang and Young, 1998; Lomax and Furness, 2000). 
 
In addition to the myenteric motor neurones, 16% of the myenteric nerves are 
interneurones that contain ACh co-released with various transmitters, depending on the 
function of the interneurone. For example, ascending interneurones involved in local 
reflexes co-release NK whereas descending local reflex interneurones co-release 
VIP/NOS/NPY/bombesin. Other myenteric interneurones are involved in secretomotor 
reflexes (containing ACh and 5-HT) or migrating myoelectric complexes (containing 
ACh and somatotropin release-inhibiting factor, SRIF) controlling mucosal ion 
transport and maintaining intestinal motility, respectively (Furness, 2000). 
 
Sensation of the gut is transmitted via myenteric and submucosal IPANs or via extrinsic 
afferents from the spinal column. IPANs of the intestine are specialised neurones that 
encode information about the state of the intestine by transducing mechanical and 
chemical stimuli that reflect tension in the gut wall and the chemical nature of its 
contents. They connect with interneurones and motor neurones to form the circuits of 
intrinsic muscle motor, secretomotor and vasomotor reflexes. The IPANs are 
characterised by Dogiel type II morphology, with a slow after hyperpolarisation 
potential, which co-release ACh and NKs, although calcitonin gene-related peptide 
(CGRP) has also been identified in mouse colon (Furness et al., 2004). Following 
activation, IPANs release substance P (Kirchgessner et al., 1992) which stimulates NK 
receptors on submucosal neurones and leads to activation of secretomotor neurones. 
Stimulation of this intramural pathway leads ultimately to release of VIP and ACh onto 
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epithelial receptors resulting in Cl
-
 secretion e.g. as demonstrated in guinea pig colon 
(Weber et al., 2001). Activation of IPANs and extrinsic primary afferents also results in 
release of SP and activation of excitatory smooth muscle motor neurones e.g. as 
observed in guinea pig ileum (Bartho et al., 1994; Bartho et al., 1999). 
 
Enteric reflexes, through activation of secretomotor neurones, move water and 
electrolytes from the interstitium of the lamina propria to the lumen, thereby controlling 
epithelial ion secretion. Enteric secretomotor reflexes also modulate blood volume and 
blood pressure detectors that change the activity of two sympathetic pathways; 
vasoconstrictor pathways and secretomotor inhibitory pathways (Furness, 2006). The 
enteric receptor for glucose, composed of T1R2 and T1R3 subunits, is located on 
enteroendocrine L cells (Shirazi-Beechey et al., 2011). Stimulation of these cells 
releases the endocrine hormones: GLP-1 and GLP-2, oxyntomodulin and PYY. 
Receptors for GLP-2 are on noncholinergic secretomotor neurones, which are activated 
by this hormone (Sigalet et al., 2007; Shirazi-Beechey et al., 2011). Thus, activation of 
the enteric receptor by glucose stimulates secretomotor neurones to return water and 
electrolytes to the lumen. Other endocrine products of L-cells, such as PYY, are 
involved in a range of functions, including modulation of fluid secretion, inhibition of 
gastric emptying, promotion of satiety, stimulation of epithelial cell growth and 
regulation of insulin secretion (Estall and Drucker, 2006; Sigalet et al., 2007; Cox, 
2007). The modulation of ion secretion by PYY and other members of the PP family is 
discussed below (see section 1.5.3.2). 
 
1.5.2 Smooth muscle contraction 
Reports suggest that the PP family can modulate smooth muscle contraction. The 
majority of studies examining the effects of PYY on colonic motor function have been 
performed in vitro (Ferrier et al., 2000; Hyland et al., 2003; Pheng et al., 1999; Sawa et 
al., 1995); electrically stimulated contractions in colonic muscle strips of guinea pig 
were inhibited following superfusion of PYY (Sawa et al., 1995) although PYY has also 
been shown to induce an elevation in basal contraction in vitro in longitudinal muscle 
from mice (Hyland et al., 2003), rats (Ferrier et al., 2000; Ferrier et al., 2002; Pheng et 
al., 1999), and human (Ferrier et al., 2002) colonic tissue. In 2011, Tough et al. 
demonstrated transient longitudinal muscle contractions after the addition of PYY (30 







 tissue. Basal tension or spontaneous 
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activity were unaltered in the presence of either BIBO3304 nor BIIE0246, indicating a 
lack of endogenous contractile tone in WT colon, however BIIE0246 did inhibit the 
subsequent response to PYY and a similar inhibition was seen with both Y1 and Y2 
receptor antagonism. This data corroborated previous studies showing PYY(3–36)-
mediated contraction in Y2
+/+
 colonic muscle, but not in  Y2
-/- 
tissue (Hyland et al., 
2003). Studies in mice (Hyland et al., 2003) and rats (Feletou et al., 1998; Ferrier et al., 
2000; Pheng et al., 1999) have revealed colonic longitudinal smooth muscle 
contractions in response to PP. In 2010, Moriya et al. demonstrated a dose-dependent 
increase in faecal weight following peripheral administration of PP in mice, and that 
faecal output in response to PP was almost completely inhibited in Y4
-/-
 mice. The data 
published by Moriya et al. was supported by a previous report (Wager-Page et al., 
1993) in which an increase in colonic intra-luminal pressure was observed with 
intravenous (i.v.) bolus injections of PP in anesthetised rats, indicative of colonic 
contractions. Furthermore, PP-induced colonic transit may be used to explain an early 
study in which genetically obese ob/ob mice exhibited diarrhoea after chronic PP 
treatment (Mordes et al., 1982). To summarise, PYY and PP coordinate changes in the 
patterns of smooth muscle contraction in wild-type colon via stimulation of Y2 and Y4 
receptors. Given that Y receptors are pivotal in intestinal absorption (see section 1.5.3), 
it is thought that these contractions play a modulatory role in the final integrated 
intestinal response. 
 
1.5.3 Epithelial ion transport 
1.5.3.1 Physiology of colonic epithelial ion transport 
The key function of the proximal colon is absorption of salt and water. Bulk transport of 









3 exchange. The remaining absorption is electrogenic and is due to 
absorption via luminal epithelial Na
+
 channels and transcellular/paracellular absorption 
of Cl
-




 absorption is present throughout the human colon. The hallmark of 
this process is the presence of epithelial Na
+
 channels (ENaCs). ENaCs, comprised of 
2α/2β/1γ subunits (Canessa et al., 1995) are located apically in colonic epithelial cells, 
through which 3 Na
+
 ions are exchanged for the basolateral uptake of two K
+
 ions, 
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in the net transfer of one positively charged Na
+
 ion across the basolateral membrane. 
Na
+
 ions diffuse into the cell along a favourable electrochemical gradient. This gradient 
reflects the low potential difference across the basolateral membrane exceeding that 
across the apical membrane, resulting in a substantial lumen negative transmucosal 
potential difference in healthy human colon in vivo and in vitro, which largely reflects 
electrogenic Na
+
 transport (Sandle et al., 1986). An interesting feature of the 
electrogenic Na
+
 absorptive process in high transepithelial resistance epithelia is the 
extreme sensitivity to micromolar concentrations of the diuretic, amiloride and related 
diuretic compounds (Canessa et al., 1994; Barbry and Hofman, 1997). In general, apical 
addition of amiloride produces Na
+
 channel blockade, inhibition of electrogenic Na
+
 
absorption, and a reduction or abolition of the transepithelial potential difference. In the 
human colon, the nature and distribution of apical Na
+
 conductances, and their 
responses to amiloride, is complex; under in vitro conditions, addition of 0.1–1.0 mM 
amiloride to distal colon decreases the potential difference by 61–94% and the short 
circuit current (Isc: an indicator of net transepithelial ionic transport when the potential 
difference is electrically “clamped” to zero) by 76–93%, whereas in proximal colon the 
electrical changes are minimal (Sandle et al., 1986). 
 







transporter (NKCC1) allows the re-entry of Na
+
 into the cell, thus resulting in an 
increase in intracellular Cl
- 
concentrations. The increase in intracellular Cl
- 
subsequently 
inhibits the activity of the ENaCs, leading to a reduction in NaCl absorption (Konig et 
al., 2001). Furthermore, basolateral K
+
 channels work to rectify increased intracellular 
K
+
 levels; the PKA-activated KVLQT1 channels and Ca
2+
 activated intermediate 
conductance K
+
 (IK) channels, through which K
+
 ions are recycled and hyperpolarise 
the cell, maintain Cl
-
 secretion.  
 
Studies in isolated sheets of human sigmoid colonic and rectal mucosa have shown that 
1 mM amiloride applied apically, decreases the Isc to a far greater extent than net Na
+
 
absorption, which suggests that a substantial fraction of net Na
+
 absorption is mediated 
by a process other than amiloride-sensitive electrogenic Na
+
 transport (Rask-Madsen 
and Hjelt, 1977). It is also clear from other studies that net Na
+
 absorption exceeds the 
Isc, and there is considerable net Cl
−
 absorption in the proximal, transverse and distal 





 absorptive process is present in all segments of the 
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colon. Furthermore, net Cl
−
 absorption and net Na
+
 absorption are equal and in part 
regulated by intracellular pH, as both are inhibited by acetazolamide, a carbonic 
anhydrase inhibitor that reduces endogenous HCO3
-
 production (Foster et al., 1983). In 
crypt and surface epithelia, Na
+
 is taken up from the apical side of the epithelium by 




 exchangers (NHE2 and NHE3). So far, three types of NHE in 
colonic epithelia have been detected. The profuse type 1 NHE is localised to the 
basolateral membrane and NHE2 and NHE3 are both expressed on the apical side of 
colonic epithelial cells, and it is thought that under control conditions, NHE3 
contributes largely to the Na
+
 absorption (Ikuma et al., 1999). Electroneutral NaCl 




 exchange; functional studies in epithelia have 




 exchangers, the 
downregulated adenoma (DRA) protein and the anion exchanger (AE). AE1 exists on 
the apical domain, whereas the AE2 protein exists basolaterally.  
 
Secretion and absorption are controlled by endocrine, paracrine, autocrine, 
immunologic, and neuronal stimuli. The major neuronal impact is due to the myenteric 
and submucosal plexi which innervate both epithelial and vascular smooth muscle cells, 
thereby controlling intestinal blood flow, secretion, and absorption in the colonic 
mucosa (Keast, 1987; Suprenant, 1994). Secretion of electrolytes is evoked by a variety 
of secretagogues, such as acetylcholine (Mall et al., 1998), vasoactive intestinal 
polypeptide (VIP; Fuchs et al., 1996), prostaglandins (Berschneider et al., 1988) and 
inflammatory mediators from enteroendocrine cells e.g. 5-HT (Borman and Burleigh, 
1996), as demonstrated in isolated human colonic mucosal preparations. One of the 
most prominent secretagogues, VIP, acts via increases in intracellular cAMP (Barrett 
and Keely, 2000); activation of the epithelial Gs coupled VPAC receptors leads to an 
elevation in the intracellular cAMP levels and hence an increase in protein kinase A 
(PKA) activity. As a result, PKA- sensitive CFTR channels, located apically, become 
phosphorylated and subsequently open (McDonald et al., 1995), resulting in Cl
-
 
secretion. Ion transport studies in CFTR
-/-
 mice or cystic fibrosis (CF) patients have 
helped elucidate the importance the CFTR channel in electrogenic Cl
-
 secretion and 
have demonstrated the necessity of functional CFTR channels in agonist-induced 
secretion. In CFTR
-/-
 mice, no secretory responses was observed to forskolin-mediated 
AC activation (Cuthbert et al., 1994a), guanylate cyclase activation (Cuthbert et al., 
1994b) or increased intracellular Ca
2+  
levels by carbachol (Cuthbert et al., 1994b) or 
lysylbradykinin (Cuthbert and Huxley, 1998) with isolated colon. Furthermore, human 
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colon mucosa from CF patients demonstrated no response to cAMP-elevating agonists 
or muscarinic Ca
2+
-mediated responses (Berschneider et al., 1988). The process of 
epithelial electrogenic anion secretion is outlined in Figure 1.9. 
 
 
Figure 1.9 Cellular model for electrogenic Cl
-
 secretion in response to VIP-
stimulated mammalian colon. Na
+
 is taken up from the apical side of the epithelium 




-ATPase generates the driving force for the 
apical Na
+




 re-enters the cell via 






 co-transporter (NKCC1), thereby 
increasing intracellular Cl
-
 concentrations. Recycling of K
+
 taken in via the NKCC1 
transporter occurs via Ca
2+
-activated intermediate conductance K
+
 (IK) channels. 
VPAC1/2 receptor activation results in a rise in intracellular cAMP, thus leading to an 
increase in PKA activity. The apical PKA-sensitive CFTR channel is subsequently 
activated, leading to Cl
-
 ions exiting the cell via this route (Harmar et al., 2004; Banks 
et al., 2005). The increased intracellular cAMP also enhances basolateral K
+
 exit by 
activating KvLQT1 channels resulting in a continuous hyperpolarised membrane 
potential and the driving force for secretion of Cl
-
 out of the cell. Adapted from 
Kunzelmann and Mall (2002). 
 
The secretory action of hormones and neurotransmitters is balanced by the inhibitory 
effects of neuropeptides, endogenous opiates, noradrenaline and growth hormones. 
Amongst these include the PP family of peptides, whose inhibitory actions on ion 
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1.5.3.2 The ability of the PP family to inhibit of ion transport in colonic epithelia  
Under voltage clamp conditions, electrogenic ion transport in polarised epithelial sheets 
or isolated mucosa can be measured, from which a resulting Isc can be recorded (for 
details see Chapter 2). This can be achieved with the Ussing chamber, which was 
originally developed in 1951 to investigate Na
+
 absorption in frog skin (Ussing and 
Zerahn, 1951). It has been well documented that each member of the PP family can 
reduce Cl
-
 secretion in a number of rodent and human models, as demonstrated in 
colonic epithelial preparations, either in culture or with muscle-stripped mucosa. Friel et 
al. (1986) were the first to report the antisecretory effects of NPY and PYY in guinea 
pig and rabbit ileum; this group demonstrated reduced Cl
-
 transport from serosa to 
mucosa in the presence of NPY. This was later corroborated by Cox et al. (1988) who 
showed NPY-mediated reductions in Isc and Cl
-
 secretion in muscle-stripped rat jejunum 
and descending colon, however only basolateral additions of PYY and NPY were able 
to inhibit the Isc. The authors reported that this effect was dependent upon endogenous 
eicosanoid formation since it was blocked by the cyclooxygenase inhibitor, piroxicam, 
reducing electrogenic chloride secretion presumably as a consequence to elevated Isc 
levels. The authors also demonstrated that NPY responsiveness could be restored, in 
piroxican pre-treated tissues, or by VIP, forskolin, prostaglandin E2 (PGE2), isobutyl-1-
methyl-xanthine (IBMX) and dibutyryl cAMP added prior to the neuropeptide. Several 
groups have now provided strong evidence for the inhibitory actions of the PP family in 
rabbit (Hubel and Renquist, 1986), guinea pig (McCulloch et al., 1987), rat isolated 
intestinal mucosa (Cox and Cuthbert, 1988; Cox and Cuthbert, 1990; Strabel and 
Diener, 1995; Tough and Cox, 1996; Nakanishi et al., 1996; Whang et al., 1997) and 
mouse mucosa, where Y1, Y2 and Y4 receptors are found (Cox et al., 2001a; Cox and 
Tough, 2002). Extensive studies have also been performed using human colon mucosa, 
demonstrating the anti-secretory response to Y1, Y2 and Y4 receptor activation (Cox and 
Tough, 2002). The authors determined that only anti-secretory responses to the Y2 
responses were sensitive to the effects of tetrodotoxin (TTX), in contrast to both the Y1 
and Y4 receptors, which were unaltered, demonstrating that the Y2 receptor type is 
predominantly pre-junctional i.e. on neurones whereas the Y1 and Y4 receptors are post-
junctional i.e. on epithelia.  
 
In 1985 the human colonic adenocarcinoma (HCA) cell line, HCA-7, was first 
established. Due to the heterogenous nature of this cell line, nine subpopulations in total 
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were isolated based on their morphology using cloning cylinders (Marsh et al., 1993). 
Of the nine subpopulations, three were found to constitutively express Y receptors: 
Colony 1 (Col-1; Y4), Colony 6 (Col-6; Y1 and Y4) and Colony 24 (Col-24; Y4). Once 
grown to confluence on semi-permeable supports, they form a polarised sheet 
(Kirkland, 1985), and ion transport studies can subsequently be performed. RT-PCR 
performed by Cox et al. demonstrated that Col-24 and to a lesser extent Col-6 cells 
express the Y4 receptor in contrast with HT-29 negative controls that Y4 receptor 
expression (Cox et al., 2001b). Functional ion transport studies with Col-24 and Col-1 
cells by the same group demonstrated receptor localisation at the basolateral domain, 
since basolateral additions of PP (following stimulation with VIP; Holliday et al., 1997; 
Cox et al., 2001b) were effective, in contrast to significantly smaller reduction in Isc 
when the peptide addition was made to the apical compartment. Furthermore, PYY was 
ineffective in either Col-24 or Col-1 indicating Y4 expression only, whereas Col-6 cells 
exhibited sensitivity to hPP, PYY, NPY and Pro
34
NPY, demonstrating both Y1 and Y4 
receptor expression (Cox and Tough, 1995). Responses to hPP in either Col-6 or Col-24 
cells were unaltered in the presence of the Y1 antagonist BIBP3226; however PYY and 
Pro
34
NPY responses in Col-6 cells were attenuated by BIBP3226 (Tough and Cox, 
1996) indicating predominant Y4 receptor activation with hPP in Col-24 cells. Different 
species PP stimulated responses in Col-24 with Y4-like pharmacology. bPP, hPP and 
pPP were equipotent while rPP, avian (a)PP and (Pro
34
PYY) were significantly less 
potent. Homologous PP desensitisation was also observed in Col-24 cells within 20 min 
of adding the first addition of PP, indicating that the different species PP (bPP, hPP and 
pPP) were activating the same population of Y4 receptors. Therefore, these functional 
ion transport studies have demonstrated Y4 receptor expression in Col-24 and Col-1 
cells, and both Y1 and Y4 receptor expression in Col-6 cells. 
 
1.6 The GIPIO collaboration 
This project was funded by the European Union's Seventh Framework Programme 
(Grant Agreement No. 223057) and coordinated by University of Leipzig. The GIPIO 
(Gastrointestinal Peptides in Obesity) collaboration was set up with EU (FP7) funding 
in 2008 in which a consortium of 4 academic institutions (Universities of Leipzig, 
Copenhagen and Dresden, and King’s College London) and 3 medium sized 
pharmaceutical companies (7TM Pharma, Zealand Pharma and PolyPeptide) were 
involved. The focus of this collaboration was to determine the contributions of key GI 
peptides in the regulation of food intake, specifically PP and PYY, with the aim to 
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develop potential anti-obesity agents that mimicked these endogenous gut hormones. 
With the promising results of Obinepitide and TM30339 in preclinical and clinical trials 
(7TM Pharma, 2008), the collaboration aimed to modify and optimise these peptides 
(via PEGylation and lipidation) to improve their metabolic stability and 
pharmacokinetic profile. A series of peptide variants based on the parent peptides 
(Obinepitide and TM30339) were subsequently produced by synthetic approaches 
(Bellmann-Sickert et al., 2011) and the investigation of these novel peptides at the 
molecular, cellular, tissue and whole animal levels was performed. 
 
1.7 Aims 
The aim of this PhD project within the GIPIO collaboration was to provide the in vitro 
pharmacological data to aid the progression of the most promising peptide candidates. 
The initial aims of this study were to characterise and compare Y receptor-mediated 
anti-secretory responses to novel dual Y2/Y4 and single Y4 receptor agonists in an 
attempt to establish the consequence of chemical modification on the pharmacological 
profiles in vitro, using an optimised Y4 expressing cell line (Col-24) and human colon 
mucosa, expressing both Y2 and Y4 receptors (as well as Y1). We sought to establish 
whether PEGylation and/or lipidation, of different size and chain length, respectively, 
would prolong the longevity of action compared with the native hormones, and whether 
potency and efficacy would be altered by these modifications. During the course of the 
study, we also set out to ascertain the receptor types mediating the anti-secretory 
response in human mucosal tissue, using selective Y1 and Y2 antagonists to establish the 
selectivity of the novel analogues. Having established the pharmacology, we 
investigated whether PEGylation or lipidation of the peptides altered subsequent Y4 
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2.1 Materials 
2.1.1 Peptides 
All commercially available peptides, unless stated otherwise, were acquired from 
Bachem Laboratories Inc. (Merseyside, U.K.). Once diluted in distilled H2O, 
subsequent aliquots were frozen at -20°C and underwent one freeze-thaw cycle prior to 
use. In this study, the porcine peptide sequence of VIP and the human sequences of PP, 
PYY and somatostatin (14-28) were used. hPP and all hPP analogues were synthesised 
and provided by Prof. A. Beck-Sickinger’s group (University of Leipzig, Germany) and 
have been listed in Table 2.1. 
 
Parent peptide Amino acid alteration Chemical conjugation Receptor preference 
hPP   Y4 
Obinepitide 
(TM30338) 
Q34 [Q34]hPP Dual Y2/Y4 
 K30, Q34 [K30(E-Pam)Q34]hPP Dual Y2/Y4 
 K30, Q34 [K30(PEG2)Q34]hPP Dual Y2/Y4 
 K30, Q34 [K30(PEG5)Q34]hPP Dual Y2/Y4 
 K30, Q34 [K30(PEG22)Q34]hPP Dual Y2/Y4 
 K22, Q34 [K22,Q34]hPP Dual Y2/Y4 
 K22, Q34 [K22(PEG5)Q34]hPP Dual Y2/Y4 
 K22, Q34 [K22(PEG22)Q34]hPP Dual Y2/Y4 
 K22, Q34 [K22(E-Pam)Q34]hPP Dual Y2/Y4 












Table 2.1 Summary of the PEG/lipid-modified peptides based on the human PP 
sequence and their Y2 and/or Y4 receptor preferences. The colours used above are 
those adopted in the results section for specific analogues. Caprylic acid (C8), lauric 
acid (C12) and palmitic acid (C16) have been abbreviated to E-Capr, E-Laur and E-
Pam, respectively, and these abbreviations have been used throughout this thesis.  
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2.1.2 Non-peptides 
The Y1 and Y2 receptor antagonist, BIBO3304 and BIIE0246, respectively, were 
provided by Boehringer Ingelheim Pharma KG (Biberach an der Riss, Germany). Each 
antagonist was diluted in dimethyl sulphoxide (DMSO) (10%), aliquoted, stored at -
20°C and discarded 48 hours after one freeze-thaw cycle. UK 14,304 (5-bromo-N-(4,5-
dihydro-1H-imidazol-2-yl)-6-quinoxalinamine), the α2-adrenoreceptor agonist (diluted 
in 10% DMSO) was purchased from Research Biochemical International (Natick, MA, 
U.S.A.). The apical Na
+
 channel blocker, amiloride, was purchased from Sigma (Poole, 
U.K), and the NKCC1 blocker, bumetanide, was purchased from Alexis Biochemicals 
(Nottingham, U.K). PEG polymers and fatty acids (caprylic acid, lauric acid and 
palmitic acid) were purchased from Sigma-Aldrich (Poole, U.K). Other additional 
reagents were sourced from Sigma (Poole, U.K.). 
 
2.2 Human tissue collection and preparation 
Human specimens taken from the distal colon were attained from patients undergoing 
resection surgery for primary carcinoma. Colonic specimens were taken from one of 
two procedures: (i) anterior resection or (ii) right hemi-collectomy. 24 hours prior to 
each procedure, informed written consent was obtained, along with ethical approval for 
the use of human tissue by The Guy’s and St Thomas’ Hospital Ethical Research 
Committee. Only gender, age, and procedure type was recorded in this study, and all 
other data remained anonymous, including previous or current medical history. 
Following excision from the patient, colonic segments were dissected (with a minimum 
margin of 10 cm from the carcinoma) by a consultant histopathologist. The specimen 
was then placed in Kreb’s- Henseleit solution (KH, composition in mM: NaCl 118, KCl 
4.7, NaHCO3 25, KH2PO4 1.2, MgSO4 1.2, CaCl2 2.5, glucose 11.1; pH 7.4) until 
muscle dissection. Using a dissection blade and a wax dissection bed, the mucosa was 
removed from the overlying smooth muscle layers and then divided into similar-sized, 
adjacent preparations. Each mucosal piece was subsequently mounted between 2 halves 





depending on the amount of mucosa available per specimen. Both the basolateral and 
apical sides were kept bathed in KH (5 ml, 37°C) and continually aerated with 95 % O2 
and 5 % CO2. 
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2.3 Cell culture 
Col-24 cells are derived from a HCA-7 cell line (Marsh et al., 1993) and once grown to 
confluence, the cells are able to form a polarised epithelial monolayer. Col-24 cells 
were maintained as described previously (Cox and Tough, 1995); cells were optimally 
grown at 37ºC in 25 cm
2
 Falcon flasks (Beckton Dickinson, U.S.A.), and kept in a 
humidified atmosphere of 95% O2/5% CO2. Dulbecco’s modified Eagle’s medium 
(DMEM; Invitrogen, U.K.) supplemented with 10% foetal calf serum (FCS) 
(Invitrogen, Paisley, U.K.), glucose (25 mM), and the antibiotics kanamycin (100 μg ml-
1
) and amphotericin B (1.2 μg ml-1) (purchased from Sigma, Poole, U.K.), was used to 
maintain the cells and replaced on a twice weekly basis. Upon becoming confluent 
(within 6 days), the cells were cleansed with 10 ml versene followed by trypsinisation 
(0.5 % w/v in versene; Worthington Biochemical Corporation, Lorne Labs, U.S.A.). To 
maintain growth, cells were split at a ratio of 1:5. Only Col-24 cells between passages 
11-24 were used in this study; additional stocks at a low passage were frozen in liquid 
nitrogen (with supplemented DMEM containing 10 % DMSO), for use in later 
experiments. 
 
2.4 Preparation of epithelial monolayers 
For ion transport studies, Col-24 cells were grown onto Millipore HAWP filters (25 mm 
diameter, pore size 0.45 μm). The filters were prepared by coating with collagen (0.25 
% w/v solution of Type VII from rat tail in 0.2 % acetic acid) and air-dried at room 
temperature for 2 days prior to use. The collagen ensured that the cells grew basolateral 
side down. Once dry, a sylgard ring (2 mm thick with central well area of 0.2 cm
2
) was 
attached to each filter using a silicone adhesive, and each filter was placed under a short 
wave ultraviolet lamp and sterilised with at least 24 hour irradiation. Once each filter 
was prepared, Col-24 epithelia in 25 cm
2
 flasks were trypsinised (as described above), 
and re-suspended in 2.4 ml DMEM. 100 μl of cell suspension (~ 2 x 106 cells) was then 
seeded into the central well of each filter. 4 seeded filters were then placed into in 90 
mm petri dishes (Falcon, Beckton Dickinson, Oxford, U.K.) and suspended onto 12 ml 
DMEM. The filters were maintained under the same conditions as the Col-24 flasks. 
Epithelial layers reached confluence within 6 days, after which they were mounted in 
Ussing chambers and ion transport studies were carried out at 6, 7 and 8 days.  
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2.5 Measurement of electrogenic ion transport 
Human intestinal sections were orientated as a flat sheet to separate two halves of a 
perspex Ussing chamber and intestinal preparations or Col-24 epithelial monolayers 
were situated vertically such that the apical membrane (also referred to as the luminal-
side membrane) faced one chamber half, whereas the basolateral membrane (also 
referred to as the blood-side membrane) faced the other half-chamber, thus separating 
the KH buffer that independently bathed each chamber half. The Ussing chambers used 
had an exposed apex area of 0.2 cm
2
 for Col-24 monolayers or 0.64 cm
2
 and 0.14 cm
2
 
for human tissue. Reservoirs above each chamber were water jacketed to enable 
warming of KH buffer to 37ºC for the human preparations. Each reservoir was filled 
with 5 ml (human mucosa) or 15 ml (epithelial monolayers) of oxygenated (95% O2/ 
5% CO2) KH buffer. 
 
Under the above conditions, the intestinal mucosa or epithelial monolayer exhibited a 
spontaneous transepithelial voltage potential (Vt), measured by electrodes connected via 
salt bridges to each chamber half. The preparations were then voltage-clamped at 0 mV 
(as shown in Figure 2.1) using a DVC1000 voltage-clamp unit (World Precision 
Instruments, Stevenage, U.K.) as described in detail previously (Cox et al., 1988). 
Voltage clamping the potential to zero eliminated the passive transepithelial driving 
force created by the electrical potential across the epithelium. Thus, the potential 
difference was negated on both sides and the current flowing through the short-circuit 
was therefore a result of the net active transport of ions across the epithelia (Ussing and 
Zehran, 1951). The resulting short-circuit current (Isc, measured in μA per unit area) was 
monitored on an LCD screen on the DVC1000 and recorded continuously on a chart 
recorder (Kipp and Zonen, Lincoln, U.K.). A reduction in Cl
-
 secretion (from 
basolateral to apical domain) was measured as a reduction in Isc.  
 
Once mounted in chambers and voltage clamped, preparations were left to stabilise until 
a stable basal Isc was achieved (normally 30-60 min for human tissue and 10-20 min for 
epithelia). A 1mV pulse was applied at the start of each experiment and the resultant Isc 
deflection was used to calculate the transepithelial resistance (TER, measured in Ω.cm2) 
using Ohms law (TER=voltage/current), providing an indication of the confluence of 
each preparation. At least one preparation was used as a control within each set of 
experiments to counteract the variability between adjacent sections of human tissue.  
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Due to Gi coupling of the receptors, activation of the Y receptors leads to a reduction in 
cAMP-dependent Cl
-
 secretion. At the start of each experiment all Col-24 monolayers 
were pre-treated with VIP (30 nM) since activation of the Gs coupled VPAC1 receptors 
causes an elevation in Isc, which remains raised for at least 15 min. Once a maximal 
level of secretion was achieved, the addition of a Y agonist was made and a reduction in 
Isc was observed (see Chapter 3, Figure 3.1 for a trace representing changes in Isc to VIP 
and hPP). Since basal currents were high in human mucosa preparations, mucosal 
preparations were not pre-stimulated with VIP, thus demonstrating a more physiological 
situation. Where the effects of the Y1 and Y2 receptor antagonists, BIBO3304 (300 nM) 
and BIIE0246 (1 µM), were investigated on subsequent agonist responses in mucosal 
preparations, the equilibration period was at least 20 min prior to addition of agonists. 
Either somatostatin (100 nM) or the α2 adrenoceptor agonist, UK 14,304 (1 µM) were 
used to verify the anti-secretory capability of the preparation following the Y agonist 
response in Col-24 monolayers or human mucosa, respectively. All additions of 
agonists, antagonists and bumetanide (200 µM) were made to the basolateral reservoir, 
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Figure 2.1 The Ussing chamber system. Mucosal sheets of human colon or Col-24 
epithelial monolayers were placed between the two halves of the Ussing chamber, 
bathed with KH buffer on either side. Voltage electrodes, one on either side of the 
preparation (Vap and Vbl), measured the transepithelial voltage and the DVC1000 
imposed an equal and opposite voltage, set at 0 mV, which voltage-clamped the tissue. 
The tissue was short-circuited by injection of a current, adjusted via a feedback 
amplifier to keep the transepithelial voltage (Vte) at 0 mV, and the resulting Isc 
(measured in µA) was continuously recorded on a chart recorder. The system was 
configured so that a reduction in Cl- secretion from the basolateral to the apical side was 
measured as a decrease in Isc. This schematic has been adapted from Tough (2005). 
 
2.5.1 Measurement of time-dependence of agonist responses 
In Col-24 monolayers each filter was pre-treated with VIP (30 nM) for 15-20 min and 
once a stable maximal Isc was achieved, peptide analogues were added to the basolateral 
reservoir. The time-dependence of the Y receptor analogues were then determined 
where agonist responses were measured for 45 min in Col-24 monolayers and 60 min in 
human colon mucosa, at a concentration of 100nM. In the event of a waning Isc after 
VIP pre-treatment, responses were measured by drawing a straight line on the trace 
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which followed the Isc 5 min prior to agonist additions. The line was extrapolated over 
the duration of the agonist response profile and the maximal difference between the 
extrapolated line and the Isc was taken as the peak response. Time course profiles were 
constructed by pooling the individual observations at each time point after agonist 
addition (t=1, 2, 3, 4, 5, 10, and then every 5 min for the duration of the response). All 
values were then expressed as the mean ± 1 S.E.M., in μA.cm-2 over a period of 45 or 
60 min. 
 
2.5.2 Concentration-response relationships  
Non-cumulative concentration response curves were analysed by non-linear regression 
using the curve-fitting software, GraphPad Prism (V.501, San Diego, CA), to establish 
EC50 values (with 95% confidence limits). For short-acting peptides, peak responses 
were generally achieved within 5 min. For longer acting peptides where responses were 
slower to peak, values were taken at approximately 45 min after addition or the time at 
which the maximum reduction in Isc was observed.  
 
2.5.3 Measurement of Y4 receptor desensitisation 
Y4 receptor desensitisation was assessed by measuring the response to a near-maximal 
single concentration of hPP (10 nM) added either 25 min after an initial addition of hPP 
(10 nM) or another short-acting agonist, or in the case of long-acting Y4 agonists (100 
nM), at 45 min. In human colon mucosa where reductions in Isc were slower to peak, the 
response to hPP (100nM) was measured 60 min after an initial addition of a dual Y2/Y4 
or Y4 agonist (100nM).  
 
2.5.4 Data analysis and statistics  
Pooled data from Ussing chamber studies are quoted as μA.cm-2, mean ± 1 S.E.M. 
 
2.5.4.1 Concentration response curves 
Y agonist concentration-response curves were constructed from single peptide additions 
to mucosa or epithelial monolayers. Statistical significances between each analogue in 
terms of maximal response size were determined using one-way analysis of variance 
(ANOVA) with either Dunnett’s or Bonferroni’s post-tests where appropriate. Single 
comparisons were made using Student’s unpaired t-test. In all cases a P value of less 
than 0.05 was considered significant. For each curve the best fit was achieved by fixing 
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the minimum value response to 0 μA, while all other parameters, such as curve maxima 
and Hill slopes were allowed to vary, unless stated otherwise. 
 
2.5.4.2 Y4 Desensitisation 
Multiple comparisons of data groups were made using ANOVA with either Dunnett’s 
or Bonferroni’s post-tests where appropriate and single comparisons were made using 
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3.1 General observations 
3.1.1 Col-24 epithelial monolayers 
3.1.1.1 Comparison of electrical parameters 
Transepithelial resistance and basal Isc values were comparable to observations seen 
previously (unpublished data, Cox et al). Once epithelial monolayers reached 
confluence within 6 days, they were mounted in Ussing chambers and ion transport 
studies were carried out for three consecutive days. A one-way ANOVA with a 
Bonferroni’s post-test demonstrated no significant differences in the electrical 
parameters between 6, 7 and 8 days ( 
Table 3.1). 
 
 Day 6 Day 7 Day 8 
Resistance (Ω.cm2) 49.8 ± 1.2 (184) 48.3 ± 1.2 (212) 45.1 ± 1.3 (92) 
Basal Isc (μA.cm
-2
) 7.7 ± 0.4 (184) 8.4 ± 0.4 (212) 8.0 ± 0.7 (92) 
 
Table 3.1 Comparison of pooled transepithelial resistance and basal Isc values in 
Col-24 monolayers. Values in parenthesis denote the number of observations.  
 
3.1.1.2 Peptide responses in Col-24 monolayers 
In each epithelial monolayer, VIP (30 nM) stimulated increases in Isc (known to be due 
to cAMP-mediated apical chloride secretion) and peak responses occurred within 15 
min (Figure 3.1, upper trace). Subsequent anti-secretory responses to hPP (10 nM) were 
observed as transient inhibitory responses, which reached their nadir within 5 min of 
addition and returned to the pre-inhibited Isc within 15 min. A second addition of hPP 
(10 nM) demonstrated homologous desensitisation of the Y4 receptor. The level of 
secretion following VIP was maintained for at least 45 min (Figure 3.1, lower trace) and 
although VIP responses began to wain to pre-stimulation levels, the level of secretion 
was sufficient to see subsequent inhibitory responses to hPP at the later time point. No 
significant difference was observed between the size of the response to hPP at the 
maximum level of VIP stimulation (-2.7 ± 0.2 μA.cm-2, n=42) compared with hPP at 45 
min after VIP addition (-2.2 ± 0.3 μA.cm-2, n=6), determined using a Student’s t-test. A 
final addition of somatostatin (100 nM) was made to each epithelial monolayer since 
this well-documented anti-secretory agent has shown previously to inhibit colonic 
mucosal ion secretion in the mouse (Samson et al., 2000; Cox et al., 2001a; Hyland et 
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al., 2003) and more importantly in Col-24 monolayers (Cox et al., 2001b). The addition 
of somatostatin, following VIP and hPP, resulted in a sustained inhibitory response 
lasting 20-30 min (see first 10 min in Figure 3.1). This data was used to make an 




Figure 3.1 Representative changes in Isc following additions of VIP (30 nM), hPP 
(10 nM) and somatostatin (100 nM) in Col-24 monolayers. The upper trace 
demonstrates the response to hPP at the maximum level of secretion after VIP pre-
treatment. Subsequent Y4 desensitisation is induced by a second addition of hPP (10 
nM). The lower trace illustrates that the level of secretion is maintained for at least 45 
min following VIP, and that the response to hPP is comparable in size to that of hPP 
added at the earlier time point. Each monolayer received a final addition of somatostatin 
(100 nM), which completely inhibited the remaining VIP-elevated Isc. Basal Isc values 




3.1.1.3 VIP responses in Col-24 epithelial monolayers  
In 2001, Cox et al. demonstrated that Y agonist responses were dependent on the level 
of VIP stimulated Isc in 129Sv mouse colon mucosa (Cox et al., 2001a). In Col-24 
epithelial monolayers, a single addition of hPP (10 nM, approximately the EC50 value) 
was added following increasing concentrations of VIP (3-300 nM). As VIP raised the Isc 
in a concentration-dependent manner (Figure 3.2A), a concomitant increase in the hPP 
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300 nM VIP (Figure 3.2B). All further Col-24 layers were therefore pre-treated with 30 
nM VIP prior to the addition of either hPP or another Y4 agonist. 
 
Figure 3.2 Changes in Isc after the addition of VIP and hPP in Col-24 monolayers. 
VIP-induced increases in Isc (3-300 nM) are shown in (A) and respective hPP-induced 
reductions (10 nM) in VIP pre-treated monolayers are shown in (B). Each bar represents 
the mean ± S.E.M. of pooled responses. * P < 0.05, compared with respective basal 
control hPP responses using one-way ANOVA with Dunnett’s post-test. n values are 
shown in parenthesis. 
 
3.1.1.4 Absence of any contribution of Na+ absorption to the VIP Isc response 
To establish whether epithelial Na
+
 channels contributed to the VIP-induced responses, 
the ENaC blocker, amiloride (20 μM) was added 15 min after VIP (30 nM). Amiloride 
had no effect on VIP stimulated Isc values (16.4 ± 2.4 μA.cm
-2
, n=4, prior to addition of 
amiloride and 16.8 ± 2.8 μA.cm-2, n=4; P > 0.05, 10 min after addition of amiloride. In 
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contrast, bumetanide (200 μM), a NKCC1 blocker which prevents basolateral Cl- entry 
(associated with sodium and potassium i.e. via NKCC1), significantly reduced VIP 
responses by 60% (from 19.8 ± 2.7 μA.cm-2, n=4, to 7.9 ± 2.4 μA.cm-2, n=4; P < 0.05, 
within 5 min of addition). Thus VIP responses in Col-24 monolayers were not mediated 
by Na
+
 absorption through apical ENaC but were dependent upon basolateral Cl
-
 entry 
via the NKCC1 channel.  
 
3.1.1.5 Responses to hPP in Col-24 epithelial monolayers 
Responses to hPP (0.3-100 nM) were concentration-dependent and provided an EC50 
value of 5.9 nM (1.0-34.0 nM) (Figure 3.3A). hPP-induced reductions in Isc became 
more transient with increasing concentrations, and the time taken to reach peak response 
reduced from 6 min (1 nM) to 2 min (100 nM) (Figure 3.3B).  
 
Figure 3.3 Responses to hPP in Col-24 epithelial monolayers. (A) Non-cumulative 
concentration-response curve for hPP after VIP (30 nM) pre-treatment. The curve 
generated the EC50 value quoted in the text. The data was pooled from 3-21 
observations, with each point representing the mean ± S.E.M. (B) A comparison of the 
time-course profiles for increasing concentrations of hPP (1 nM, 10 nM and 100 nM) 
over a 25 min period with n values indicated in parenthesis. 
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3.1.1.6 Desensitisation of hPP responses in Col-24 monolayers 
In naive epithelial monolayers only pre-treated with VIP, hPP (10 nM) reduced the Isc 
by -2.8 ± 0.2 μA.cm-2 (n=42), however a second subsequent addition of hPP (10 nM, 
added 25 min after the first addition) demonstrated Y4 receptor desensitisation; the 
second addition reduced the Isc by 0.2 ± 0.2 μA.cm
-2
, n=20, P < 0.001 (a 92.9 % 
difference). This was a concentration-dependent effect, where increasing concentrations 
of the initial hPP addition caused further attenuation of the second hPP response (10 
nM, Figure 3.4).  
 
Figure 3.4 Desensitisation of hPP-activated Y4 responses in Col-24 monolayers.  
Following pre-treatment of monolayers with increasing concentrations of hPP (1-300 
nM, responses to a second addition of hPP (10 nM, shown above) demonstrated a 
concentration-dependent reductions in Isc as the initial concentration of hPP increased. 
Each bar represents the mean - S.E.M with n values shown in parentheses. *** P < 
0.001, * P < 0.05 compared with control hPP (‘Cntrl’, 10 nM) responses in naive 
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3.1.2 Human colon mucosa 
3.1.2.1 Patient ages and mucosal electrical parameters 
Transepithelial resistance and basal Isc values of colonic mucosa (obtained from either 
anterior resection or right hemi-collectomy procedures) from male and female patients 
of a similar age are compared in Table 3.2. Since no statistical differences were 
observed between the electrical parameters, experimental data was pooled from both 
genders.  
 
3.1.2.2 hPP responses in human colon mucosa 
In contrast to the transient responses observed in Col-24 monolayers, pooled responses 
to hPP (100 nM) in human colon mucosa were significantly slower in the rate of onset 
(peaking within 10-15 min) followed by sustained reductions in Isc (Figure 3.5A). 
Responses to hPP in human mucosa were also concentration-dependent, where 0.1 nM - 
1 µM inhibited Isc, generating an EC50 value of 8.8 nM (4.6-17.0 nM, n=3) (Figure 
3.5B). Y4 receptor signalling in human colon mucosa also exhibited desensitisation 
(Figure 3.5C), where a subsequent addition of hPP (100 nM) in preparations pre-treated 
with hPP (100 nM) led to a significantly smaller response, compared with that observed 
in naïve preparations. Responses to anti-secretory controls, PYY (100 nM) and the α2-
adrenoceptor agonist, UK 14,304 (1 µM) were unaffected, demonstrating specificity in 
Y4-activated Gi coupling. Thus, PYY and UK 14,304 were used as internal controls to 
assess the Y2 (and Y1) and α2 signalling of each preparation in addition to the overall 
anti-secretory capability of the mucosa. A representative trace demonstrating peptide 
responses in human mucosa is shown in Figure 3.5D. Responses to PYY were faster in 
the rate of onset compared with hPP but comparable in size and were maximal by 20 
min (-8.0 ± 0.7 μA.cm-2, n=122). UK 14,304 consistently produced further reductions in 
Isc (-21.0 ± 1.6 μA.cm
-2
, n=122) indicating the potent nature of the anti-secretory agent.  
 
 Male Female 
Age (years) 59.0 ± 3.3 (10) 63.5 ± 5.3 (12) 
Resistance (Ω.cm2) 57.8 ± 5.1 (54) 52.4 ± 3.5 (72) 
Basal Isc (μA.cm
-2
) 76.4 ± 6.6 (54) 90.0 ± 5.1 (72) 
Table 3.2 Comparison of ages, resistances and basal Isc values in human colon 
mucosa from male and female patients. Values in parentheses denote the number of 
observations. 
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Figure 3.5 hPP responses in human colon mucosa. (A) Pooled time course profiles of 
hPP (100 nM, n=3-10), added at t=0. (B) Cumulative concentration-response curve in 
naïve preparations (n=3). The curve provided the EC50 value as quoted in the text. (C) 
Desensitisation of the hPP-activated Y4 responses. (D) Representative responses to hPP, 
PYY (both at 100 nM) and the α2-agonist, UK 14,304 (1 µM). The value to the left of 
the trace is the basal Isc (in μA.0.64 cm-
2
). Each bar or point represents the mean ± 
S.E.M and n values are shown in parentheses. * P < 0.05 compared with control hPP 
(‘Cntrl’, 100 nM) responses measured using Student’s t-test. 
 
3.2 Functional assessment of Obinepitide ([Q34]hPP) 
By replacing Pro
34
 with Gln in the amino acid sequence of hPP, a dual, specific single 
digit nanomolar agonist at both the hY2 and the hY4 receptor was obtained, Obinepitide 
([Q
34
]hPP). Position 34 has previously been found to be crucial in differential receptor 
recognition through the design of the prototype hY1 selective ligand [Pro
34
]NPY 
(Fuhlendorff et al., 1990). To assess whether this modification was tolerated and 
whether this dual agonist peptide was able to activate both the Y2 and Y4 receptors, Y4 
agonism and Y2/Y4 agonism were characterised in Col-24 epithelial monolayers and 
human colon mucosa (in the absence/presence of a Y2 antagonist), respectively. 
 
3.2.1 [Q34]hPP time courses and concentration-dependent effects in Col-24 
epithelial monolayers and colonic mucosa 
In Col-24 monolayers, the time course of a single near-maximal concentration of 
[Q
34
]hPP (100 nM) was rapid, reducing Isc with a peak response within 5 min (-1.3 ± 0.2 
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µA.cm
-2
; n=3). Although the size of the response to [Q
34
]hPP was 50% reduced 
compared to that of hPP (-2.7 ± 0.3 µA.cm
-2
; n=12), the transient Isc responses were 
comparable in terms of rate of onset (P > 0.05 determined at each time point from 1-5 
min), both returning to pre-stimulation levels within 20 min of addition (Figure 3.6A). 
In human colon mucosa, a 100 nM concentration of each peptide showed [Q
34
]hPP to be 
significantly slower in the rate of onset compared with hPP in this Y2/Y4 receptor-
expressing preparation (Figure 3.6B). 
 
Figure 3.6 Comparison of the anti-secretory responses to hPP and [Q
34
]hPP. Time 
course profiles of pooled [Q
34
]hPP responses compared with the native hormone, hPP, 
in (A) Col-24 monolayers and (B) human colon mucosa. [Q
34
]hPP (100 nM in both 
preparations) and hPP (10 nM in Col-24 and 100 nM in human mucosa) were added 
basolaterally at t = 0 min. Data are presented as means ± SEM, while n numbers are 
indicated in parenthesis. * P < 0.05 determined using a Student’s t-test.  
 
As expected, responses to [Q
34
]hPP were concentration-dependent in both assays. This 
modification resulted in a 6-fold lower potency with [Q
34
]hPP compared with hPP in 
Col-24 monolayers (36.0 nM (18.0-73.0) and 5.9 nM (1.0-34.0), respectively), although 
statistically there was no significant difference in the efficacy between the two peptides 
(P > 0.05) (Figure 3.7A). In human colon mucosa, both [Q
34
]hPP and the native 
hormone exhibited similar EC50 to that observed in Col-24 monolayer (38.0 nM (16.0-
92.0) and 8.8 nM (4.6-17.0), respectively) and in fact [Q
34
]hPP displayed significantly 
increased efficacy (P < 0.01) in this Y2/Y4 (and Y1) expressing tissue (Figure 3.7B). 
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Figure 3.7 Concentration-response profiles for [Q
34
]hPP compared with hPP. (A) 
Non-cumulative pooled responses in Col-24 monolayers and (B) cumulative pooled 
responses in human colon mucosa, generating EC50 values quoted in the text. Each point 
represents the mean ± 1 S.E.M. of pooled data. Statistical differences were determined 
using Student’s t-test, where ns = no significant difference, * P < 0.05 and ** P < 0.01. 
 
3.2.2 Determination of Y receptor types mediating the anti-secretory response to 
[Q
34
]hPP in human colon mucosa 
To confirm dual agonism, responses to [Q
34
]hPP were measured in the presence of the 
competitive Y2 antagonist BIIE0246. [Q
34
]hPP (100 nM) was partially sensitive to pre-
treatment with BIIE0246 (1 µM) in human colon mucosa (Figure 3.8). The basal Isc was 
also raised by BIIE0246, revealing tonic Y2 activity, as previously reported (Cox and 
Tough 2002, Hyland et al. 2003). The size of the response to [Q
34
]hPP in the presence 
of BIIE0246 was reduced but not significantly so compared to [Q
34
]hPP alone (Figure 
3.8), confirming the ability of this analogue to activate Y4 and (to a lesser degree) Y2 
receptors in these preparations. 
 
Figure 3.8 The effect of Y2 antagonism on the anti-secretory response to [Q
34
]hPP 
in human colon mucosa. The Y2 antagonist BIIE0246 alone raised Isc and anti-
secretory responses to [Q
34
]hPP (100 nM) in the presence of BIIE0246 (1µM) were 
partially inhibited. Each bar represents the mean ± 1 S.E.M. of pooled responses and the 
n numbers are shown in parenthesis. 
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3.2.3 Desensitisation of hPP responses in Col-24 monolayers with [Q34]hPP 
Responses to hPP (10 nM) added 25 min after pre-treatment with increasing 
concentrations of [Q
34
]hPP (100 nM) elicited concentration-dependent reductions in the 
size of the second hPP response (Figure 3.9), comparable to that of the native hormone 
(see Figure 3.4). The desensitisation of hPP-activated responses were significant at 
concentrations of 10 nM and higher of [Q
34
]hPP (P < 0.01, Figure 3.9A). A significant 
degree of Y4 desensitisation was also observed in human colon mucosa, where pre-
treatment with 100 nM [Q
34
]hPP caused significant reductions in the response size to 
hPP (100 nM; Figure 3.9B). 
 
 
Figure 3.9 Desensitisation of the hPP Y4 responses after activation by [Q
34
]hPP. 
(A) Responses to hPP (10 nM) added 25 min after pre-treatment with increasing 
concentration of [Q
34
]hPP (1 nM-1 µM) in Col-24 monolayers. (B) Responses to hPP 
(100 nM) added 60 min after pre-treatment with [Q
34
]hPP (100 nM) in human colon 
mucosa. Each bar represents the mean ± 1 S.E.M and n values are shown in parentheses. 
Significant differences are shown, where * P < 0.05, ** P < 0.01, *** P < 0.001, 
compared with control hPP (‘Cntrl’, 10nM) responses, measured using a one-way 
ANOVA and Dunnett’s post-test. 
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To elongate the actions of [Q
34
]hPP, a Lys at position 30 was introduced by our 
collaborators that enabled site-specific modification with either a 2, 5 or 22 kDa PEG 
moiety (referred to as PEG2, PEG5 and PEG22) or a palmitoyl (Pam) moiety. The 
introduction of Lys
30
 resulted in retention of the binding capacity and demonstrated 
nanomolar affinities for both the hY2 and hY4 receptor, as demonstrated by competitive 
binding assays in which 
125
I-labeled binding ligands were incubated at a constant 
concentration together with the analogues in varying concentrations on COS7 cells 
transfected with the receptor to be investigated (Bellmann-Sickert et al, 2011). Due to 




]hPP, this peptide was unavailable for 









]hPP, exhibited a marginal decrease in IP3 accumulation subsequent to 
hY4 activation (Beck-Sickinger et al. Appendix 1.0, Table 1) compared to the 




]hPP with palmitic acid resulted in a 
retention of potency in the case of the hY2 and hY4 receptor (Beck-Sickinger et al. 
Appendix 1.0, Table 1). 
 






The impact of increasing PEG polymer size and fatty acid modification on longevity of 
action was investigated and compared with [Q
34
]hPP responses. In Col-24 monolayers, 













(100 nM) resulted in reductions in Isc that were prolonged, where maxima was not 
reached until 45 min (Figure 3.10A). Although the effect of a PEG2 modification 
resulted in a sustained anti-secretory response, there was no significant difference in the 
maxima compared with [Q
34
]hPP (at 4 min versus 45 min with PEG2-peptide), albeit at 
a later time point. On the other hand, modification with PEG5 was well tolerated and 
resulted in a much greater response size; maximum reductions in Isc were significantly 




]hPP (P < 0.001) at the 
same time point. Conversely, modification with a PEG22 polymer was detrimental to 
the peptide’s ability to reduce Isc and resulted in a significant loss in biological activity 









]hPP, was also 
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Interestingly, each PEG-modified peptide exhibited a delay in the rate of onset; an effect 










]hPP (Figure 3.10B). 
 





in Col-24 monolayers. (A) Reductions in Isc in response to a near maximal 

















]hPP are shown for a period of 45 min. (B) A 
magnification of early time points between 0 and 15 min for each modified peptide. 
Data are presented as the means ± 1 SEM, while n numbers are indicated in parenthesis. 
Multiple comparisons were made using one-way ANOVA with Bonferroni’s post-test 
of the peak response size, ** P < 0.01, *** P < 0.001 compared with each analogue.  
 
In human colon mucosa single basolateral additions of the same agonists (100 nM) also 





]hPP reached its maximum within 12-15 min. Again, 









]hPP were comparable in their time course 
profiles, with similar maximal responses generated (however there were no statistically 
significant differences compared with the that of [Q
34
]hPP). Additionally, each peptide 








]hPP being more 





]hPP (100 nM) displayed a complete loss of anti-secretory activity, 
with no reduction in Isc being observed within the 45 min observation time. Increasing 




]hPP still demonstrated the absence of 
biological activity (data not shown).  
 























]hPP are shown for a period of 45 min. (B) A magnification of early time 
points between 0 and 15 min for each modified peptide.  Data are presented as the 
means ± 1 SEM, while n numbers are indicated in parenthesis. Multiple comparisons 
were made using one-way ANOVA with Bonferroni’s post-test and there were no 
significant differences.  
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3.3.2 PEG polymer and palmitic acid responses in Col-24 epithelial and colonic 
mucosal preparations 





]hPP variants were due to the PEG polymers and palmitic 
acid side chains per se, additions of PEG2, PEG5, PEG22 and palmitic acid (all at 100 
nM) were made to both Col-24 monolayers (Figure 3.12A) and colon mucosa 
preparations (Figure 3.12B). Within the observation time of 45 min, all side chains had 
no effect upon Isc levels in either preparation. 
 
Figure 3.12 Lack of activity with PEG2, PEG5, PEG22 and palmitic acid. No 
changes in Isc were seen following additions of each side chain (100 nM) in (A) Col-24 
monolayers and (B) human colon mucosa. Data are presented as the means ± 1 SEM, 
while n numbers are indicated in parenthesis.  
 





responses in human colonic mucosal specimens  
In binding studies performed by our collaborators (Beck-Sickinger et al., see Appendix 




]hPP exhibited nM potency for the hY1 receptor (albeit 
two orders of magnitude lower than Y4 and Y2 activities). To ascertain whether Y1 
activation occurred in isolated human colonic specimens (known to express Y1 as well 
as Y4 and Y2 receptors; Tough and Cox, 2002; Hyland et al., 2003; Tough et al., 2006), 
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tissues were pre-treated with an optimal concentration of the Y1 antagonist, BIBO3304 
(300 nM), which alone raised Isc levels from the basal level of secretion, indicating tonic 
Y1 activity (as observed previously, Tough and Cox, 2002). Although Isc levels were 
raised in tissues following BIBO3304 (71.9 ± 22.3 μA.cm-2, n=5) these levels of 




]hPP did not alter significantly to those 




]hPP only (87.7 ± 17.5 μA.cm-2, n=5). 
 




]hPP (100 nM) were not 
significantly reduced (Figure 3.13). In fact, the size of the response was larger (but not 
significantly so). In the presence of both BIIE0246 (1 µM) and BIBO3304 (300 nM), 




]hPP was partially inhibited (P < 0.05) 




]hPP in naive preparations, 





]hPP. It should be noted however that pre-existing Isc level following dual 
addition of BIIE0246 and BIBO3304 (86.4 ± 13.0) was not statistically significant 
compared to that seen in naive tissues where no antagonist was added.  
 
 





]hPP in human colon mucosa. Increases in Isc were observed in 
response to BIBO3304 (300 nM) and BIIE0246 (1 µM) in naive preparations, 




]hPP (100 nM) 
are compared in the absence/presence of antagonists as shown, and statistical 
differences were determined using a Student’s t-test, where * P < 0.05, *** P < 0.001. 
Each bar represents the mean ± 1 S.E.M. of pooled responses with n numbers shown in 
parenthesis.  
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3.3.4 Concentration-response relationships between [K30, Q34]hPP modified 
analogues 
In Col-24 monolayers, concentration-response curves indicated that chemical 
modifications were well tolerated with no apparent detriment to agonist potency. In fact, 
all chemically modified peptides were an order of magnitude more potent compared 
with their unmodified peptide, [Q
34
]hPP (Figure 3.14). The resulting EC50 values are 
shown in Table 3.3. A one way ANOVA and Bonferroni’s post-test revealed 













]hPP and their non-modified predecessor (P < 0.01). 
 
 
Figure 3.14 Peptide responses in Col-24 monolayers. Non-cumulative concentration-

















]hPP (n=3-5) compared with 
[Q
34
]hPP (n=3-9). The peak responses for PEGylated and lipidated peptides were 
measured at approx. 45 min compared with [Q
34
]hPP at 5 min (grey dashed line), 
generating EC50 values and 95% confidence limits quoted in Table 3.3. Each point 
represents the mean ± 1 S.E.M of pooled data. Statistical differences were determined 
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Peptide EC50 value (nM) 95% confidence 
[Q
34




















]hPP 11.1 3.4-36.0 
 




]hPP EC50 values (with 95% 
confidence limits). Data was calculated from non-cumulative concentration-response 
curves obtained from Col-24 monolayers. 
 












]hPP on subsequent Y4 
receptor desensitisation was assessed next. The measurement of hPP (10 nM) responses 




]hPP variant (100 nM) revealed 
unexpected differences that indicated an apparent lack of desensitisation specifically 
with PEG5 and perhaps the PEG2 analogue (Figure 3.15) not seen with any other non-









]hPP concentrations were unaltered compared 










]hPP (0.1 nM- 1 µM) additions resulted in partial inhibition of 
subsequent hPP responses, which were significantly reduced compared to hPP ‘Cntrl’ 
values in a concentration-independent manner (Figure 3.15C). 
 










(1-300 nM) significantly attenuated further Y4 signalling to subsequent hPP responses 
(P < 0.01). Importantly, the different PEG polymers or palmitic acid (100 nM) side 
chains alone had no effect upon Y4 desensitisation (Figure 3.15) indicating that the 
differential sizes of the subsequent hPP response were a peptide-specific effect. Thus it 
appears that the lipidated PP analogue is internalised rapidly while PEGylated peptides 
do not cause significant Y4 receptor desensitisation at the same low concentration once 
bound to the Y4 receptor. This divergence was also observed in imaging studies 
performed by our collaborators (Discussed in Chapter 4), where Y4 receptor 
internalisation was determined with the use of a yellow fluorescent protein (YFP)-
tagged Y4 receptor.  




Figure 3.15 Desensitisation of hPP-activated responses following pre-treatment 




]hPP variants in Col-24 monolayers. 
Desensitisation of hPP responses (10 nM throughout) added 45 min after increasing 

















]hPP, showing differential desensitisation 
of subsequent hPP responses. Responses to hPP following different PEG or palmitic 
acid side chains are shown to the right of each histogram (hatched bars). Each bar 
represents the mean ± 1 S.E.M with n numbers shown in parenthesis. Statistical 
differences from ‘Cntrl’ hPP responses were determined using ANOVA and Dunnett’s 
post-test, where * P < 0.05, ** P < 0.01 and *** P < 0.001. 
 
Given the divergence in Y4 receptor desensitisation between the PEGylated (specifically 
PEG5) and palmitoylated peptide observed in Col-24 layers, desensitisation of hPP 













]hPP was assessed in isolated colon mucosa 
(Figure 3.16). The limited access to human tissue precluded assessment of a range of 
modified agonist concentrations upon hPP desensitisation. Despite this, human colon 




]hPP (100 nM) resulted in a significant 
reduction in the subsequent hPP responses (73.1 % ± 0.9, n=5) compared with ‘Cntrl’ 





]hPP (100 nM) also significantly reduced the subsequent 
hPP response by 71.0 % ± 0.4  (n=4), contrary to the lack of desensitisation observed in 





]hPP desensitised the Y4 receptor and unexpectedly, the loss in Y4 




]hPP (96.0 %), albeit with 2 
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observations. Importantly, this loss in Y4 signalling was not a direct result of the PEG 
polymer, since PEG22 (100 nM) had no significant effect upon the Y4-mediated hPP 
response size (Figure 3.16). 
 
Figure 3.16 Desensitisation of hPP activated responses following pre-treatment 
with chemically modified analogues in human colon mucosa. Desensitisation of hPP 













]hPP, and after PEG22 polymer (100 nM, 
hatched bar). Each bar represents the mean ± 1 S.E.M with n numbers shown in 
parenthesis. Statistical differences from ‘Cntrl’ hPP responses were determined using 
ANOVA and Dunnett’s post-test, where * P < 0.05. 
 





]hPP variant and their respective PEG/lipid conjugates did not affect other Gαi-
coupled anti-secretory responses; 100 nM somatostatin responses were unaltered 
(Figure 3.17A&B) in Col-24 monolayers, as well as 1 µM UK 14,304 responses (Figure 
3.17C&D) in human colon mucosa, suggesting Y4 receptor specificity of the PEG/lipid-
modified dual Y2/Y4 agonists.  
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Figure 3.17 Responses to somatostatin (100 nM) and UK 14,304 (1 µM) in Col-24 





]hPP variants. Selectivity of Gαi- coupled signalling 
demonstrated by insignificant changes in the response to somatostatin (100 nM) after 

















]hPP and (B) their respective PEG polymer or fatty acid (all at 100 
nM) in Col-24 monolayers. Responses to UK 14,304 (1 µM) in human colon mucosa 
are shown in (C) and (D). Each bar represents the mean ± 1 S.E.M with n numbers 
shown in parenthesis. There were no statistical differences from control hPP responses 
as determined by ANOVA with Dunnett’s post-test. 
 




A lysine substitution at position 30 of the PP sequence has proven to be a successful 
linker for PEG polymer conjugation with respect to functional Y4 anti-secretory 
responses in both colonic specimens. Initial studies performed by our collaborators have 
revealed a 20-fold longer half life with a PEG22ylated K
22





]hPP, determined by incubation of both peptides 
(modified with fluorophore  5(6)-carboxyfluorescein) with porcine liver extract 
homogenates (as a measure of protease resistance) and in vitro bioavailability 
(unpublished data, Made et al.). Lysine modification at this poition also led to 
nanomolar activity at both the Y2 and Y4 receptor with only a small loss in potency with 
increasing PEG size, in addition to selectivity over the Y1 and Y5 receptor, as 
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determined by an IP3 turnover assay (see Appendix 1.0 for Y receptor potencies). Since 
these analogues displayed promising in vitro properties, it was important to test their in 




]hPP equivalents..  
 










]hPP, exhibited a comparable 
time course profile to hPP and [Q
34
]hPP, where a rapid rate of onset and maxima at 
approximately 5 min was observed with 100 nM (Figure 3.18). The presence of a PEG5 





followed by prolonged reductions in Isc with an indication of maxima being reached at 
45 min. Interestingly, the presence of a PEG22 polymer led to complete inactivity 




]hPP also displayed 




]hPP; onset did not occur until 8 min 





the difference in the rate of onset between the two palmitoylated peptides, overall 
maxima were comparable.  
 
The trends in the time course profiles observed in Col-24 monolayers were reproduced 









]hPP, which appeared to reach maxima at 









inactive, however it must be noted that there were no significant differences in the 
maximum response size generated between all peptides. 
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in Col-24 monolayers. (A) Reductions in Isc in response to a near maximal 



















]hPP are shown for a period of 45 min. (B) A 
magnification of early time points between 0 and 15 min for each peptide. Data are 
presented as the means ± 1 SEM, while n numbers are indicated in parenthesis. Multiple 
comparisons were made using one-way ANOVA with Bonferroni’s post-test of the peak 
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]hPP are shown for a period of 45 
min. (B) A magnification of early time points between 0 and 15 min for each peptide.  
Data are presented as the means ± 1 SEM, while n numbers are indicated in parenthesis. 
Multiple comparisons were made using one-way ANOVA with Bonferroni’s post-test 
and there were no significant differences in the maxima. 
 






]hPP variants and their PEG-/lipid- derivatives were assessed for their 
Y4 potency in Col-24 monolayers. A K
22
 modification of [Q
34
]hPP resulted in a peptide 
which was 3 times more potent than [Q
34
]hPP itself, as determined by concentration-









]hPP with a PEG5 polymer was 




]hPP was an order of 




]hPP. The response maxima used to determine the 
potencies however were achieved at different time points (approximately 5 min for the 













]hPP demonstrated increased potency 
compared with its non-PEGylated equivalent, the efficacy did not significantly differ 
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]hPP was inactive 
across the concentration range used (0.3-1 µM, only 1 µM is shown in Figure 3.20). The 
consequence of palmitoylation was significantly increased efficacy compared with 
[Q
34













]hPP and hence 3 






]hPP also displayed a 
significantly increased efficacy compared with the PEG5 equivalent and this was in 





]hPP series of peptides.  
 
 
Figure 3.20 Peptide responses in Col-24 monolayers. Non-cumulative concentration-




















]hPP is shown. The peak responses for PEGylated and lipidated 






]hPP at 5 
min, generating EC50 values and 95% confidence limits quoted in Table 3.4. Each point 
represents the mean ± 1 S.E.M of pooled data, with n numbers shown in parenthesis. 
Statistical differences were determined using a one way ANOVA with Bonferroni’s 
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Peptide EC50 value (nM) 95% confidence 
[Q
34






















]hPP 9.6 4.5-20.0 
 




]hPP EC50 values (with 95% 
confidence limits). Data was calculated from non-cumulative concentration-response 
curves obtained from Col-24 monolayers shown in Figure 3.20. 
 






As observed with hPP and [Q
34





Col-24 monolayers resulted in a concentration-dependent reduction in subsequent hPP 









]hPP variants exhibited similar 




]hPP variants in terms of Y4 




]hPP, there was a significant lack 




]hPP additions (0.1-100 nM) (Figure 
3.21B), indicating that modification with PEG5 permits repeated Y4 receptor activation 






]hPP resulted in significant Y4 desensitisation at a 





]hPP (although this was not a concentration-dependent 





]hPP (Figure 3.21D), despite complete inability of the 




]hPP) in both Col-24 monolayers 
and human colon mucosa. As mentioned previously, the PEG5 and PEG22 polymers 
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Figure 3.21 Desensitisation of hPP-activated responses following pre-treatment 




]hPP variants in Col-24 monolayers. 
Desensitisation of hPP responses (10 nM throughout) added 45 min after increasing 

















]hPP, showing differential desensitisation 
of subsequent hPP responses. Responses to hPP following different PEG or palmitic 
acid side chains are shown to the right of each histogram (hatched bars). Each bar 
represents the mean ± 1 S.E.M with n numbers shown in parenthesis. Statistical 
differences from ‘Cntrl’ hPP responses were determined using ANOVA and Dunnett’s 
post-test, where * P < 0.05, ** P < 0.01 and *** P < 0.001. 
 





]hPP (100 nM and 3µM, Figure 3.22), despite the PEG22 variant being 
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]hPP in human colon mucosa. Desensitisation of hPP responses (100 




]hPP (100 nM and 3 
µM) and the PEG22 polymer (100 nM, hatched bar). Each bar represents the mean ± 1 
S.E.M with n numbers shown in parenthesis. Statistical differences from ‘Cntrl’ hPP 
responses were determined using ANOVA and Dunnett’s post-test, where * P < 0.05. 
 








]hPP peptide demonstrated 
receptor specificity in their actions as subsequent Gαi-coupled somatostatin responses 
were not significantly affected in Col-24 monolayers (Figure 3.23A) and neither were 
Gαi-coupled α-adrenoceptor responses, as determined by UK 14,304 responses in human 
colon mucosa (Figure 3.23B). 
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Figure 3.23 Responses to somatostatin and UK 14,304 in Col-24 monolayers and 





]hPP variants. Selectivity of Gαi- coupled signalling demonstrated 
by insignificant changes in the response to somatostatin (100 nM) after pre-treatment 

















]hPP. (B) Responses to UK 14,304 (1 µM) after pre-treatment of the same 
peptides in human colon mucosa. Each bar represents the mean ± 1 S.E.M with n 
numbers shown in parenthesis. There were no statistical differences from control hPP 
responses as determined by ANOVA with Dunnett’s post-test. 
 
3.4.4 Summary of results with [K30, Q34]hPP and [K22, Q34]hPP analogues 
As shown previously, responses to Y agonists in Col-24 epithelial monolayers were 
anti-secretory via activation of basolateral Y4 receptors (Cox et al., 2001b) and were 
dependent on VIP stimulated ion secretion. Utilising Col-24 monolayers in this study, 
anti-secretory responses to hPP were transient, with peak responses being reached at 
approximately 5 min. The dual Y2/Y4 receptor agonist, [Q
34
]hPP, displayed a 
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comparable rapid time course profile to that of hPP, and selective blockade of Y2 
receptors using a competitive Y2 antagonist revealed the dual capacity of this analogue 
in human colonic mucosa. Modification at position 22 with lysine was well tolerated, 
demonstrated by increased Y4 potency. 
 




]hPP series of peptides, the addition of a PEG polymer 
resulted in responses that were delayed in onset, and the extent of delay correlated with 
the size of the PEG, where PEG22 > PEG5 > PEG2. PEG5 conjugation seemed to be 
well tolerated with significantly increased efficacy compared with the PEG2 and the 
non-modified [Q
34
]hPP, as observed in Figure 3.14. Palmitoylation of [Q
34
]hPP was 
also well tolerated in terms of efficacy and potency and displayed equi-effective 
responses compared to the PEG5-conjugated peptide in Col-24 epithelial layers. 
Importantly, despite having nM selectivity for the Y1 receptor (indicated by IP3 




]hPP derivative demonstrated significant Y2 
and Y4 functional output in human colon mucosa with no significant Y1 activity, 
revealing high Y2 and Y4 receptor functional output for the novel peptide. The addition 
of a lysine linker at position 22 also enabled successful PEG and lipid conjugation, as 
determined by their prolonged anti-secretory responses and well preserved potency, 
with the exception of PEG22 conjugation, which was unfavourable to both potency and 





]hPP exhibited an unexpected resistance to hPP-activated 




]hPP. On the contrary, 
palmitoylation of both peptide variants seemed to facilitate desensitisation, revealed by 
the significant loss of further Y4 signalling in Col-24 epithelia, even after low nM 
concentrations of palmitoylated agonist. Interestingly, both PEG22-ylated variants 
resulted in partial inhibition of subsequent hPP responses, despite a complete lack of 






3.5 Functional assessment of TM30339  
TM30339 (hPP2-36), is a Y4 selective agonist with improved stability compared to hPP. 
The native hormone is normally a substrate for DPP-IV degradation due to the presence 
of Pro at position 2. Thus, by removing the first residue, a peptide is generated which is 
no longer a substrate for DPP-IV (European patent application, reference no. 
EP2060266B1, 2005). Importantly, the Y4 receptor is not dependent on the residue 
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located at position 1, unlike the Y1 receptor, thus hPP2-36 has increased selectivity 
against the Y1 receptor. 
 




In Col-24 monolayers, responses to single additions of hPP2-36 (100 nM) were transient, 
reducing Isc with a peak response at 4 min (-1.5 ± 0.3µA.cm
-2
; n=6). This profile was 
comparable to 10 nM hPP, peaking at 5 min (-2.7 ± 0.3 µA.cm
-2
; n=12). Modification at 
position 22 with lysine ([K
22
]hPP2-36) was well tolerated and resulted in maximal 
response of -3.0 ± 0.7 µA.cm
-2
; n=3), reaching a peak at 5 min. No significant 
difference was observed in the rate of onset between the peptides, however hPP 
generated a larger response size compared to hPP2-36 (Figure 3.24A). In human colon 
mucosa, a 100 nM concentration of hPP and hPP2-36 revealed no significant differences 
between these two in terms of maximum peak response, although a slightly faster rate of 
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Figure 3.24 Comparison of the anti-secretory responses to hPP2-36 and [K
22
]hPP2-36. 
Time course profiles of pooled anti-secretory responses in (A) Col-24 monolayers and 
(B) human colon mucosa. hPP2-36 and [K
22
]hPP2-36 (100 nM in both preparations) and 
hPP (10 nM in Col-24 monolayers and 100 nM in human mucosa) were added 
basolaterally at t = 0 min. Data are presented as means ± 1 SEM, while n numbers are 
indicated in parenthesis. Statistical significances between hPP and hPP2-36 were 
determined using a one way ANOVA with Bonferroni’s post-test, where * P < 0.05 and 
** P < 0.01. One way ANOVA with Dunnett’s post-test determined no significant 
difference between hPP and hPP2-36 in human colon mucosa.  
 
3.5.2 Concentration response relationships for hPP2-36 and [K
22
]hPP2-36 
Responses to hPP2-36 and [K
22
]hPP2-36 were concentration-dependant in Col-24 
monolayers and the resulting concentration-response curves produced equipotent EC50 
values of 4.8 nM (95% confidence, 2.5 - 9.1) and 7.6 nM (95% confidence, 4.4-13.0), 
respectively (Figure 3.25). 
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Figure 3.25 Concentration-response profiles for hPP2-36 and [K
22
]hPP2-36 compared 
with hPP. Non-cumulative pooled responses to hPP (n=3-21), hPP2-36 (n=3-9) and 
[K
22
]hPP2-36 (n=3-5) in Col-24 monolayers, generating EC50 values quoted in the text. 
Each point represents the mean ± 1 S.E.M. of pooled data. One way ANOVA with 
Bonferroni’s post-test determined a significant difference between hPP and hPP2-36, P < 
0.05 
 




Concentration-dependent reductions to subsequent hPP (10 nM) responses after pre-
treatment with increasing concentrations of hPP2-36 (0.1 nM –100 nM) were observed, 
with 1 nM hPP2-36 being the threshold effective concentration to cause significant Y4 
receptor desensitisation (P < 0.05) (Figure 3.26A). This effect was analogous to that 
seen with the native hormone hPP. Likewise, in human mucosa, 100 nM hPP2-36 also 
caused significant reductions in subsequent hPP responses (100 nM, P < 0.05) (Figure 
3.26B). [K
22
]hPP2-36 also induced concentration-dependent reductions of hPP responses 
in Col-24 monolayers, with significant desensitisation observed with 3 nM [K
22
]hPP2-36 
(P < 0.001) (Figure 3.27) and 10 nM [K
22
]hPP2-36  or above resulted in a complete loss 
in response to hPP.  
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Figure 3.26 Desensitisation of hPP activated Y4 responses by hPP2-36 in Col-24 
monolayers and colon mucosa. (A) Desensitisation of hPP responses in Col-24 
monolayers (10 nM throughout) added 25 min after increasing concentrations of hPP2-
36.  In (B) desensitisation of hPP responses (100 nM) in human colon mucosa, added 60 
min after hPP2-36 (100 nM). Each bar represents the mean ± 1 S.E.M with n numbers 
shown in parenthesis. Statistical differences from control hPP responses were 
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Figure 3.27 Desensitisation of the hPP activated Y4 responses by [K
22
]hPP2-36. 
Responses to hPP (10 nM) added 25 min after pre-treatment with increasing 
concentration of [K
22
]hPP2-36 (0.3 nM-100 nM) in Col-24 monolayers. Each bar 
represents the mean ± 1 S.E.M and n values are shown in parentheses. *** P < 0.001 
and * P < 0.05 compared with control hPP (‘Cntrl’, 10 nM) responses, measured using a 
one-way ANOVA and Dunnett’s post-test. 
 
3.6 Functional assessment of fatty acid- and PEG conjugated [K22]hPP2-36 
analogues 
Since modification of [Q
34
]hPP with palmitic acid demonstrated an improved in vitro 
pharmacological profile, the [K
22
]hPP2-36 variants were chemically conjugated with a 
short chain (C8), medium chain (C12) and long chain (C16) fatty acid moiety and 
investigated for enhanced anti-secretory capabilities in both colon preparations. Given 
that PEG22 modification of the [Q
34
]hPP series led to a loss in biological activity, 
reductions in Isc were measured with [K
22
(PEG22)]hPP2-36 to discern whether 
modification at a different site on the hPP sequence would improve the anti-secretory 
profile.  
 




All three lipidated peptides were found to inhibit VIP-stimulated Cl
-
 secretion In Col-24 




(E-Pam)]hPP2-36 (100 nM) 
resulted in monophasic prolonged anti-secretory responses which were equi-effective at 




(E-Pam)]hPP2-36 displayed a 
slower onset of action compared with the non lipidated [K
22
]hPP2-36 (Figure 3.28B). 
Interestingly, [K
22
(E-Capr)]hPP2-36 (100 nM) displayed a biphasic anti-secretory 
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response, with an initial transient phase that appeared to peak at 5 min (-1.8 ± 0.5 
µA.cm
-2
; n=3), resembling that of the unmodified [K
22
]hPP2-36, followed by a sustained 
anti-secretory response. This second phase appeared at ~10 min and peaked within 45 





(E-Pam)]hPP2-36. Modification of [K
22
]hPP2-36 with a PEG22 
polymer resulted in a complete loss of biological activity. No reduction in Isc was 
observed of this large peptide (100 nM, or 3 µM) during the observation period (Figure 
3.28). 
 
Figure 3.28 Time course profiles of chemically modified [K
22
]hPP2-36 variants in 










nM and 3µM – dashed line) are shown for a period of 45 min, demonstrating loss of 
activity with a PEG22 modification. (B) A magnification of early time points between 0 
and 15 min for each modified peptide. Data are presented as means ± 1 SEM, while n 
numbers are indicated in parenthesis. Multiple comparisons were made using one-way 
ANOVA with Bonferroni’s post-test, ** P < 0.01, compared with each analogue.  
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(E-Pam)]hPP2-36 demonstrating comparable 
rates of onset and time to peak, both of which were monophasic in nature (Figure 3.29). 
[K
22
(E-Capr)]hPP2-36 also displayed the biphasic nature observed in Col-24 monolayers 
with an initial transient peak and a subsequent sustained anti-secretory response. Again, 
the anti-secretory ability of [K
22
(E-Capr)]hPP2-36 was greater than that seen with longer 
fatty acids (Figure 3.29), however, in human colon mucosa a one way ANOVA with 
Bonferroni’s post-test did not show any significant differences between the peak 
responses of the peptides. As observed in Col-24 monolayers, little anti-secretory 
activity was observed with [K
22
(PEG22)]hPP2-36 in isolated mucosa (Figure 3.29). 
 
Figure 3.29 Anti-secretory responses to chemically modified [K
22
]hPP2-36 variants 









(PEG22)hPP2-36 (100 nM) are shown 
for a period of 45 min, demonstrating reduced efficacy following a PEG22 
modification. (B) A magnification of early time points between 0 and 15 min for each 
modified peptide. Data are presented as means ± 1 SEM, while n numbers are indicated 
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in parenthesis. Multiple comparisons were made using one-way ANOVA with 
Bonferroni’s post-test.  
 
3.6.2 Fatty acid responses in epithelial and mucosal preparations 
It is well documented that the release of PYY and GLP-1 from enteroendocrine L cells 
can be activated by a range of luminal nutrients such as fatty acids (Anini et al., 1999; 
Hirasawa et al., 2005). Limited published data has reported that both GPR40 (Itoh et al., 
2003) and GPR120 (Hirasawa et al., 2005) specifically detect long-chain fatty acids, 
and for this reason, the response to the fatty acid side chains were assessed in both 
preparations and compared with the PEG22 side chain. This was to determine whether 
reductions in Isc were an indirect effect of the fatty acids and to rule out the possibility 
of PYY-mediated Y1 anti-secretory responses in human colon mucosa. In both colonic 
preparations, all fatty acid side chains had no effects upon Isc levels (Figure 3.30). 
 
 
Figure 3.30 Anti-secretory responses to fatty acid side chains and PEG22. Lack of 
change in Isc to caprylic acid, lauric acid, palmitic acid and PEG22 (100 nM) following 
VIP (30 nM) stimulation in (A) Col-24 monolayers and (B) human colon mucosa. Data 
are presented as means ± 1 SEM, while n numbers are indicated in parenthesis. 
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(PEG22)]hPP2-36 in Col-24 monolayers 
The ability of [K
22
(E-Capr)]hPP2-36 to inhibit Cl
-
 secretion was biphasic in nature, as 
demonstrated by a pooled time course profile in Col-24 monolayers. The concentration 
response relationship indicated anti-secretory activity being maximal between 100 and 
300 nM (Figure 3.31). Segregating the two components of the [K
22
(E-Capr)]hPP2-36 
response demonstrated an initial transient phase, generated an EC50 value of 3.9 nM (1.2 
- 13.0 nM), which did not significantly differ from [K
22
]hPP2-36 (3.4 nM, 0.6 -18.0 nM). 
The second prolonged anti-secretory phase had a 10 fold lower EC50 value of 35.0 nM 
(22.0-56.0 nM) however a much greater efficacy; the size of the peak response to 
[K
22
(E-Capr)]hPP2-36 (100 nM) during the 2
nd
 phase was 83.2% larger compared with 
the maximal response size during the 1
st
 peak to the same peptide.  
 
 





(E-Capr)hPP2-36. Responses to [K
22
]hPP2-36 (measured at ~5 min) are shown with a 
grey dashed line. Anti-secretory responses to [K
22
(E-Capr)hPP2-36 are shown, 
representing the size of the response in the first transient phase (n=4-7, measured at ~5 
min, dashed pink line) compared with the subsequent prolonged phase (n=3-4, 
measured at ~45 min, unbroken pink line). All curves generated EC50 values and 95% 
confidence limits quoted in the text. Each point represents the mean ± 1 S.E.M of 
pooled data. 
 
In addition to exhibiting protracted responses compared to [K
22
]hPP2-36, increasing the 





(E-Pam)]hPP2-36 both retained the high potency observed with their non-
lipidated predecessor (Figure 3.32), indicated by equipotent EC50 values (5.6 nM (1.4-
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22.0 nM), compared with 6.6nM (0.5-79.0 nM) for [K
22
(E-Pam)]hPP2-36, respectively) 
both of which were increased compared with [K
22
(E-Capr)]hPP2-36. Modification of 
[K
22
]hPP2-36  with PEG22 resulted in a significant loss of biological activity at 
concentrations ranging from 1 nM to 3 µM. 
 







(PEG22)hPP2-36 in Col-24 monolayers. Anti-
secretory responses to [K
22
(E-Laur)hPP2-36 (n=3-4) and [K
22
(E-Pam)hPP2-36 (n=3-5) are 
compared with the non lipidated [K
22
]hPP2-36 peptide (n=3-5). The response to 100 nM, 
1 µM and 3 µM [K
22
(PEG22)hPP2-36 demonstrates lack of potency and efficacy 
compared with the lipidated variants. The peak response was measured at approximately 
45 min compared with [K
22
]hPP2-36 at 5 min (grey dashed line), generating EC50 values 
and 95% confidence limits quoted in the text. Each point represents the mean ± S.E.M 
of pooled data. 
 






Desensitisation studies with these lipidated variants (at different concentrations) in Col-
24 monolayers revealed a significant loss of further Y4 signalling indicated by 
reductions in subsequent hPP responses. Since [K
22
(E-Capr)]hPP2-36 displayed a 
biphasic anti-secretory response, the size of the response to hPP (10 nM) was measured 
after the first phase (25 min) and second phase (45 min) following pre-treatment with 
increasing concentrations of [K
22
(E-Capr)]hPP2-36 (0.1- 100 nM) to investigate whether 
the receptor remained sensitive despite continuing Y4 signalling. Reductions in 
subsequent hPP responses after pre-treatment with [K
22
(E-Capr)]hPP2-36 were 
concentration-dependent (Figure 3.33) and responses remained desensitised 45 min after 
the addition of the lipidated peptide (10 nM, P < 0.01), signifying a loss in further Y4 
signalling despite an on-going downstream anti-secretory response. Importantly, hPP 
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responses after addition of caprylic acid (100 nM) did not exhibit significant 
desensitisation compared with control hPP responses (see hatched bars to right of each 
histogram in Figure 3.33).  
 
Figure 3.33 Desensitisation of hPP activated responses after pre-treatment with a 
short chain fatty acid conjugated [K
22
]hPP2-36 variants in Col-24 epithelial 
monolayers. Desensitisation of hPP responses (10 nM throughout) added 25 min (A) or 
45 min (B) after increasing concentrations of [K
22
(E-Capr)]hPP2-36, compared with Y4 
desensitisation following hPP (10 nM). The response to hPP after pre-treatment with 
caprylic acid (Capr, 100 nM) is shown to the right of both histograms. Each bar 
represents the mean ± 1 S.E.M of pooled date with n numbers shown in parenthesis. 
Statistical differences from ‘Cntrl’ hPP responses were determined using ANOVA and 
Dunnett’s post-test, where * P < 0.05, ** P < 0.01 *** P < 0.001. 
 





(0.1-100 nM) led to significantly reduced hPP responses at concentrations as low as 
0.1nM, suggesting high potency activation of the Y4 receptor and subsequent 
desensitisation with the longer fatty acid-conjugated peptides. Lauric acid and palmitic 
acid did not apparently cause significant Y4 receptor desensitisation (Figure 3.34). 
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Figure 3.34 Desensitisation of hPP activated responses following pre-treatment 
with lauric acid and palmitic acid conjugated [K
22
]hPP2-36 variants in Col-24 
epithelial monolayers. Desensitisation of hPP responses (10 nM throughout) added 45 





Pam)]hPP2-36, compared with Y4 desensitisation following hPP (100 nM). Responses to 
hPP after pre-treatment with lauric acid (Laur) and palmitic acid (Pam) are shown to the 
right of each histogram. Each bar represents the mean ± 1 S.E.M of pooled date with n 
numbers shown in parenthesis. Statistical differences from ‘Cntrl’ hPP responses were 
determined using ANOVA and Dunnett’s post-test, where * P < 0.05, ** P < 0.01 *** 
P < 0.001. 
 
Unlike the lipidated variants, the PEGylated low potency agonist, [K
22
(PEG22)]hPP2-36 
(1-100 nM), did not reduce subsequent hPP responses in Col-24 monolayers (Figure 
3.35), as expected. A concentration of 1 µM however, significantly desensitised 
subsequent hPP responses and at 3 µM [K
22
(PEG22)]hPP2-36 even more so, despite the 
lack of anti-secretory activity of the peptide at these high concentrations (Figure 3.32). 
The PEG22 polymer alone had no effect upon Y4 receptor activation (Figure 3.35).  
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Figure 3.35 Desensitisation of hPP activated responses following pre-treatment 
with increasing concentrations of [K
22
(PEG22)]hPP2-36 in Col-24 epithelial 
monolayers. Desensitisation of hPP responses (10 nM throughout) added 45 min after 
increasing concentrations of [K
22
(PEG22)]hPP2-36, compared with Y4 desensitisation 
following hPP (10 nM). The PEG22 polymer alone had no effect upon Y4 receptor 
desensitisation. Each bar represents the mean ± 1 S.E.M of pooled date with n numbers 
shown in parenthesis. Statistical differences from ‘Cntrl’ hPP responses were 
determined using ANOVA and Dunnett’s post-test, where * P < 0.05, *** P < 0.001. 
 
An analogous pattern of desensitisation with the lipidated [K
22
]hPP2-36 variants was 
observed in human colon mucosa (Figure 3.36); subsequent responses to hPP (100 nM) 
were significantly more desensitised with the longer fatty acid conjugate, [K
22
(E-
Pam)]hPP2-36 than with all other [K
22
]hPP variants. An 89.0% reduction in the hPP 
response was observed with [K
22
(E-Pam)]hPP2-36 compared with a 58% reduction seen 
with [K
22
(E-Capr)]hPP2-36 . Unexpectedly, preliminary data indicates that 
[K
22
(PEG22)]hPP2-36 caused a 94% reduction in subsequent hPP responses compared to 
hPP responses in naive mucosa. This was in contrast to the resistance to desensitisation 
with [K
22
(PEG22)]hPP2-36 observed in Col-24 monolayers at the same concentration 
(100 nM). 
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Figure 3.36 Desensitisation of hPP activated responses after pre-treatment with 
lipidated and PEG22 conjugated [K
22
]hPP2-36 variants in human colon mucosa. 










(PEG22)]hPP2-36 (100 nM), compared with Y4 desensitisation following hPP (100 
nM). Each bar represents the mean ± 1 S.E.M of pooled date with n numbers shown in 
parenthesis. Statistical differences from ‘Cntrl’ hPP responses were determined using 
ANOVA and Dunnett’s post-test, where * P < 0.05. 
 
Desensitisation of the Y4 receptor was not a direct effect of the fatty acids or PEG22 
polymer side chain in human colon mucosa studies (Figure 3.37). Although responses to 
hPP following lauric acid and PEG22 (both at 100 nM) were approximately 50 % and 
25 % reduced compared with hPP in naive mucosal preparations, these responses were 
not statistically significant to hPP ‘cntrl’ response. The limited access to human tissue 
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Figure 3.37 Desensitisation of hPP activated responses following pre-treatment 
with lauric acid or PEG22 polymer in human colon mucosa. Responses to hPP (100 
nM throughout) added 60 min after lauric acid or PEG22 (100 nM), compared with Y4 
desensitisation following hPP (100 nM). Each bar represents the mean ± 1 S.E.M of 
pooled date with n numbers shown in parenthesis. Statistical differences from ‘Cntrl’ 
hPP responses were determined using ANOVA and Dunnett’s post-test, where * P < 
0.05. 
 
3.6.5 Specificity of desensitisation induced by [K22]hPP2-36 variants  
Y4 desensitisation studies revealed significant reductions in response size to hPP 
following the addition of lipidated [K
22
]hPP2-36 variants. The [K
22
]hPP2-36 variants were 
specific in their ability to activate Gαi- coupled signalling of the Y4 receptor since 
subsequent responses to inhibitory somatostatin (100nM) (Figure 3.38A) and UK 
14,304 (1 µM) (Figure 3.38C) were not significantly different compared to control 
somatostatin and UK 14,304 responses in Col-24 monolayers and colon mucosa, 
respectively. The fatty acids and PEG22 polymer alone additionally had no significant 
effects upon non Y4 Gαi- coupled signalling in both preparations, as demonstrated in 
Figure 3.38B and Figure 3.38D. 
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Figure 3.38 Effect of [K
22
]hPP2-36 modified analogues and their respective 
PEG/lipid conjugates on subsequent somatostatin (100 nM) and UK 14,304 (1µM) 
responses in Col-24 monolayers and human mucosa, respectively. Selectivity of Gαi- 
coupled signalling demonstrated by insignificant changes in the response to 









(PEG22)]hPP2-36, and (B) their respective fatty acid or 
PEG polymer (all at 100 nM) in Col-24 monolayers. Responses to UK 14,304 in human 
colon mucosa are shown in (C) and (D). Each bar represents the mean - 1 S.E.M with n 
numbers shown in parenthesis. Statistical differences from control hPP responses were 
determined using ANOVA and Dunnett’s post-test. 
 
3.7 Summary of results 
All lipidated variants of hPP2-36 were found to inhibit the elevated Isc induced by VIP, 





24 epithelial monolayers). Modification with the short chain fatty acid, E-Capr, 
interestingly exhibited a first phase transient profile, followed by a sustained reduction 
in Isc.  This first phase was absent from longer lipidated agonists (E-Laur and E-Pam). 
Therefore, the anti-secretory activity of the conjugates correlated with the length of the 
fatty acid chain, with the minimal requirement for possessing the enhanced prolonged 
monophasic anti-secretory activity being somewhere between 9 and 11 carbons atoms. 
Removal of the fatty acid group from the glutamate linker completely abolished the 
enhancement of the activity (as observed with [K
22
]hPP2-36). Importantly, neither 
caprylic acid, lauric acid nor palmitic acid had any effect upon Isc in both Col-24 
monolayers and human tissue. Furthermore, increasing lipid length correlated with 
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increased latency of activation in both preparations, where [K
22
(E-Pam)]hPP2-36 
exhibited the slowest rate of onset. In addition to displaying protracted responses 
compared to [K
22
]hPP2-36, peptides conjugated to a fatty acid equal to or longer than 8 
carbons retained their high potency. The extent of Y4 receptor desensitisation also 
positively correlated with the lipophilicity of the peptides, with palmitic acid and lauric 
acid conjugated peptides demonstrating significantly enhanced inhibition of further Y4 
signalling compared with their non-lipidated predecessor. [K
22
(E-Capr)]hPP2-36 also 
exhibited a concentration-dependent desensitisation profile which was more akin to that 
seen with the unmodified [K
22




]hPP2-36  with a PEG22 polymer resulted in a complete loss of anti-
secretory activity in Col-24 monolayers (100 nM) and a considerable loss in human 
mucosa (100 nM). The concentration response relationship (Figure 3.32) demonstrated 
a loss in Y4 potency and efficacy compared with the lipidated and non-modified 
[K
22
]hPP2-36  derivatives. This is in contradiction to IP3 signalling data generated by our 
collaborators (Beck-Sickinger et al. see Appendix 1, Table 3), where the EC50 for the Y4 
receptor was 5.3 nM. As predicted from functional data produced in Col-24 monolayers, 
subsequent hPP responses were unaffected in the presence of [K
22
(PEG22)]hPP2-36 (1-
100 nM) confirming the absence of Y4 activation. However a higher concentration of 
[K
22
(PEG22)]hPP2-36 (3 µM) caused significantly reduced hPP responses, despite a lack 
of anti-secretory response to this large peptide, and this may possibly be due to an 
allosteric effect on the Y4 receptor as a result of the PEG22 polymer when conjugated to 






]hPP2-36 variants displayed high specificity towards the Y4 receptor, 
demonstrated by the lack of desensitisation observed with somatostatin and UK 14,304 
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4.1 Measurement of ion transport in colonic epithelial preparations 
The present investigation utilised the heterogeneous colonic epithelial cell line, Col-24, 
which originates from a human adrenocarcinoma (HCA-7) (Marsh et al., 1993). Col-24 
cells exhibit key morphological characteristics including the ability to grow on a plastic 
surface as a confluent polarised epithelial sheet, the existence of microvilli at the apical 
but not the basolateral domain and the presence of apical tight junctions. In addition, 
these cells have the capacity to form domes as a consequence of vectorial fluid transport 
in confined areas of an epithelial monolayer (Kirkland, 1985). Based on their 
morphology, nine subpopulations have been isolated (Marsh et al., 1993) and of these, 
three have been identified that constitutively express Y1 & Y4 receptors; Col-1, Col-6 
and Col-24. RT-PCR studies have demonstrated Y4 receptor expression in both Col-24 
and Col-6 epithelia, although to a much lesser extent in the latter cell line, compared 
with HT-29 positive controls transfected with hY4 and hY1 receptors (Cox et al., 
2001b). Constitutive Y4 receptor expression was observed in Col-24 cells and were 
primarily selected as the most appropriate cell line to compare the anti-secretory effects 
of novel Y4 receptor agonists since PYY-mediated Y1 responses were absent in Col-24 
cells (Y1 receptors are expressed in Col-6 cells; Tough & Cox, 1996) and secondly, nM 
concentrations of hPP result in transient inhibitory responses. Despite Y4 expression, the 
use of Col-6 epithelia in this study was not considered appropriate due the constitutive 
co-expression of the Y1 receptor (Tough & Cox, 1996) and the added complication of 
atypical Y4 receptor expression, resulting in uncharacteristic Y4-like responses (Cox et 
al., 2001b). Cultured epithelial cell lines have been successfully utilised to study 
hormone-stimulated transepithelial ion transport. Despite the fact that a large number of 
cell lines are derivatives of human colorectal adenocarcinomas (Fogh and Trempe, 
1975; Leibovitz et al., 1976), not many can maintain the polarity of their tissue of origin 
(Pinto et al., 1983). Col-24 cells served as model epithelia in this study as they have the 
capability to differentiate into polarised intestinal cells and grow as a monolayer on a 
semi-permeable support (Cuthbert et al., 1987), exhibiting a distinct brush boarder at 
the apical domain and the presence of tight junctions connecting neighbouring cells 
(Kirkland, 1985). 
 
Although the use of a cultured epithelial cell line in this functional study offered the 
benefit of studying epithelial responses in the absence of neurones or other mucosal cell 
types, the use of more complex human mucosal preparations was invaluable, allowing 
the measurement of Y1, Y2 and Y4-mediated anti-secretory responses (Cox and Tough, 
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2002; Hyland et al., 2003). Immunohistochemical and functional studies have 
confirmed selective basolateral epithelial localisation of the Y1 and Y4 receptor, where 
their activation occurs in response to PYY and NPY (Y1) or to PP (Y4) (Mannon et al., 
1999; Tough et al., 2006; Cox, 2007). This is in contrast to the neuronal localisation of 
the Y2 receptor (in mouse and human), where anti-secretory responses are mediated via 
NPY, PYY and their shortened equivalents, NPY(3–36) and PYY(3–36) (Cox and 
Tough, 2002; Hyland et al., 2003; Wang et al., 2010). In the absence of any selective Y4 
receptor antagonists, the use of selective Y1 and Y2 receptor antagonists (BIBO3304 and 
BIIE0246, respectively) in human colon mucosal preparations has allowed the 
pharmacological dissection of the most promising analogues, and has also helped 
elucidate the functional significance of these peptides in controlling colonic ion 
secretion for the first time. 
 
The main goal of this work was to utilise the Ussing chamber technique to evaluate the 
effects of PEGylation and lipidation on the behaviour of novel peptides in terms of their 
longevity of action, potency and efficacy. Although data generated from the Col-24 cell 
line does not strictly mimic that seen in vivo, the human origin of this cell line means 
that there is no interspecies variation. Therefore the Col-24 cell line can be considered 
comparative to human colon mucosa with respect to intestinal absorption. In addition, 
experiments with isolated human colon mucosa have replicated and confirmed the 
trends seen in the Col-24 cell line. Simultaneous biochemical measurements in COS-7 
cells were performed by our collaborators within the GIPIO project; these included 
ligand binding and IP3 signal transduction (see Appendix 1.0), which were crucial in 
identifying the most promising drug candidates with high receptor specificity and 
potency at each Y receptor. The functional data presented herein aimed to provide more 
biologically relevant information regarding ligand potency and efficacy with the added 
benefit of Y receptor antagonists to block the functional response and confirm 
specificity observed with the biochemical assays, hence bridging the gap between 
biochemical assays and in vivo animal studies. Furthermore, the ability to assess how 
the novel GIPIO peptides modulate target systems in vitro has also been advantageous 
in the early screening process, as potential side effects have also been envisaged (see 
section 4.7), thus facilitating hypothesis-driven in vivo studies. 
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4.1.1 Electrical parameters 
In the present study, transepithelial resistance and basal Isc values in Col-24 monolayers 
(Table 3.1) were comparable to observations seen previously with the same cell line 
(Cox and Tough, unpublished data) and also comparable to published data observed 
with Col-1 epithelial monolayers (Holliday et al., 1997). In human colon mucosa, basal 
Isc and resistance values varied (Table 3.2) but were not significantly different from 
previous studies (Tough & Cox 2002) with human tissue, or between the genders. 
Inconsistency between human colonic specimens has been observed in a number of 
other studies (Marrero et al., 1998; Tominaga et al., 1996). Marked variations have 
been reported in the distal colon; Marrero et al reported a resistance range of 52 to 220 
Ω·cm2 (Marrero et al., 1998) following endoscopic mucosal resection from normal 
human volunteers. An explanation for this variability might be a divergence in the 
biopsy and mounting techniques employed by different groups, resulting in varying 
degrees of tissue damage, and a loss in tissue integrity.  In comparison to the published 
data regarding transepithelial resistance, the data presented in this thesis exhibited error 
margins of less than 10 % observed between male and female mucosal preparations 
(Table 3.2), thus demonstrating uniformity in the dissection technique used.   
 
4.1.2 Anti-secretory Y responses are dependent on VIP stimulation 
Following Gs-coupled stimulation of VPAC1 receptors by VIP, Cl
-
 ions exit the cell via 
the PKA-sensitive, apical CFTR channel, which becomes activated in response to 
increased intracellular cAMP (Harmar et al., 2004; Banks et al., 2005; see Figure 1.9). 
Cox et al. (2001b) previously reported Col-24 epithelia sensitivity to increasing VIP 
concentrations and subsequent analysis of pooled data generated an EC50 value of 2.9 
nM, which was similar to that observed in Col-1 and Col-6 epithelia (Holliday et al., 
1997; Cox & Tough, 1995, respectively). In this thesis, increasing concentrations of 
VIP were used to raise the levels of anion secretion and maximally effective hPP 
responses were observed following 30 nM and 300 nM VIP compared with basal 
responses (Figure 3.2A), confirming that the response to hPP is dependent upon the 
secretory state of the monolayer. These results are comparable with a study performed 
in mouse descending colon (Tough, 2005) which demonstrated the dependence of hPP 
and PYY responses on the level of VIP-stimulated Isc. These results are also comparable 
with additional previous studies in mouse descending colon (Cox et al., 2001a) and rat 
jejunum (Cox and Cuthbert, 1988) in which responses to a single concentration of NPY 
were enhanced by pre-stimulation of the mucosa with increased VIP concentrations.  In 
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either mouse or rat mucosa, the maximally effective NPY response was observed 
following 30 nM VIP. In addition to the enhanced NPY responses following VIP, Cox 
and Cuthbert (1988) found that stimulation with PGE2, forskolin, IBMX and dibutyryl 
cAMP also allowed enhanced NPY responses. Thus it can be concluded that Gi coupled 
Y receptors require an accumulation of intracellular cAMP in order to exert their 
effects. Human mucosa preparations were not pre-treated with VIP since basal Isc levels 
were sufficiently high and subsequent hPP-mediated reductions in Isc were consistent 
between each mucosal preparation studied. This high level of basal secretion has also 
been reported in previous studies utilising human mucosa (Cox and Tough, 2002; 
Tough et al., 2006), where VIP was not used to pre-stimulate the basal Isc. 
 
4.1.3 Y1 and Y2 receptor antagonists cause elevated Isc levels in human colon 
mucosae, indicative of anti-secretory tone 
The pharmacology associated with the novel analogues under investigation with the 
most promising in vitro profiles was established with the use of the competitive Y1 and 
Y2 receptor antagonists, BIBO3304 and BIIE0246, respectively. The use of these 
selective antagonists have been fundamental to the pharmacological characterisation of 
NPY, PYY, PYY(3-36) and PP, particularly in human colonic tissue co-expressing 
several Y receptors, and have thus allowed us to reveal the functional significance of Y1 
and Y2 receptors in the anti-secretory response to novel Y2/Y4 analogues (with potential 
Y1 functional activity) in this study. Wieland et al. first demonstrated Y1 competitive 
antagonism with BIBO3304; the Y1 antagonist displayed a 1000-10000-fold lower 
affinity for the h/r Y2, Y4 and Y5 receptor, compared to subnanomolar affinity at the Y1 
receptor in cells stably transfected with the h/r Y1 receptor or cells endogenously 
expressing the Y1 receptor (SK-N-MC cells; Wieland et al., 1998). Shortly after, Doods 
and co-workers revealed competitive antagonism with BIIE0246; specific binding of 
radiolabelled NPY was completely displaced by the Y2 antagonist from hY2 receptors 
expressed on SMS-KAN cells. Furthermore, treatment with the Y2 antagonist did not 
compete with high concentrations of NPY (up to 1 μM) at the human Y1, Y4 and Y5 
receptor (Doods et al., 1999). Dumont and colleagues provided further evidence of 
competition, by demonstrating the ability of BIIE0246 to compete for specific 
[
125
I]PYY(3-36) binding sites with high affinity in HEK293 cells transfected with the 
rat Y2 receptor, while being inactive at the Y1, Y4 and Y5 receptor types. In the same 
study, competition at the Y2 receptor was also observed in rat brain and human frontal 
cortex membrane homogenates (Dumont et al., 2000). The Y2 antagonist was 
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subsequently used in rat hypothalamic slices to demonstrate inhibition of basal and 
NPY(13-36)-stimulated NPY release, revealing the pre-synaptic role of for the Y2 
receptor (King et al., 2000). Although several other potent Y1 antagonists have been 
developed, such as LY- 357897 (Hipskind et al., 1997) and J-104870 (Kanatani et al., 
1999), many in vitro and in vivo studies have extensively documented the 
pharmacological profile of BIBO3304. The Y1 receptor antagonist does not appear to 
induce any adverse cytotoxicity, making this compound the antagonist of choice for 
pharmacological studies. Furthermore, BIIE0246 is the preferred Y2 receptor antagonist 
due to its high affinity and the large volume of data that supports its selective profile.  
 
In this thesis, additions of both BIBO3304 and BIIE0246 to isolated preparations of 
human colon mucosa revealed elevated levels of Isc compared to the basal level of 
secretion in these specimens. Increases in Isc in response to both antagonists have 
previously been reported in isolated human colon mucosa (Cox and Tough, 2002; 
Hyland et al., 2003; Tough et al., 2011) and can be explained by the alleviation of 
endogenous inhibitory tone mediated via release of PYY and NPY. A separate study 
found that the BIIE0246-mediated increases in Isc were absent in mucosa from Y2
-/-
 
mice (Hyland et al., 2003), indicating that the responses were due to selective blockade 
of the Y2 receptor. More recently, Tough et al. (2011) demonstrated the role of PYY in 
mediating Y1 inhibitory tone, since this was absent in PYY
-/-
 mouse mucosa. 
Interestingly, NPY
-/-
 and WT tissue exhibited the same levels of Y1 receptor-mediated 
tone (which was also reported by Hyland, 2003) and only when both peptides were 
ablated were Y1 and Y2 tonic activities lost. The authors therefore concluded that Y1 
anti-secretory tone is predominantly epithelial in origin and PYY-mediated; while Y2 
receptor-mediated tone is neuronal and mediated via both PYY and NPY, but 
predominantly by the latter. Furthermore, this group distinguished that Y1 tone is 
epithelial derived, compared to Y2-mediated tone, which is neuronal in origin; however 
PYY released from L cells is thought to also play a role in Y2 tone (Tough et al., 2011). 
The observations presented herein have further provided evidence of tonic activation of 
both the Y1 and Y2 receptor, demonstrating the functional significance of these 
receptors in the gut to maintain a reduced secretory state. 
 
  122 
4.1.4 Responses to chemically modified agonist are slower in human colon 
mucosa compared with Col-24 monolayers 
Although pharmacological similarities exist between the two human mucosal 
preparations used in these studies, differences in the functional profiles to chemically 
modified agonists are also apparent. The most evident difference between epithelial 
monolayer responses and isolated colonic mucosae was that responses to all non-
modified, PEGylated and lipidated peptide agonists were slower to peak in the latter 
preparation. With isolated mucosa experiments, the colonic segment was dissected to 
remove the external muscle layer and submucosa. The remaining mucosa strip was 
mounted in the Ussing chamber with the epithelial cell layers and underlying lamina 
propria still intact. The lamina propria, a vascularised region of loose connective tissue, 
which acts as the interface between the bloodstream and mucosal endocrine cells, may 
present a barrier to the basolateral additions of agonists, particularly large molecular 
weight molecules. In contrast, with the epithelial monolayers growing on HAWP filters, 
such basolateral barriers were not present and therefore the increased time-to-peak on 
addition of basolateral agonist is expected. The transient response profiles of non-
modified peptides in Col-24 monolayers, but not in human preparations, may also be 
attributed to their rapid degradation by peptidases, whereas the peptidase-resistant 
PEGylated peptides are predicted to have increased stability and hence a more 
prolonged duration of action (see section 4.3.1 for further detail). 
 
4.2 Pharmacological assessment of [Q34]hPP 
Modification of hPP with a Q
34
 substitution led to the dual Y2/Y4 receptor agonist, 
Obinepitide ([Q
34
]hPP). This modification resulted in a 6-fold lower potency compared 
with hPP in both Col-24 monolayers and human colon mucosa. This reduction in 
potency with [Q
34
]hPP compared to the native hormone was also replicated by data 
generated by our collaborators (Beck-Sickinger et al., see Appendix 1.0), in which IP3 
accumulation was measured for human Y receptors expressed in COS-7 cells. [Q
34
]hPP 
stimulated IP3 accumulation with a 1.7-fold lower potency at the Y4 receptor compared 
with hPP. In epithelial monolayers, there was no significant difference in Y4 efficacy 
between [Q
34
]hPP and the native peptide. In human colon mucosa, [Q
34
]hPP was in fact 
significantly more efficacious than the native peptide, demonstrating both its Y2 and Y4 
functional activity. An interesting observation in this study was a significantly slower 
time to peak with [Q
34
]hPP compared with native hPP in human mucosa (Figure 3.6B) 
but not in Col-24 monolayers. There was no significant difference in the rate of onset 
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within the first 5 min time point, only the time taken to reach maxima with 100 nM. A 
contributory factor to this latency may be the loose connective tissue in the mucosal 
preparations (as discussed in section 4.14), although this does not explain why 
responses to [Q
34
]hPP were slower compared with hPP. The additional Y2 activation 
with [Q
34
]hPP is unlikely to contribute to the slower response, given the neuronal origin 
of these receptors as opposed to the epithelial derived Y4 receptors.  The differential 
response observed between the two peptides in human mucosa is yet to be determined.   
 
4.2.1 Co-stimulation of hY2 and hY4 by [Q
34
]hPP 
It is well known that the Y receptors recognise either the combined N- and C-terminal 
ends of the PP-fold peptides as for the hY1 and hY4 receptors or only the C-terminal 
amino acid sequence TRQRY-NH2 of PYY and NPY as for the hY2 receptor (Schwartz 
et al., 1990; Beck-Sickinger et al., 1994). The C-terminal sequence is also crucial for 




 in either NPY or PYY led to a 
peptide that lost its hY2 receptor affinity and consequently was highly selective for the 
hY1 receptor (Fuhlendorff et al., 1990). The opposite exchange in hPP, i.e. the 
replacement of P
34
 with a Q
34
 residue, led to the development of Obinepitide, a single 
digit nanomolar dual specific hY2 and hY4 receptor selective agonist (Schwartz et al., 
2006) as confirmed in the present study. Here, in human colon mucosa, we 
demonstrated functionally that the response to Obinepitide was partially inhibited 
(although not significantly so) in the presence of the Y2 antagonist, BIIE0246 (Figure 
3.8), proving the dual agonist capacity of this peptide. This was also in accordance with 
IP3 signal transduction data whereby Y2 potency for [Q
34
]hPP was 4000-fold higher 
compared to the Y2 potency measured for hPP (Beck-Sickinger et al., see Appendix 1.0, 
Table 1.0).   
 
4.3 PEGylation of novel dual Y2/Y4 and single Y4 receptor agonists  
4.3.1 PEGylation results in increased longevity of agonist action  




]hPP, and the selective Y4 agonist [K
22
]hPP2-
36, both exhibited a rapid rate of onset and transient response profiles in epithelial 
monolayers that were akin to hPP, reaching their maximum response (with 100 nM) at 





]hPP was unstable (Beck-Sickinger et al. unpublished data) and therefore the 
synthesis of this unmodified peptide was not performed and not available for functional 
testing. The most apparent effect of PEGylation was that the in vitro kinetics was slower 
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]hPP with PEG 
polymers of varying molecular weights (PEG2, PEG5, PEG22) resulted in prolonged 
agonist responses, where maxima (with 100 nM) was not reached until 45 min (Figure 
3.10A). The time taken for each peptide to reach their respective maxima was faster 
with the smaller molecular weight PEGylated peptides and slower with the larger 
PEGylated peptides, and this trend was replicated in human mucosal preparations 




]hPP peptides additionally demonstrated 
prolonged anti-secretory profiles in both Col-24 monolayers and human mucosa, again 
with an indication of the peak response being reached at 45 min in the former 







]hPP2-36 variants did not reveal protracted responses, in fact there was 
no activity within the observation period of 45 min (discussed in more detail below, 
section 4.3.4). Crucially, in both colonic preparations, all PEG polymer sizes had no 
effect upon Isc levels, confirming that all Y4-mediated anti-secretory observations were 
agonist-induced and not a non-specific action of the PEG polymers.  
 
In vivo, the characteristic increase in longevity of action demonstrated by the 
conjugation of a PEG polymer to a peptide is thought to occur via two major 
mechanisms; reduced clearance of the peptide via the kidneys and enhanced protection 
from enzymatic cleavage, together resulting in increased bioavailability. The 
mechanism by which PEG reduces kidney clearance is through increased hydration; two 
H2O molecules bind to the each ethylene glycol unit thus significantly increasing both 
the hydrodynamic radii by 5- to 10-fold and the molecular weight compared to their non 
PEGylated equivalents (Harris & Chess, 2003). In vitro characterisation of the 
PEGylated hPP variants in Col-24 monolayers and human colon mucosa demonstrated 
prolonged reductions in Isc; this is thought to be in part attributed to the PEG polymer 
shielding the peptide and reducing access to peptidases. The mechanism underlying this 
enzyme protection may be due to a constant movement and flexibility of the PEG 
polymer subsequently allowing successful interactions between the PEG-conjugated 
peptide and the receptor with high affinity. This model was described by Fishburn in 
2007, whereby the author explained the possibility of the hydrated PEG polymer 
forming a barrier over the peptide domain, thus decreasing the incidence of successful 
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Figure 4.1 A schematic illustrating the mechanism by which a PEG polymer can 
provide shielding against peptide degradation. Interaction between a plasma 
peptidase and a PEG-conjugated peptide is hindered in the presence of a high molecular 
weight PEG chain. The flexibility of the PEG polymer permits the possibility of various 
configurations, which may decrease the likelihood of interaction between the plasma 
peptidase and the target peptide. Taken from Fishburn, 2007. 
 
4.3.2 Enzymatic cleavage of chemically modified PP analogues 
A small number of studies have attempted to reveal the peptidases involved in the 
metabolism of PP; Adamo and Hazelwood (1989) were the first group to demonstrate 
degradation of aPP via soluble endopeptidases. Shortly afterwards, Tasaka and 
colleagues (1989) utilised 
125
I-PP and the acid saline extract (ASE) of rat submaxillary 
gland to assess peptide breakdown; ASE led to significant PP degradation, which was 
inhibited in the presence of a thiol protease inhibitor (Tasaka et al., 1989). Although PP 
is a weak substrate for DPPIV compared to NPY and PYY (Mentlein et al., 1993; 
Schon et al., 1991), DPPIV cleavage has been demonstrated by Nausch et al. (1990). 
 
Over the last few years, several groups have focused on establishing the stability of the 
native peptide and have attempted to reveal, via amino acid substitutions, which amino 
acid positions play a key role in stability and whether further chemical modifications 
can enhance the resistance to degradation. Baxter et al. (2010, abstract only) determined 
whether PP analogues with substitutions at specific positions were targeted by DPPIV 
and the neutral endopeptidase, NEP and whether the peptides were resistant to 
breakdown by both enzymes, in vitro and in vivo. With the use of high performance 
liquid chromatography (HPLC) and matrix assisted laser desorption/ionisation-time of 
flight mass spectrometry (MALDI-TOF-MS), this group reported that both DPPIV and 
NEP were involved in the breakdown of PP. Furthermore, cleavage points were 
determined at position 20 and 30 when incubated with NEP in vitro. In vivo, incubation 
with the NEP inhibitor, phosphoramidon, enhanced reduction in food intake after two 
hours following a dose of 150 nmol/kg of PP. Additionally, PP plasma levels increased 
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mice. Thus, PP analogues with targeted substitutions were shown to prevent breakdown 
by NEP and DPPIV, demonstrated by reduced metabolite formation in vitro and 
improved food intake inhibition in mice. 
 
More recently, Tan et al. (2012) described the development of a peptidase-resistant hPP 
analogue (PP 1420). PP 1420 differs from hPP by five amino acid substitutions and the 
addition of a glycine residue at position 0. In a double-blinded, placebo-controlled 
randomised study, subcutaneous injection of PP 1420 (2, 4, 8 mg) to male subjects 
demonstrated a prolonged elimination t1/2 compared with the native hormone. With all 
doses, Cmax was achieved one hour after dosing and then subsequently began to fall with 
an elimination t1/2 ranging from 2.4 - 2.6 hours. Given the fast elimination t1/2 of PP 
1420, the authors predicted frequent patient dosing to maintain plasma drug levels over 
the course of 24 hours. Thus, this phase 1 study has not only demonstrated the 
successful substitution of select amino acids in the hPP sequence, thereby resulting in 
an extended terminal elimination t1/2 compared with the native hormone, but more 
importantly, promising tolerability in human subjects.  
 
As previously discussed, Bellman-Sickert and colleagues demonstrated successful 




]hPP (Bellman-Sickert et al., 2011). Our 





]hPP variants in human plasma against peptidase 
degradation. With the use of reversed phase-HPLC, fluorescence detection and MALDI-










]hPP demonstrated the greatest stability, with 90 % 
intact peptide still remaining post observation period (144 hours). A smaller PEG 
moiety (PEG2) also exhibited an increased resistance to proteolytic degradation, 
although this effect was less pronounced compared with the larger molecular weight 























Although peptide degradation was not measured in this thesis, the encouraging data 





]hPP variants, and this data may be used to predict increased 




]hPP variants examined in this thesis, since 
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prolonged anti-secretory activity was observed in vitro in Col-24 monolayers. It has 
been reported that analogues of PP in which the Met and Ala at position 30 and 22, 
respectively, are replaced by Lys are especially beneficial in having a longer half-life in 
blood plasma than native PP. Preliminary, unpublished data generated within the GIPIO 





]hPP and the corresponding PEGylated analogue 
with porcine liver extract homogenates. In keeping with the prolonged reductions in Isc 





]hPP variants (Made et al., unpublished data). Interestingly, an 




]hPP, despite the lack of 
functional activity seen in both Col-24 monolayers and human colon mucosa. This may 
be due to the large PEG chain sterically hindering the receptor binding site in an attempt 
to block exposure to proteolytic destruction (Figure 4.1).  
 
The instability of Y receptor peptide agonists against proteolytic enzymes is the most 
discouraging factor for their therapeutic use as new treatment modalities. Although the 
short metabolic stability of the native peptides can be compensated by continuous i.v. 
infusion, this does not fundamentally overcome the effect of rapid degradation via 
proteolytic enzymes. Thus, the development of a prolonged-acting form of a Y2, Y4 or 
Y2/Y4 agonist in vivo has been the focus of much recent research. While the 
effectiveness of PEGylation in enhancing the stability of peptide pharmaceuticals has 
been validated for years, the underlying mechanism remained poorly understood until 
recently. The published data described above have helped to refine the mechanism 
behind the increased stability and prolonged action, corroborating the data presented in 
this thesis.  
 
4.3.3 PEGylation results in a latency in response activation 
Interestingly, all PEGylated peptides in this study displayed latency in onset, with larger 
PEG-peptide sizes inducing a greater degree of delay (as observed in epithelial 
monolayers and human mucosa). This delay in onset may be a result of a slower rate of 
peptide-receptor association and a number of factors could be responsible for the 
reduction in apparent activation rates of PEGylated peptides. Very few studies have 
been published regarding PEGylated agonist-GPCR molecular interactions and many 
have been largely based on PEGylated antibodies. Kubetzko et al. (2005) studied the 
PEGylation of an antibody construct and published two mechanisms that may be 
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involved; intra-molecular and inter-molecular blocking. With the former, the PEG 
moiety is thought to directly obstruct the antibody’s binding region, and with the latter, 
the PEG polymer could deter binding of the antibody to adjacent sites in the bound 
conformation. With the use of binding assays on HER-2-overexpressing cells and mass-
transport limited BIAcore measurements, Kubetzko et al. (2005) demonstrated that over 
90% of the PEGylated antibody constructs in solution exist in an intra-molecularly 
blocked conformation (with the PEG moiety directly obstructing the antibody’s binding 
region). This theory may in part explain why PEGylated molecules exhibit low 
immunogenicity and high resistance to proteolytic destruction in vivo, since they are 
predominately shielded by the PEG moiety itself. Nevertheless, the favourable 
characteristics of PEGylation may still be achieved with strategies such as short or 
branched PEGylation, or even with more novel approaches such as reversible 
PEGylation (Peleg-Shulman et al., 2004) to avoid loss in therapeutic activity.  
 
In terms of the PEGylated peptides assessed in this study, there is a clear correlation 
between the molecular weight of the PEG polymer and the degree of latency in 








]hPP variants in Col-24 monolayers 
(Figure 3.10B and Figure 3.18B). This is suggestive of the intra-molecular blocking 
described above (Kubetzko et al., 2005) whereby PEGylation at these sites is likely to 
sterically hinder Y4 receptor association by the PEG itself. This is in accordance with 







(PEG22)]hPP2-36. It is predicted that the delayed rate of 
onset observed in Col-24 monolayers is a result of slow association of the peptide to the 
binding target, since the delayed rate of onset was not observed with the non-PEGylated 
counterparts. Although association rates were not determined directly, this is the most 
likely hypothesis.  
 
4.3.4 The effect of PEGylation on peptide efficacy and potency 
Although a PEG polymer has the capacity to enhance the overall bioavailability of a 
peptide, this is often detrimental to the receptor binding affinity, as a consequence of 
steric hindrance. Thus, although the equilibrium between the pharmacokinetic and 
pharmacodynamic properties is altered in the presence of the PEG side chain, the 
improved efficacy coupled with the potential for reduced patient dosing outweigh the 
disadvantage of a loss in binding affinity. The main objective of early PEGylation 
attempts was to enhance drug exposure and minimise the risk of adverse events, 
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however little attention was paid to conserving receptor potency. Recently, more 
consideration has gone into maximising drug exposure, whilst retaining drug potency.  
Unlike the transient responses to hPP and all other non-modified peptides, the 
PEGylated peptides demonstrated a delay in the rate of onset, followed by sustained 
reductions in Isc. To construct concentration-response curves and make an assessment of 
potency, responses to each concentration of PEGylated peptide were taken at the 
maxima produced and in most cases, this was at 45 min. The resultant concentration-




]hPP series of peptides (Figure 3.14) 
illustrate that peptide modification with a PEG2 polymer generated a maxima that was 
only marginally greater (and not significantly so) than that of hPP but was significantly 









]hPP with a 5 kDa PEG thus resulted in increased longevity of 
action coupled with superior efficacy compared with its non-PEGylated counterpart 
[Q
34




]hPP was also 





highlighting the role that PEG molecular weight above a threshold concentration may 
play in controlling the interaction at the receptor. In this case, the mechanism of inter-
molecular blocking may be involved, where the PEG tail may be hindering other 
receptor sites in the vicinity and reducing the feasibility of successful peptide-receptor 
interactions. This is a likely possibility for the Y4 receptor, since evidence indicates 
close proximity (receptor homodimerisation) in plasma membrane microdomains. 
Homodimerisation of the rhesus (rh) Y4 receptor was first reported by Berglund and co-
workers (Berglund et al., 2003b); each rhY receptor was fused to RLUC at the carboxy 
termini of the receptor and a green fluorescent protein (GFP) was subsequently fused to 
rhY4 receptor. Using BRET2 technology, Berglund et al. established that the rhY4 
receptor exists as a dimer prior to stimulation at the cell surface of HEK293 cells, and 
then dissociates following agonist binding. High BRET2 ratios, indicative of a close 
association of RLUC-tagged rhY4 receptors and GFP, also confirmed Y4-specific 
homodimerisation. High cell expression levels for the rhY4-GFP were observed in this 
study. Since it has been reported that recombinant protein over-expression in cells can 
encourage receptors to come together in an atypical manner (Devi, 2001), Berglund et 
al validated their findings by demonstrating no significant difference between the 
expression levels of the RLUC-tagged rhY4 receptor and the RLUC-tagged human 
opioid δ and μ receptors in addition to the rhY2 receptor, thus  providing confirmation 
that the homodimerisation was a particular characteristic of the rhY4 receptor and not a 
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consequence of protein over-expression. In addition to these findings, Berglund et al. 
also reported a lack of rhY4 receptor heterodimerisation with other members of the Y 
receptor family; aside from dimerisation with itself, the rhY4 receptor interestingly 
displayed a high degree of interaction with the Y2 receptor. High sequence homology is 
thought to play a role in determining heterodimerisation between receptors (Ramsay et 
al., 2002); interestingly, the Y2 and Y4 receptors share a much lower sequence identity 
compared with the Y1 and Y4 receptor, however the lowest BRET2 ratio for 
heterodimerisation was unexpectedly observed between the latter pair of receptors. In 





peptide, and the fact that the Y4 receptor can exist as a homodimer, it is likely that the 
PEG tail may be inter-molecularly interacting with adjacent unbound Y4 receptors 
within the dimer, significantly hindering further binding. 
 




]hPP series of peptides demonstrated slightly 
increased potencies relative to [Q
34














compared with 36.0 nM for [Q
34
]hPP) in Col-24 monolayers. This retention in Y4 
potency was in accordance with the IP3 data generated by our collaborators, where all 
PEGylated peptides exhibited nM Y4 receptor potencies (see Appendix 1.0, Table 1). A 
K
22
 modification interestingly resulted in differential effects upon Y4 signalling 















]hPP did exhibit a 10-fold higher potency compared with the unmodified 




]hPP with a PEG22 polymer was in 




]hPP was inactive 









]hPP showed that it 
had reduced affinity for the Y4 receptor (Bellman-Sickert et al., 2011). Interestingly, IP3 










nM). This loss in Y4 efficacy and potency was also observed with [K
22
(PEG22)]hPP2-36 
(Figure 3.32), despite demonstrating nM affinity for the Y4 receptor in IP3 accumulation 
studies (see Appendix 1.0, Table 2). This difference could be attributed to the difference 
in time points when measuring potency in both assays. The measurement of IP3 
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production is taken at 5 min after agonist addition since IP3 levels typically reach a peak 
within a few seconds. In the functional assay with Col-24 monolayers, due to the 
latency in the rate of onset of an anti-secretory response, measurements of the maximum 
reduction in Isc are not measured until approximately 45 min, when steady state is 
reached. 
 
The enhanced and prolonged responses to PEGylated peptides have been described 
previously in vivo (DeCarr et al., 2007). In lean C57BL/6 mice, administration of 
PYY(3-36) (2.5 µmol/kg) induced a considerable (42%) reduction in food intake 
compared with control mice at a 4 hour time point. Twenty four hours after the 
administration of  PYY(3-36), a significant 9% reduction was still observed. The 
PEG5ylated PYY(3-36) variant (PEG5-PYY(24-36)-L
31
) resulted in a loss in efficacy 
compared with the non-modified PYY(3-36), where 5.6 µmol/kg induced a 22% 
reduction in food intake at 4 hours and minimal reduction at 24 hours. No activity was 
seen with the peptide at 4 hours when the PEG size was increased to 40 kDa (PEG40-
PYY(24-36)-L
31
), however a small reduction of 12% and 8% was measured at 24 and 
48 hours, respectively. Therefore modification of the native peptide with a 5 or 40 kDa 
PEG polymer did not lead to a significant improvement in efficacy compared with 
PYY(3-36). Interestingly, administration of PEG20-PYY(24-36)-L
31
 at the same 
concentration induced a similar reduction in food intake to PYY(3-36) (42 % at 4 
hours), although contrary to that seen with PYY(3-36), the result remained statistically 
significant at 24 and 46 hours. Therefore significant reductions in food intake were 
reported 24 and 48 h subsequent to the administration of PEG20 and PEG40-conjugated 
PYY(3-36) variants, suggesting an increased longevity of action in comparison to 
PYY(3-36) itself. Interestingly, the largest PEG modification (PEG40-PYY(24-36)-L
31
) 
did not elicit a response within the 4 hour observation period, thus corroborating 
findings in this thesis that larger PEG-conjugated peptides display a latency in the rate 
of onset, suggestive of the intra-molecular blocking described above (Kubetzko et al., 
2005). 
 
The preservation of potency observed in this thesis between PEGylated and non-
PEGylated peptides corroborates findings reported by Lumb et al. (2007) who described 
a Y2 selective PEGylated peptide and its capacity to decrease food consumption in both 
lean and diet induced obese mice. Peptide 1, consisting of the 25-36 amino acid core 
sequence of hPYY conjugated to an N terminally positioned 2-mercaptonicotinic acid, 
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displayed superior Y2 receptor affinity in vitro. In order to achieve enhanced efficacy in 
vivo, the amine of the N-terminal modifying group was changed to a thiol moiety 
suitable for site-specific modification with a PEG polymer. Replacement of the 
methylmercapto moiety with a thiol followed by PEGylation via a maleimide group 
either with the linear PEG structure of 5 or 20 kDa or with a branched 40 kDa PEG 
polymer resulted in analogues that exhibited in vitro activity at the Y2 receptor 
comparable to that of the non-PEGylated analogue. The authors concluded that in 
general, PEG size or branching does not have a significant effect on in vitro Y2 receptor 
binding or activation, with the EC50 and Ki values at the Y2 receptor within 2-fold of the 
values of the non-PEGylated peptides. 
 
The data presented in this thesis regarding peptide potency is in partial agreement with 
finding reported by Lumb et al. (2007). Although this group have demonstrated a 
conservation in potency with PEGylated PYY analogues with molecular weights of 5, 







this study exhibited a significant loss in Y4 potency. PEG22-ylation at position 22 of the 
PP sequence is therefore detrimental to potency and efficacy, as determined by 
functional anti-secretory activity in both colonic preparations. The evidence presented 
herein warrants investigation into the clinical significance of the increased stability of 
PEGylated hPP analogues in vivo. 
 
4.4 Effect of PEGylation on Y4 receptor desensitisation 











]hPP2-36 derivatives, the ability of PEGylated variants 
to induce desensitisation to a subsequent response to hPP was assessed. The transient 
nature of hPP responses is indicative of rapid Y4 receptor desensitisation in the presence 
of an agonist, and is comparable to that seen with epithelial Y1 receptors (Holliday et 
al., 2005). Early studies performed by Voisin et al. reported an inability of the Y4 
receptor to desensitise in CHO cells, but this was possibly due to the 24 hour exposure 
to PP and also a failure to measure degradation of the agonist (Voisin et al., 2000). The 
same group also reported the inability of hY4 receptors tagged at the C terminus to 
redistribute from the plasma membrane after 24 h pre-treatment with hPP, however this 
was contradictory to findings reported by Parker et al. (2001 and 2002) whereby it was 
shown that [
125
I]PP was effectively and rapidly sequestered from the plasma membrane 
into endosomes by rat Y4 receptors in the same cell line. Using BRET, Berglund et al. 
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demonstrated recruitment of β-arrestin 2 following Y4 receptor activation with hPP. In 
this thesis, hPP (3-300 nM) reduced VIP stimulated Isc in a concentration-dependent 
manner in Col-24 monolayers (Figure 3.4). Following the initial response to 10 nM 
hPP, responses to a subsequent second addition of hPP (10 nM) were abolished due to 
homologous desensitisation. Homologous and cross-desensitisation of constitutively 
expressed Y4 receptors has been demonstrated previously in human colonic epithelial 
monolayers using species variant PPs (Cox et al., 2001b).  
 
The literature regarding Y2 receptor internalisation is controversial. It has been reported 
that this Y receptor type internalises slowly (Berglund et al., 2003; Gicquiaux et al., 
2002; Ouedraogo et al., 2008). In contrast, other studies have demonstrated rapid 
internalisation of the Y2 receptor after agonist treatment in HEK293 cells, with a rate 
comparable with the hY1 and hY4 receptors (Holliday et al., 2005; Bohme et al., 2008; 
Kilpatrick et al., 2010). Recently, Walther et al. (2010) confirmed with the use of 
fluorescence microscopy that hY2 receptor internalisation was not limited to HEK293 
cells; internalisation was measured in two human cell lines known to express the 
receptor endogenously, SMS-KAN and MHH-NB-11. Walther et al. demonstrated a 
comparable mode of internalisation in all three cell lines and could therefore conclude 
that hY2 receptor internalisation was not dependent on the cell type but that it occurred 
in cells that endogenously express the receptor. This group revealed rapid arrestin-3 
recruitment to the plasma membrane upon hY2R stimulation in all 3 cell lines tested. 
Quantification of receptor internalisation in the presence or absence of arrestin-3 over-
expression by cell surface ELISA, as well as analysis of hY2R/arrestin-3 interaction by 
BRET, strongly suggested an arrestin-3-dependent internalisation process, consistent 
with the data obtained by fluorescence microscopy. Thus, Walther et al. published the 
first direct demonstration of hY2R interaction with arrestin-3 and this was in good 
agreement with BRET2 studies showing slow association rates of the rhesus Y2R with 
arrestin-3 in HEK293 cells (Berglund et al., 2003). 
 




] derivatives, Y4 desensitisation studies revealed 





]hPP; no significant Y4 desensitisation occurred in the presence of 0.3 – 
1000 nM of the peptide. This lack of desensitisation to subsequent hPP responses was 




]hPP (1-1000 nM), however a significant 
reduction in the hPP response was recorded with 30 nM peptide. Increasing the PEG 





]hPP) resulted in partial inhibition of hPP responses between 0.1 
and 1000 nM and this reduction in the size of the hPP response was also observed in 









]hPP (0.1-100 nM) 
did not induce Y4 receptor desensitisation in Col-24 epithelia (Figure 3.21B), whereas 





1000 nM, but not 100 nM). This observation was surprising since the PEG22-peptide 
did not exhibit a measurable anti-secretory response in both Col-24 monolayers and 
human colon mucosa. All PEGylated peptides within this study demonstrated 
differential profiles in terms of efficacy. Both PEG5-ylated peptides demonstrated high 






















]hPP was inactive.  
 
Up until the last two decades, ligand-mediated activation of GPCRs and downstream 
signalling events were thought to be a linear process; this theory explained that one 
GPCR could be activated by a number of agonists which could then induce one distinct 
stable conformation. It is this one conformation which was thought to permit the 
coupling of one G-protein subtype, resulting in the same intracellular responses 
mediated by stimulation or inhibition of the receptor. A number of studies have recently 
suggested that the efficacy of an agonist is not always indicative of observations seen in 
experimental data, leading to the several novel theories that may help predict a more 
accurate response with a given agonist. These theories suggest that a receptor can 
employ a number of diverse active conformations once activated and stabilised by an 
agonist (Kenakin, 2007), leading to the stimulation of distinct effectors corresponding to 
that receptor (Urban et al., 2007; Violin and Lefkowitz, 2007). An expansion of this 
model is that various agonists for one receptor subtype could also induce differential 
mechanisms of desensitisation, since one distinct receptor conformation may acquire 
enhanced or reduced affinity for regulatory proteins such as GRKs or arrestin. 
 
Studies with the β2-AR have been pivotal in establishing ligand-directed signal 
specificity. In 2008, Drake et al. demonstrated that a range of β2-AR ligands displayed 
considerable bias towards β-arrestin signalling. Despite their low efficacy for G-protein-
dependent signalling, each ligand was capable of stimulating β-arrestin translocation to 
a much greater degree relative to their efficacy (Drake et al., 2008). It was subsequently 
  135 
determined that biased ligands for β-arrestin collectively shared a common structural 
feature, promoting the idea that ligand-receptor complexes can adopt stable 
conformations which encourage recruitment of β-arrestins. More recently, the use of 
biophysical techniques, such as intra-molecular FRET (fluorescent resonance energy 
transfer) have allowed the comprehensive real-time examination of active receptors. In 
2009, Zurn et al. utilised a C-terminally labelled α2-AR with CFP (cyan fluorescent 
protein) and introduction of a fluorescein arsenical hairpin binder, targeted to different 
sites in the third intracellular loop of the α2-AR, to demonstrate that a number of 
receptor rearrangements occur upon binding to both partial and full agonist, revealed by 
differences in FRET efficiencies (Zurn et al., 2009). 
 
Agonist-mediated signal specificity has also been well documented with the opioid 
receptors; unlike the μ-opioid receptor agonists etorphine and [D-Ala2,N-MePhe4, Gly-
ol]enkephalin (DAMGO), which can  promote recruitment of arrestin to the μ-opioid 
receptors and induce rapid internalisation, the μ-opioid agonist, morphine, cannot (Keith 
et al., 1996). It was once thought that the paradoxical feature of morphine to induce 
little desensitisation despite the ability to stimulate receptor signalling was a 
consequence of transient receptor binding, resulting in activation but not 
phosphorylation of the receptor. At the time, further supporting data was provided by 
Zhang et al who demonstrated morphine to act as a partial agonist (Zhang et al., 1998), 
thus providing another explanation for morphine’s ineffectiveness in stimulating GRK-
mediated phosphorylation and arrestin recruitment. An additional study further 
corroborated these findings utilising HEK-293 cells over-expressing GRK2. Over-
expression of the regulatory protein resulted in arrestin translocation to the μ-opioid 
receptor and internalisation (Bohn et al., 2004). However more recent studies have 
challenged the initial findings and have demonstrated full agonism at the μ-opioid 
receptor, despite the lack of ability to promote arrestin recruitment and internalisation, 
and also the existence of GRK2 over-expression (Groer et al., 2007; Xu et al., 2007). 
Johnson et al. went on to demonstrate that both morphine and DAMGO induced rapid 
desensitisation of a K+ current via different mechanisms in HEK293 cells expressing a 
G protein-coupled inwardly rectifying K+ channel (Johnson et al., 2006). The addition 
of a PKC inhibitor led to a reduction in morphine-mediated desensitisation, although the 
same was not observed with DAMGO; desensitisation was only observed in the 
presence of a dominant negative mutant form of GRK2 when co-transfected. From these 
findings it was concluded that both morphine and DAMGO are able to exert differential 
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stabilisation effects upon the μ-opioid receptor by coupling to G proteins and activating 
the inwardly rectifying K+ channel, but possessing a varying affinity for GRK2 and 
PKC. Several studies have now shown that a decline in ligand-induced signalling is not 
always indicative of the ligand’s ability to desensitise its receptor. The data described 
above suggests that regulation of receptor activation and subsequent receptor 
phosphorylation is in part dependent on the ligand itself, thus opening the possibility of 
developing pharmaceuticals that are highly efficacious but do not result in tolerance.  
 
A further and more likely explanation for the lack of desensitisation observed with the 
PEG5-ylated peptides is that the process of internalisation is disrupted due to the 
presence of the PEG polymer. This hypothesis has been verified by our collaborators 
with the use of stably transfected HEK-293 cells with an enhanced YFP-tagged Y4 
receptor and co-localisation with TAMRA-(5(6)-carboxytetramethylrhodamine) 
peptides (Figure 4.2A). With 100 nM TAMRA-hPP, Mäde et al (unpublished) 
demonstrated fast and specific internalisation of EYFP-tagged Y4 receptor and the 
unmodified ligand in co-localisation experiments (Figure 4.2B; for full experimental 



















]hPP (1µM) demonstrated impaired cellular uptake (Figure 4.3) relative 
to hPP under the same conditions. Thus, it seems the EYFP-hY4R internalised more 
slowly when incubated with a PEGylated peptide conjugate, with the peptide possibly 
anchored within the cell membrane. This effect was contrary to the fast and specific 





]hPP demonstrated poor internalisation at 30 min and very little 
internalisation at 60 min.  
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Figure 4.2 Localisation of hY4 receptor C-terminally fused to EYFP in HEK293. 
(A) No agonist; hY4R-EYFP prior to stimulation of the receptor shown in green, 
TAMRA-modified peptide shown in red with nuclei visualised with Hoechst33342 
shown in blue, and a 3 x magnification of a chosen cell is shown at the far right. The 
scale bar represents 10 µm. (B) Stimulation with unmodified peptide (hPP, 100 nM) 
elicits rapid internalisation of the receptor-peptide complex (hY4R-EYFP and peptide 
co-localisation is shown in yellow). The upper and lower images of (B) demonstrate 
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Figure 4.3 Stimulation of HEK-293 cells expressing hY4R-EYFP co-localised with 
PEGylated peptides. hY4R-EYFP is shown in green, TAMRA-modified peptide shown 
in red with nuclei visualised with Hoechst33342 shown in blue. A 3 x magnification is 









]hPP results in 
weaker internalisation of the receptor-peptide complex, than that observed after hPP 
under equivalent conditions (Figure 4.2). The upper and lower images here demonstrate 
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To address the impact of arrestin on the internalisation process, co-transfection of arr-3-
mCherry with hY4R-EYFP was performed in HEK-293 cells and again analysed by 
fluorescence microscopy. Prior to agonist treatment receptor- EYFP fluorescence was 
mainly localised in the plasma membrane and arr-3-Cherry fluorescence was 
homogenously distributed in the cytoplasm. hPP (100 nM) stimulation led to a rapid 
redistribution of arr-3-mCherry from a diffuse cytoplasmic to a membrane-associated 
vesicular pattern only for the unmodified peptide. For the PEGylated peptides, no arr-3-
mCherry translocation was detected, as indicated by the sustained diffuse distribution of 




Figure 4.4 Time-dependent arrestin3-promoted hY4R internalisation upon  









EYFP and arrestin-3 localisation prior to stimulation, with the receptor shown in green, 
arr-mCherry shown in red, with nuclei visualised with Hoechst33342 shown in blue and 
a 3 x magnification (far right-hand images). The scale bar represents 10 µm throughout. 
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]hPP,  did not induce Y4 receptor desensitisation in Col-24 monolayers 









]hPP however did 
partially reduce further Y4 signalling (as demonstrated by subsequent reduced hPP 
responses), even without the presence of arrestin in HEK-293 cells, demonstrated by 
our collaborators (Figure 4.4D). There could be several reasons for this; the large 
PEG22 polymer conjugated to the peptide may interact with the receptor in such a way 
as to prohibit the formation of the receptor state that recruits β-arrestin. Another 









]hPP may not be due to desensitisation of the 
receptor at all, but allosteric hindrance of the receptor binding site caused by the large 
PEG side chain, blocking subsequent binding. Furthermore, we cannot exclude the 
possibility that there may be a transient interaction of the Y4 receptor-peptide complex 
with β-arrestin that is not detected within the time frame of the imaging experiments 





]hPP may mediate GPCR internalisation in an arrestin-
independent manner, however as shown in Figure 4.3, the peptide is also not 
internalised and thus the former explanations are more plausible. PEG22-ylation of the 
[K
22





]hPP, but was analogous to the partial agonism and partial 









demonstrating a lack of hPP desensitisation with concentration range of 1-100 nM in 
Col-24 monolayers (Figure 3.29). A concentration of 1 µM however, did result in a 
significant loss in subsequent hPP responses and at 3 µM [K
22
(PEG22)]hPP2-36 even 
more so, despite the low efficacy of this PEG-22 modified [K
22
]hPP2-36 analogue in both 
colonic preparations at these high concentrations (Figure 3.26). 
 
The ability of PEGylated analogues to disrupt the process of internalisation has been 
reported previously. In 2010, Sen et al. PEGylated the recombinant coagulation factor 
VIIa (rFVIIa), which is widely used for treatment of haemophilia, and is cleared from 
the circulation rapidly with a plasma half-life of 2–4 hours. This group investigated the 
effect of 
125
I- labelled rFVIIa and glycoPEGylated rFVIIa on binding to its cellular 
receptors and its subsequent internalisation in endothelial cells and fibroblasts. 
Modification of rFVIIa with PEG impaired rFVIIa binding to both endothelial cell 
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protein C receptor and tissue factor (TF) on cell surfaces. The internalisation of 
PEGylated rFVIIa in endothelial cells and fibroblasts was markedly lower compared to 
the internalisation of rFVIIa in these cells. This group concluded that the reduced 
internalisation was attributed to alterations in electrostatic binding or steric hindrance as 
a consequence of the PEG chain and not a loss of specific receptor recognition, given 
that a near normal activation of factor X by glycoPEGylated rFVIIa on TF expressing 
cells was observed (Sen et al., 2010). 
 
In addition, Dapp et al. (2011) studied the PEGylation of a series of PEGylated BN(7-
14) analogues (radiolabelled bombesin conjugates) for imaging and therapy in breast 
and prostate tumours (with molecular weights of 5 kDa, 10 kDa and 20 kDa). 
Incubation of PC-3 cells at 37°C with the radiolabelled PEG conjugates demonstrated 
cell uptake when measured at 0.25, 0.5, 1, 2, 4 and 24 hours. For each analogue, 1 μM 
unlabelled BN(1-14) was used to determine nonspecific binding of surface-bound and 
internalised activity. After 30 min of PC-3 incubation, the non-modified 99mTc-Lys-
BN analogue displayed maximum internalisation, which remained stable for 2 hours. 
Internalisation was markedly lower with all PEGylated analogues, and the time taken to 
reach a plateau of internalised fraction was delayed (between 4 and 24 hours). This data 
was consistent with the theory of disrupted or slower binding kinetics associated with 
the PEGylated BN analogues compared with their non-PEGylated counterparts. The 
PEG5 modified BN variants displayed the most favourable in vivo pharmacokinetic 
properties such as enhanced clearance from the blood plasma and preferential excretion 
via the renal route. The authors also reported a 2.9% ± 0.9%, 1.7% ± 1.4% and 1.2% ± 
1.2% internalisation rate for the PEG5, PEG10 and PEG20- conjugated BN analogues, 
respectively, expressed as a percentage of total radioactivity added per million cells (% 
per 10
6
 cells); although these values do not significantly alter between each other, there 
is evidently a trend for increased internalised fraction which is dependent upon the size 
of the PEG entity. To conclude, this study reported PEGylation to be an effective 
modification to improve the pharmacokinetic profile of novel BN analogues. The 
impaired intracellular uptake observed in this study also corroborates the reduced Y4 









]hPP peptide variants by our collaborators.  
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4.5 Lipidation of novel dual Y2/Y4 and single Y4 agonists  
4.5.1 Lipidation results in protracted responses and a retention in Y4 potency 
The effect of N-terminal conjugation with a fatty acid moiety has been well 
documented; the increased stability of the secondary peptide results in increased 
longevity of action in comparison to the native peptide (Knudsen et al., 2000; 
Yamamoto et al., 2003). Previously, our collaborators demonstrated that palmitoylation 




]hPP) increased the biological activity of the peptide 
(Bellman-Sickert et al., 2011). Bellman-Sickert et al. achieved in vitro stabilisation as 
well as a longer in vivo half-life and subsequently higher bioavailability. Furthermore, 
this group observed a more persistent and retarded uptake of the lipidated peptide in the 
rat and a re-distribution to the liver instead of the kidneys indicating a reduced risk of 
toxicity. Initial studies on food intake revealed that lipidation prolonged the anorectic 
effect compared to the unmodified analogue. Given the observation described above, 
the lipidated hPP analogues were further investigated as potential anti-obesity agents. 
The findings reported in this thesis were designed to complement this study (Bellman-
Sickert et al., 2011) and to determine if the introduction of an N-terminal long-chain 








]hPP variants would further enhance 
biological activity and potency at the Y2 and Y4 receptor. Furthermore, an assessment of 
varying fatty acid lengths on the Y4-mediated anti-secretory capabilities of the 
[K
22
]hPP2-36 series of peptides was also made. 
 











(E-Pam)]hPP2-36, demonstrated similar anti-secretory profiles, with reductions in Isc 




]hPP peptide in Col-24 
monolayers. In human colon mucosa, the response to [K
22
(E-Pam)]hPP2-36 was almost 




]hPP, indicating greater 
efficacy with the dual Y2/Y4 lipidated agonist, compared with the single Y4 lipidated 
agonist. This result is not surprising due to the dual expression of the Y2 and Y4 receptor 
in human colonic specimens. Modification of [K
22
]hPP2-36 with lauric acid (C12) 
produced equi-effective responses compared with [K
22
(E-Pam)]hPP2-36 indicating that 
further elongation of the lipid side chain from C12 to C16 was not detrimental to 
agonist activity. Basolateral additions of [K
22
(E-Capr)]hPP2-36 (C8) resulted in a switch 
from a monophasic transient profile (seen with the non-lipidated [K
22
]hPP2-36) to a 
biphasic response in epithelial monolayers, with an initial inhibitory phase that reached 
a nadir at 5 min followed by a second more prolonged secretory phase that lasted over 
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45 min (Figure 3.37). Time course profiles of the same lipidated analogues in human 





(E-Pam)]hPP2-36 were delayed in the 
rate of onset compared with hPP2-36 and inhibited Isc to the same degree. Similarly, 
[K
22
(E-Capr)]hPP2-36 displayed an initial reduction in Isc followed by a second anti-
secretory phase. The biphasic nature of the caprylic acid-conjugated peptide response 
has not been reported to my knowledge in any previous studies, however the 
intermediary response may be due to the length of the chain (C8); the caprylic acid 
conjugate may be short enough so as to not alter the binding kinetics of the peptide 
compared with the non-lipidated analogue, hPP2-36, but may be sufficiently long to 
increase the overall stability and shield the core peptide from proteolytic destruction, 
hence resulting in a second prolonged secretory effect.  
 
All fatty acid side chains were inactive in both colonic preparations. The fact that 
caprylic acid, along with lauric and palmitic acid, were all inactive (at 100 nM), 
confirms that the anti-secretory responses to each lipidated peptide was a result of Y4 
receptor activation, and not a result of L-cell derived PYY release into the lamina 




(E-Capr)]hPP2-36, all lipidated peptides displayed a delay in the onset of 
action. This characteristic latency has also been reported by a group comparing the 
pharmacokinetic and pharmacodynamic properties of a long-acting lipidated (C14) 
insulin analogue. Subcutaneous injection of NN304 into a para-umbilical skin fold of 11 
healthy volunteers resulted in a predictable linear elevation in total plasma NN034 
concentration, when compared with Neutral Protamine Hagedorn (NPH)-insulin during 
euglycaemic glucose clamp studies. Interestingly, peak concentrations were not 
achieved until after 4-6 hours after administration. Furthermore, the maximal glucose 
infusion rate observed with NN034 was not as transient compared to its non-lipidated 
counterpart, NPH-insulin, at an equivalent dose. NN304 also demonstrated a slower rate 
of onset, demonstrated by a considerably higher tmax (Heinnemann et al., 1999). 
 
All lipidated peptides presented herein exhibited equal potency compared to the non-
lipidated peptide. Additional studies examining the effects of increasing carbon side 
chain length on peptide activity have also revealed conserved potency after lipid 
conjugation. Todorovic et al. (2005) examined the effect of increasing the alkyl chain 
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length at the N-terminal by integrating long-chain fatty acids on the His-DPhe-Arg-Trp-
NH2 tetrapeptide, an agonist at the melanocortin receptors (MCR). A total of twelve 
lipidated analogues were developed to target the mouse MC1R and MC3R-MC5R, and 
the MC1R expressed in human melanocytes. Tetrapeptides modified with a minimum of 
9 alkyl groups did not display enhanced potency at the mMC(3-5) receptors but did 
retain their potency compared to their non lipidated control, despite the addition of up to 
16 carbons to the core peptide. In contrast, all His-DPhe-Arg-Trp-NH2 tetrapeptides 
targeted to the mMC1R demonstrated a superior potency compared with the non-
acylated control. A 20-200 fold improvement in potency was reported at the MC1R 
compared with the nonacylated peptide; however modification with fatty acids 
consisting of a minimum of eight carbons provided no additional improvement in 
potency at the MC1R. Interestingly, a 10, 11, 12 and 15 carbon conjugation resulted in a 
10-fold reduction in potency in comparison to the 8 carbon variant, although all other 
lipidated tetrapeptides exhibited equal potency compared to the C8 variant. Thus, 
Todorovic et al. successfully showed enhanced potency of the tetrapeptide when 
conjugated to a short chain fatty acid such as the octanoyl (C8), nonanoyl (C9), and 
decanoyl (C10) variants, whereas although long chain fatty acid conjugation was not 
unfavourable in terms of potency, there was no further contribution compared with their 
shorter fatty acid-conjugated counterparts. Data reported by Todorovic et al. (2005) 
resembles that seen with the lipidated dual Y2/Y4 and single Y4 peptides presented in 





]hPP (described in more detail below, section 4.5.2). Furthermore, 
although a 20-200 fold enhancement of potency at the MC1R was reported by 
Todorovic et al. for all 12 analogues tested, the lipidated peptides presented in this 
thesis all retained their potency and were equi-effective compared with the non-
lipidated control, [K
22
]hPP2-36 in Col-24 monolayers.  
 
4.5.2 Palmitoylation retains Y2 and Y4 activity with no significant Y1 effects.  











demonstrated the most promising pharmacological profiles. Concerns over nM Y1 





]hPP, as indicated in binding studies by our collaborators, Appendix 1.0) led to 
use of the selective Y1 (BIBO3304) to discern the role of the Y1 receptor in mediating 




]hPP on the Y1 (also Y2 and Y4)-expressing 
human colonic mucosa.  Here responses to the dual Y2/Y2 receptor agonist were 
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unaltered in the presence of BIBO3304 but were significantly attenuated in the presence 
of BIIE0246 (Figure 3.13); this study highlighted the selectivity of the dual agonist for 
the Y2 receptor over the Y1, and since the latter is associated with the cardiovascular 
side effects (Malmstrom et al., 2002), this makes the lipidated peptide highly desirable 
as a therapeutic treatment.  
 
4.5.3 Effect of lipidation on Y4 receptor desensitisation  
Contrary to the lack of Y4 receptor desensitisation observed with the PEGylated 








]hPP series of peptides, lipidation of each 
peptide series resulted in rapid, significant desensitisation. In Col-24 monolayers, low 




]hPP significantly reduced further Y4 signalling 





nM) also resulted in a significant reduction in the subsequent hPP responses compared 
with ‘Cntrl’ hPP (100 nM), mimicking the loss of hPP responses observed in Col-24 




]hPP (0.3-100 nM) in Col-24 
monolayers significantly reduced subsequent hPP responses. With regard to the fatty 
acid-conjugated [K
22
]hPP2-36 series of peptides, the extent of Y4 receptor desensitisation 
positively correlated with the lipophilicity of the peptides, with palmitic acid- and lauric 
acid-conjugated peptides demonstrating significantly enhanced inhibition of further Y4 
signalling compared with their non-lipidated predecessor. [K
22
(E-Capr)]hPP2-36 also 
exhibited a concentration-dependent desensitisation profile which was more akin to that 
seen with the unmodified [K
22
]hPP2-36  peptide. 
 
This divergence in Y4 desensitisation compared with the PEGylated equivalents was 
also observed in imaging studies performed by our collaborators, with the use of stably 










]hPP (Figure 4.5) which was also associated 
with intense arrestin-3 recruitment (Figure 4.6).  
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]hPP. (A) hY4R-EYFP shown in green prior to agonist addition; 
TAMRA-modified peptide is shown in red, hY4R-EYFP and peptide-receptor merged 
(yellow) with nuclei is visualised with Hoechst33342 blue, and a 3 x magnification of a 
chosen cell is shown in the far right images. The scale bar represents 10 µm. (B) 




]hPP results in rapid and intense 
internalisation of the receptor-peptide complex. The upper and lower images 








  147 
 





]hPP. (A) hY4R-EYFP and arrestin-3 localisation 
prior to stimulation by an agonist; with the receptor shown in green, arr-mCherry shown 
in red,  nuclei visualised with Hoechst33342 shown in blue and a 3 x magnification 
shown on the right. The scale bar represents 10 µm. (B) Redistribution of arr-mCherry 
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Pam)]hPP2-36, displayed intense arrestin recruitment compared with unmodified 
[K
22
]hPP2-36 (Figure 4.7), however quantification of the amount of arrestin recruited and 
the time taken for recruitment is required to determine whether internalisation of the Y4 
receptor is dependent on fatty acid chain length. 
 
 
Figure 4.7 Time-dependent arrestin3-promoted hY4R internalisation upon agonist 
stimulation with lipidated [K
22
]hPP2-36 variants. (A) No agonist; hY4R-EYFP and 
arrestin-3 localisation prior to stimulation, with the receptor shown in green (localised at 
the plasma membrane), arr-mCherry shown in red (ubiquitously localised in the 
cytoplasm), and nuclei visualised with Hoechst33342 shown in blue, and a 3 x 
magnification of identified individual cells (white boxes) are shown at the far right. The 
scale bar represents 10 µm. Following agonist binding, redistribution of arr-mCherry is 





36 and (D) [K
22
(E-Pam)]hPP2-36 (all at 100 nM), indicated by the increase in yellow 
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The last decade has seen the use of lipidation in drug development rise, particularly with 
cell penetrating peptides (CPPs); lipid tails have been conjugated to CPPs in order to 
enhance their membrane binding and penetration, an effect that is thought to occur 
through endocytosis and not a receptor-dependent mechanism. Pham et al. (2004) 
developed an amidated oligoarginine (HIV Tat peptide mimetic, R7), which was 
conjugated to a myristate (C14) moiety at the N-terminus. The lipoprotein was labelled 
with fluorescein isothiocyanate (FITC) on the C-terminal lysine side chain to monitor 
its cellular uptake and intracellular distribution using fluorescence microscopy and flow 
cytometry. Pham et al. demonstrated that the addition of a myristate side chain to R7-
FITC significantly enhanced its association with cells and the extent of Tat peptide 
internalisation. However, there was little evidence of increased cytosolic labelling 
suggesting that the lipopeptide was simply associating with the membrane rather than 
translocating across it. Similar findings using myristoylated oligoarginine peptides in 
three different cells lines (Jurkat cells, human Tlymphoma 8E5, and myeloma U266B1 
cells) were observed (Lee and Tung, 2010) and both studies demonstrated that the 
extent of myristoyl-mediated cell association was dependent on the length of the 
arginine chain. The possibility exists that the lipid aids initial membrane interaction but 
the lipid tail positioned in the bilayer may hinder the penetrating capacity of the peptide. 
Lee and Tung did however provide evidence that a myristoylated R11 peptide was able 
to gain access to the cytosol (Lee and Tung, 2010).  
 
Data concerning peptide conjugation to a myristate side chain is contradictory. Two 
groups have demonstrated the interaction of a myristate-conjugated peptide with 
artificial membranes and cells and have suggested that otherwise impermeable peptides 
may gain access to cells via attachment to this lipid group (Ensenat-Waser et al., 2002; 
Nelson et al., 2007). Several studies have supported this notion; Fernandez-Carneado et 
al. (2005) demonstrated that fatty acylation of the N terminus of proline-rich CPPs 
enhance their cellular uptake into HeLa cells. Conjugating the anti-metabolite drug 
methotrexate with fatty acids, specifically through tris lipidation, enhances cellular 
uptake and leads to improved anti-tumour activity in a mouse melanoma model (Lockett 
et al., 2000). More recently, Dudley et al. (2011) synthesised a series of florescent 
molecules, dansyl ethylenediamine and phenylalanine dansyl ethylenediamine, which 
were acylated with either acetate (C2), caproic (C6), enanthate (C7), myristate (C14), or 
palmitate (C16). Each conjugate (25 µM) was examined for entry and localisation into 
cultured CHO cells by assessing total gross florescence retention and cellular 
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microscopic florescence patterns. Conjugates with myristate or palmitate demonstrated 
the most enhanced lipophilic property with entry into cells and localisation in the 
cytoplasm (Dudley et al. 2011).  It is now widely accepted, under experimental 
conditions that CPPs can translocate directly across the plasma membrane of cells. 
 
The enhanced uptake of a lipidated peptide/receptor complex through the plasma 
membrane is thought to occur via anchoring of the covalently linked fatty acid moiety 
to the membrane itself, thus facilitating rapid internalisation/translocation. 
Destabilisation of the plasma membrane is considered to result from targeting of 
specific intracellular loops of the GPCR by the lipid moiety, enhancing ionic 
permeability of the bilayer. This theory has been widely acknowledged, since enhanced 
membrane association occurs following the addition of a hydrophobic group to a 
peptide (Slepnev et al., 1995; Dunphy and Linder 1998; see Figure 4.8). 
 
 
Figure 4.8 Representation of the possible interaction between a lipidated ligand (L) 
and the Y4 receptor embedded in the phospholipid bilayer. The interaction between 
the long chain of the fatty acid residue and the lipid bilayer may enable ligand-receptor 
interaction in several steps. The ligand may accumulate at the cell surface (A) and 
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4.5.4 Persistent Y4 signalling despite rapid desensitisation 
An interesting observation with the lipidated analogues was the continual Y4-mediated 
anti-secretory responses despite the apparent desensitisation of the receptor (indicated 
by the loss of signal to a subsequent addition of hPP). This was followed by rapid 
arrestin recruitment and internalisation demonstrated by the imagining data by our 
collaborators. Quantification of real-time cAMP generation is now possible with the 
utilisation of FRET tools. In 2009, two groups reported internalisation to be a 
prerequisite for continual Gs GPCR/G-protein signalling from an intracellular 
endosomal compartment (Calebiro et al., 2009, Ferrandon et al., 2009), contradicting 
the classical model of GPCR signalling.  
 
Ferrandon et al. studied the effects of two native ligands, parathyroid hormone (PTH) 
and paracrine acting PTH-related protein (PTHrP) on the signalling of the parathyroid 
hormone receptor (PTHR), and proposed a link between the stability of the hormone-
bound receptor complex and the capacity to promote a persistent cAMP-mediated 
signal. The authors demonstrated conformational modifications within the G-protein 
and PTHR as well as cAMP activity in real time using FRET, and reported persistent 
receptor activation of the G-protein signal response in the presence of PTH, but not 
PTHrP. Stimulation with PTH also induced co-trafficking of the PTHR into early 
endosomes coupled with its Gs protein, in contrast to PTHrP stimulation, which led to 
dissociation of Gs protein from the PTHR, before promoting internalisation. The 
contradictory response to PTH and PTHrP was attributed to a stable association of the 
PTHR with PTH allowing a continual active conformation of the receptor-ligand 
complex. These data were further supported by the fact that a dynamin dominant 
negative mutant resulted in an inhibition in cAMP production, leading to desensitisation 
of the PTHR receptor (Ferrandon et al., 2009). The authors concluded that a protective 
mechanism was involved; uptake into an endosomal compartment may shield the 
receptor-hormone complex from β-arrestin-facilitated desensitisation, thus allowing 
sustained GPCR signalling.  
 
In 2009, Calebiro et al. supported these findings by reporting rapid internalisation of the 
thyroid stimulating hormone receptor (TSHR) coupled with its associated Gs protein and 
AC after stimulation with thyroid stimulating hormone (TSH). In addition, the TSH-
induced cAMP signal remained persistent and did not desensitise. Interestingly, the 
authors concluded that the process of internalisation prohibited receptor-hormone 
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dissociation since sustained cAMP generation was not observed with transient TSH 
stimulation, only with prolonged stimulation. As observed with the TSHR, 
internalisation of the PTHR–PTH complex was not associated with desensitisation of 
the cAMP response but rather with persistent signalling. 
 
Evidence provided by these two groups supports the idea of persistent signalling to AC 
by internalised GPCRs and may help elucidate why prolonged Y4-mediated anti-
secretory signals have been observed to chemically modified hPP analogues in this 
study. A possible mechanism for the differential Y4 responses observed with the 
modified peptides could be attributed to a stable association of the Y4 receptor/peptide 
complex in a prolonged active conformation. The lipid/PEG moiety may serve to 
position the core peptide into a conformation which has either a high or low association 
with arrestin, but permits the internalisation of the complex in the presence of the lipid, 
allowing continual receptor signalling. Thus, a possible explanation for the loss in 
subsequent hPP responses in Col-24 monolayers and human colon mucosa may be due 
to a loss in total cell surface receptor expression, rather than desensitisation of the 
receptor. This would explain why anti-secretory responses continue 45 min after the 
addition of a lipidated peptide, but responses to hPP are lost in this time period. In 
keeping with these findings, rapid internalisation was observed for all lipidated 
analogues in imaging experiments. Although fast arrestin recruitment was also 
measured, it would now be interesting to quantify the extent of arrestin-mediated 
phosphorylation of the receptor, compared with the native hormone. 
 
Whilst these two reports provide strong evidence for the continuation of Gs-mediated 
GPCR signalling in endosomal compartments, an additional study reported intracellular 
Gi-dependent signalling; FTY720, an immunomodulator drug used in the treatment of 
multiple sclerosis, predominately targets the Gi/ Gq-coupled sphingosine-1-phosphate 
receptor 1 (S1P1) (Kappos et al., 2006). Upon binding to the receptor (Mandala et al., 
2002), the receptor-ligand complex undergoes endocytosis from the cell surface (Oo et 
al., 2007). Mullershausen et al. demonstrated inhibition of forskolin-induced cAMP 
production 5 hours post internalisation in addition to MAPK activation, despite almost 
complete co-localisation of the S1P1 receptors within vesicular compartments at the 
same time point (Mullershausen et al., 2009). Furthermore, internalisation of the 
receptor resulted in a loss of IP3 signalling, which is in accordance with the view that 
generation of IP3 takes place solely at the plasma membrane. One explanation for this 
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observation is that internalisation occurs with the ligand-GPCR-AC complex as one 
macromolecular entity. Whilst the ligand is still bound to the receptor, the complex 
remains active. Although the functional data presented in this thesis along with the 
imagining data performed by our collaborator does not provide direct proof to support 
the inhibition of cAMP via the Y4 receptor, these results do give an indication for the 
existence of persistent Y4 receptor signalling. To the best of my knowledge, all studies 
to date to monitor persistent cAMP signalling by GPCRs have been performed in cells 
in tissue culture. Thus, the physiological significance of persistent cAMP signalling by 
GPCRs is yet to be elucidated. 
 
4.6 Current pharmacotherapies in development for obesity and the 
potential of Obinepitide and TM30339 analogues 
While there is extensive evidence that points to the acute anorexigenic effects of both 
the Y2 and Y4 agonists, the rapid degradation of PYY and PP, and short circulating half-
lives, imply that use of the native peptides may not be so successful with respect to 
chronic treatment. Moreover, PYY(3-36) or PP administered to the CNS of rodents has 
been shown to promote appetite (Clark et al., 1987; Asakawa et al., 1999; Corp et al., 
2001). This is thought to be due to high local concentrations of these hormones 
pharmacologically stimulating orexigenic Y1 and Y5 receptors. In addition, the 
therapeutic window for PYY(3-36) is relatively narrow, with low doses proving 
ineffective and high doses causing nausea (Degen et al., 2005).  
 
A number of endogenous hormones implicated in metabolic conditions have undergone 
successful PEGylation to enhance their bioavailability, including GLP-1 (Lee et al., 
2005; Lee at al., 2006), calcitonin (Shin et al., 2004), insulin (Shechter et al., 2008) and 
NPY (Ortiz et al., 2007). In the case of PEG-calcitonin, Shin et al. attempted to reduce 
the rate of administration by improving the pharmacokinetic–pharmacodynamic profile; 
the 2kDa PEG moiety of the polypeptide promoted slower absorption by reducing the 
permeability across the nasal epithelium (Shin et al., 2004). However, not all intranasal 
formulations have been successful; pre-prandial intranasal PYY(3-36) was tested in 
obese patients for two weeks, but was not found to reduce body weight. Intranasal 
administration resulted in transiently high circulating levels of PYY associated with 
nausea (Gantz et al., 2007). PYY analogues which show moderately increased but 
persistent circulating levels following administration may be more useful in the 
treatment of obesity. A PEGylated selective Y2 receptor agonist has been shown to 
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outperform PYY(3-36) in reducing food intake in mice (DeCarr et al., 2007), suggesting 
that PEGylation of specific Y2 receptor agonists may improve their therapeutic 
potential.  
The GIPIO collaboration aimed to address these shortcomings above by developing 
more stable, longer acting and highly selective analogues. By developing a hPP 
analogue with additional Y2 affinity, as is the case of Obinepitide ([Q
34
]hPP), fewer side 
effects were predicted compared with selective Y2 analogues (see section Figure 4.7). 
Obinepitide has been shown to inhibit food intake in obese individuals up to nine hours 
after subcutaneous administration in phase I/II trials (7TM Pharma, 2008). In addition, 
recent developments of PEGylated or fatty acid acylated Obinepitide variants have 
demonstrated improved pharmacokinetic properties compared to a non-modified human 
PP analogue (Bellmann-Sickert et al., 2011), and for these reasons, the novel peptides 
assessed in this study deserve further investigation into their potential as anti-obesity 
therapies. Likewise, TM30339 (hPP2-36) proved efficacious in diet-induced obese mice 
by reducing body weight in phase I/II trials (7TM Pharma, 2008) and thus the sustained 
functional Y4 responses and high potency observed with the palmitic acid/lauric acid-
conjugated variants makes a stronger case for in vivo studies with the lipidated peptides.  
 
4.7 Peripheral Y2 and Y4 mechanisms and potential side effects 
In parallel with their central anorexigenic activities, both the Y2 and Y4 receptors exhibit 
multiple peripheral mechanisms via PP, PYY and PYY(3-36); several of these 
mechanisms are inhibitory and play a pivotal role in the regulation of digestive 
processes, including inhibition of electrolyte secretion (Playford et al., 1990; Cox and 
Tough, 2002), reduction in gastric acid secretion, slowing of gastric emptying and upper 
GI transit, and slowing of colonic motility, working in combination to modulate food 
intake and energy expenditure. 
 
Receptor-mediated colonic absorption via a combination of Y1, Y2, or Y4 receptors in 
human specimens occurs as a result of attenuated apical Cl
−
 secretion, although Y5 
agonists are ineffective within the GI tract (Cox et al., 2001a; Cox and Tough, 2002). 
Since chemically modified PEGylated or lipidated Y2/Y4 or single Y4 agonists 
consistently demonstrated prolonged reductions in Isc in isolated human mucosa, there is 
a potential for unwanted side effects such as reduced ion and electrolyte secretion and 
hence constipation. The functional observations in this study provide a strong 
justification for the dual agonists to be used not only as anti-obesity treatments, but also 
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in conditions such as severe diarrhoea (since CFTR-mediated Cl
−
 secretion in the 
intestine is accountable for a number of secretory diarrhoeas). The long-acting selective 
Y4 agonists (PEG/lipid-[K
22
]hPP2-36) offer further advantages to clinical treatment, due 
to the limited peripheral localisation of the Y4 receptor (in contrast to the extensive 
distribution of Y1 and Y2 receptors). 
 
As well as their fundamental importance in gut in terms of electrolyte absorption, 
several studies have now documented profound inhibitory effects of both the Y2 and Y4 
(and Y1) receptors on gastric acid secretion and upper GI motility. Field et al recently 
reported an inhibition of both gastric emptying and gastric acid secretion, and an overall 
reduction in the mouth-to-caecum transit time following i.v. infusion of PYY in humans 
(Field et al., 2010). The inhibitory effect on gastric secretion is thought to be Y1 and Y2-
mediated through actions in brainstem and stomach (Yang, 2002). With respect to upper 
small intestinal transit, PYY acts to slow transit by inducing an ‘ileal brake’ mechanism 
(Lin et al., 1996; Maljaars et al., 2008), contributing to satiation. These findings have 
been supported by Tough et al. (2011), who recently demonstrated significantly 
increased transit in PYY-/- mice compared with WT mice. A slightly increased upper 
GI transit following i.p. administration of BIIE0246 to WT mice was also observed, 
suggesting that the slowing of transit by endogenous PYY occurs through peripheral Y2 
and possibly Y1 receptors. Interestingly, the authors demonstrated an equal basal rate 
for gastric emptying in both PYY and NPY KO mice compared to WT mice; Tough et 
al. suggested this could be attributed to the lack of PYY’s peripheral mechanism to 
inhibit upper intestinal transit, coupled with NPY’s ability to stimulate gastric emptying 
through a central pathway (via activation of the dorsal vagal complex; Mönnikes et al., 
2000), thus counteracting each other. Limited data exist for the effects of PP on gastric 
emptying. Early reports suggested the inability of bPP to inhibit gastric emptying in 
human subjects (Adrian et al., 1981), although other groups successfully went on to 
demonstrate an inhibitory role of the native peptide in rats (Okumura et al., 1994), mice 
(Asakawa et al., 2003) and humans (Schmidt et al., 2005), which was recently 
confirmed to be dependent on intact vagal signalling (Field et al., 2010). A considerable 
amount of evidence cumulatively indicates that rapid gastric emptying is strongly 
related to increased food consumption and obesity, whereas a delay in emptying is seen 
in patients with conditions such as cachexia and anorexia (Duggan and Booth, 1986; 
Inui, 1999; Inui, 2002). For this reason it is predicted that the novel PEG/lipid dual 
  156 
analogues may illicit further anorexigenic actions in vivo, by inducing a Y2/Y4-mediated 
slowing of gastric emptying.  
 
Exogenous NPY, PYY and PP can evoke Y2 and Y4 receptor-mediated contractility of 
colonic smooth muscle (Pheng et al., 1999; Hyland et al., 2003). In 2010, Wang et al. 
demonstrated sustained inhibitory effects on basal- and stress-stimulated colonic 
propulsive motor function following i.p. administration of PYY(3–36) or PYY in 
conscious mice, an effect which was Y2 receptor-mediated (Wang et al., 2010). Tough 
et al. (2011) corroborated these findings by reporting that the slowing of colonic transit 
was dependent upon Y2 activation, via PYY and NPY. The authors reported a Y2-
mediated contraction of smooth muscle (via PYY, inhibited by a Y2 antagonist), thought 
to be a consequence of inhibition of tonic drive to the longitudinal muscle. PYY’s tonic 
role in longitudinal muscle contraction is highlighted by the explosive diarrhoea 
observed in mice following administration of BIIE0246 (Wang et al., 2010). 
Several studies have revealed the role of PP in inducing longitudinal smooth muscle 
contractions in colonic tissue from mice (Hyland et al., 2003) and rats (Feletou et al., 
1998; Ferrier et al., 2000; Pheng et al., 1999). In 2010, Moriya et al. demonstrated a 
dose-dependent increase in faecal weight following peripheral administration of PP and 
almost complete inhibition of PP-induced faecal output in Y4
-/-
 mice, suggesting PP 
enhances colonic transit via the Y4 receptor. With the use of RT-PCR, Ferrier et al. 
established high levels of Y4 receptor expression within the muscle layers of the colon, 
particularly within the proximal and distal colon (Ferrier et al., 2002). Lower expression 
levels however were found within the mucosa, indicating that Y4 receptors within the 
colonic muscle layers are likely to be involved in colonic transit, whereas mucosal Y4 
receptors most likely play a key role in modulating colonic ion absorption in vivo. 
 
Unfortunately, the therapeutic significance of PYY(3-36) is limited by the nausea and 
vomiting induced by exogenous administration of the peptide, predominantly at higher 
doses (Gantz et al., 2007; le Roux et al., 2008). Le Roux et al. reported nausea in 
human subjects following i.v. PYY(3-36) at super-physiological doses, although no 
further reductions in food intake were observed (le Roux et al., 2008). Here the authors 
suggested that PYY(3-36) can decrease the amount of food intake without the onset of 
nausea, however reaching a certain threshold concentration may induce nausea but with 
no additional decrease in food intake. In contrast to PYY, nausea is not observed in 
human subjects following administration of PP, despite reductions in food intake 
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(Batterham et al., 2003; Jesudason et al., 2007; le Roux et al., 2008), making PP 
analogues more attractive from a clinical perspective. Promising data published by Tan 
et al. (2012) reported no adverse events or any clinical concern when monitoring the 
tolerability of the novel Y4 peptide, PP 1420, in healthy human volunteers. PP 1420 
exhibited comparable results to the placebo with regards to changes in vital signs, 
haematology, biochemistry, urinalysis and ECG readings. Additionally, a visual 
analogue scales (VAS) assessment, used to measure the grading of nausea severity, 
indicated no significant level of nausea following administration of the novel Y4 
analogue (Tan et al., 2012). 
 
Since prolonged anti-secretory responses have been observed with both PEGylated and 
lipidated Y2/Y4 and single Y4 peptide variants in vitro, in vivo evaluation will be 
essential in understanding the potential adverse effects associated with the peptides. 
Although high doses of the gut hormones may cause aversive effects, it is predicted that 
administration of lower doses of gut hormones in combination may limit the likelihood 
of undesirable effects such as nausea, yet provide a synergistic action on the inhibition 
of food intake. To circumvent the weak but significant interaction of PYY(3-36) and PP 
with the orexigenic Y1 and Y5 receptors (Gerald et al., 1996 and Kanatani et al., 2000, 
respectively), a combination of the dual Y2/Y4 analogue along with Y1 or Y5 receptor 
antagonist may further increase the overall anorexigenic effect. Furthermore, signalling 
data provided by our collaborators has shown weak interaction of these peptides with 
both the Y1 and Y5 receptor (see Appendix 1.0), making these peptide clinically far 
more desirable.  
 
Modulating gut hormones to control appetite is still under-developed as a 
pharmacotherapy, although the proof-of-concept is provided by the success of GLP-1 
therapy, for patients with type 2 diabetes. Despite numerous studies demonstrating the 
use of GLP-1 in the treatment of type 2 diabetes, the endogenous peptide undergoes 
rapid degradation by DPP-IV, thus resulting in the need for continuous subcutaneous 
injection for clinical efficacy (Drucker and Nauck, 2006). Liraglutide, the human GLP-1 
analogue, is a glucose-lowering agent with a significantly prolonged action compared 
with the native GLP-1 which has been achieved through fatty acid acylation. Liraglutide 
exhibits increased affinity for blood albumin and therefore allows once-daily 
subcutaneous administration. In the UK, liraglutide 1.2 mg/day now represents an 
additional therapy widely available for very obese (BMI ≥ 35.0 kg/m2) patients or for 
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those unsuitable for insulin and are failing to meet targets for glycaemic control with 
oral agents (NICE technology appraisal guidance, 2010). While this emphasises the 
importance of suppressing weight gain in the treatment of type 2 diabetes, the only class 
of currently available clinically applicable drugs that induce weight loss are GLP-1 
receptor agonists. Thus, the chemically modified gut hormones in this thesis present a 
promising opportunity for anti-obesity pharmacotherapy and with restricted localised 
peripheral and central Y receptor targets, few nonspecific side effects are predicted. 
 
4.8 Concluding statement  
Due to the side effects and limited efficacy of the anti-obesity mono-therapies currently 
available, there is an urgent need for a dual treatment with enhanced efficacy, selectivity 
and sustained activity. The GIPIO collaboration has aimed to address this problem by 
developing dual agonists that exhibit both Y2 and Y4 anorexigenic properties, in 
addition to a range of selective Y4 analogues with improved in vitro and in vivo 
characteristics over the native hormone, hPP. The results herein provide preclinical 
evidence in two human preparations that PEG- and lipid-modified PP analogues retain 
full potency and display enhanced in vitro characteristics. More specifically, it suggests 









]hPP have well-preserved dual receptor biological activity as compared with 
hPP. The anti-secretory effects of single Y4 lipidated agonists, based on the hPP2-36 
parent peptide, were also studied with an emphasis on the effects of changes in the fatty 
acid chain length on in vitro activity. The agonists were additionally well tolerated in 
terms of in vitro properties, with long chain fatty acid modification causing a 
predictable increase in longevity of action. Since the Y4 receptor has a more discrete 
peripheral localisation than Y1 or Y2 receptors, the limited expression is beneficial in 
terms of drug development. As well as the potential as anti-obesity benefits, selective 
Y4 receptor agonists could also be used to modulate GI function with limited side-
effects compared with agents targeting the more ubiquitous Y1 and Y2 receptors. For the 
treatment of conditions responsive to Y4 agonism, such as obesity and intestinal hyper-
secretion, it would be more desirable to use longer-acting Y4 receptor selective agonists.  
 
The results in this study demonstrated a resistance to Y4 receptor desensitisation when 
stimulated with a PEGylated analogue and a contradictory enhancement of 
desensitisation following stimulation with a lipidated analogue. This divergence was 
further supported by florescence imaging studies; our collaborators demonstrated that 
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the ligand-bound Y4 receptor remained anchored to the plasma membrane following 
activation by PEGylated peptides and in contrast was rapidly internalised following 
activation with lipidated peptides. Taken together, these data suggest that a chemically 
modified agonist’s in vitro kinetics and efficacy differentially modulate the mechanism 
of receptor-mediated endocytosis. The physiological regulation of GPCRs (through 
desensitisation and internalisation) may influence the clinical development of tolerance 
and dependence in response to chronic drug treatment. For example, the lack of 
desensitisation with a PEGylated peptide could be clinically desirable due to the lack of 
tolerance predicted with these analogues, whereas the rapid loss of Y4 receptor 
responsiveness with a fatty acid conjugated peptide may be less predictable due to the 
possibility of rapid removal of the receptor from the plasma membrane but persistent 
signalling of internalised Y4 receptors. Further investigations are warranted to elucidate 
the life cycle of the Y4 receptor; membrane targeting, ligand binding, signalling, 
internalisation, recycling and degradation will all help provide new insights into the 
mechanism of receptor signalling in the presence of a chemically modified ligand. 
Furthermore, it is predicted that the selective activation of both the Y2 and Y4 receptors 
have promising potential for the treatment of obesity and the results consequently merit 
the investigation of these peptides in humans to establish their clinical efficacy and 
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Peptide synthesis 
Peptide analogues were synthesised by solid-phase peptide synthesis (SPPS). For 
synthesis, the Rink amide resin (4-(20,40-dimethoxyphenyl)-fluorenylmethoxy 
carbonyl-aminomethyl-phenoxyacetoamido-norleucylaminomethyl) was used in order 
to obtain an amidated C-terminus as already described in the literature (Rennert et al., 
2006). Site-specific modification by PEG2, PEG5, PEG22 and palmitic acid was 
achieved at the N
ε
-amino group of Lys at position 22 or 30. This group could 
specifically be removed by hydrazine, thereby releasing the free amino group. To 
prevent a loss in affinity and to increase water solubility, the Pam group was linked to 
the peptide by a glutamyl spacer, coupled to Lys
30
 via the γ-carboxyl group of an N-
terminally fluorenylmethoxycarbonyl (Fmoc) and C-terminally tert-butyl (tBu) 
protected Glu. PEG-polymers of either 2 kDa, 5 kDa or 22 kDa were selectively 
incorporated at a lysine side chain in solution using a photocleavable protecting group at 
the N-terminus which was then removed after PEGylation. Modified peptides were 
characterised by reversed-phase HPLC and mass spectrometry. Purification was carried 
out by RP-HPLC. 
 
Agonist induced IP3 generation 
Potency of the analogues on each human Y receptor type was determined by performing 
concentration-response experiments in COS-7 cells transiently transfected with the Y 
receptor as well as a promiscuous G-protein, p7TM678. This ensured that the Y 
receptor coupled through a Gq pathway leading to an increase in IP3 turnover. One day 
after transfection COS-7 cells were transferred to 96-well culture plates at a density of 
30,000 cells per well and incubated for 24 hours with 0.5 μCi of [3H]-myo-inositol in 
100 μl medium supplemented with 10% FCS, 2 mM glutamine and 0.01 mg/ml 
gentamicin per well. Cells were washed twice in buffer, 20 mM HEPES, pH 7.4, 
supplemented with 140 mM NaCl, 5 mM KCl, 1 mM MgSO4, 1 mM CaCl2, 10 mM 
glucose, 0.05% (w/v) bovine serum; and incubated in 100 μl buffer supplemented with 
10 mM LiCl at 37° C for 30 min. After stimulation with various concentrations of 
peptide for 60 min at 37° C, cells were extracted with 50 μl 10% ice-cold perchloric 
acid followed by incubation on ice for 30 min. 20 μl of the perchloric acid cell solution 
was transferred into a 96 wells plate. 80 μl of SPA YSI beads (12.5 mg/ml) (=1 
mg/well) was added, the plate was sealed and shaken up to 30 min. After centrifugation 
for 5 min at 1500 rpm, the amount of radioactive phosphoinositide produced in response 
to increasing concentrations of agonist was analysed with a Packard Topcounter and 
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]hPP series (Table 2.0) and the hPP2-36 series of peptides (Table 3.0).  
 
Y4 receptor imaging studies  
Cell culture 
HEK293 cells stably transfected with the human Y4-receptor and C-terminally fused to 
eYFP (HEK293-hY4R-eYFP) as described in Böhme et al. 2008 were cultured in 
DMEM/Ham's F-12 (1:1) without L-glutamine containing 15% (v/v) heat-inactivated 
fetal calf serum FCS and 100 µg/mL hygromycin B. Cells were grown as monolayers 
and grown to confluence at 37 °C in a humidified atmosphere of 5% CO2 and 95% air. 
 
Fluorescence microscopy 
For live cell imaging experiments cells were seeded into sterile μ-Slides 8 well (ibidi 
GmbH, Martinsried, Germany) and cultured to 80 % confluency. Transient cell 
transfection was performed using up to 0.9 μg hY4-eYFP-pVitro2 plasmid-DNA and 0.1 
µg of a β-arrestin3-mCherry construct (Walther et al. 2010) and up to 2 μl 
Lipofectamine™ 2000 Transfection Reagent. Prior to ligand stimulation, cells were 
starved in Opti-MEM
®
 reduced serum medium for 30 min and stimulated with 100 nM 
of either fluorescent-labeled peptide or non-fluorescent labeled conjugates in Opti-
MEM
®
 reduced serum medium at 37 °C for different time periods (10 min, 30 min or 60 
min). Stimulation was terminated by washing the cells with Hanks' balanced salt 
solution (HBSS) and cells were imaged. The cell nuclei were visualized with Hoechst 
33342 (1 μg/ml; Sigma-Aldrich, Taufkirchen, Germany) for 10 min at room 
temperature. Glass cover slips were mounted on microscope slides with FluoromountG 
(Carl Roth GmbH & Co. KG, Wiesbaden, Germany). Fluorescence images from living 
cells were obtained with an Axio Observer microscope equipped with an ApoTome 
imaging system and a Heating Insert P Lab-Ek S1 unit (Zeiss, Jena, Germany). 
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Table 3.0 EC50 values generated by an IP3 accumulation assay, induced by 
chemically modified hPP2-36 derivatives. Potency and selectivity of the peptide 
analogues with their subsequent Y receptor preferences, determined by an IP3 turnover 
assay. Experiments were performed with COS-7 cells transiently transfected with the 
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